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ABSTRACT 
The pharmacokinetics of phenytoin is complicated by the nonlinearity of the dose-
concentration relationship which is a consequence of capacity-limited metabolism. 
Individualized therapy with phenytoin is therefore optimally required. As no data are 
available on the population pharmacokinetics of phenytoin in the V\/estem Cape, this study 
was undertaken to address this issue. This study was conducted prospectively primarily 
to: (1) investigate the influence of various patient variables on the population 
pharmacokinetic parameters of phenytoin, (2) assess whether the parallel Michaelis-
Menten and first-order elimination model provides a better fit to the data than the 
Michaelis-Menten model, (3) determine population pharmacokinetic parameter estimates 
of phenytoin representative of the patient population, and (4) validate and compare the 
dinical applicability of the parameter estimates and the models. 
The study population comprised 332 black and coloured, adult, male and female epileptic 
patients residing in the VVestem Cape, South Africa. All patients were on phenytoin 
monotherapy for the management of their epilepsy and no drugs known to interfere with 
phenytoin pharmacokinetics were taken concurrently. Clinical pharmacokinetic dosing 
services were initiated at 9 dinics from which patients were selected for this study. The 
service entailed a patient interview, a chart review, drug analysis and provision of either 
a written or verbal consultation report. 
The data were analyzed using NONMEM (nonlinear mixed-effects modelling), a computer 
programme designed for population pharmacokinetic analysis that allows pooling of data 
from many individuals. The Michaelis-Menten and the parallel Michaelis-Menten and first-
order elimination models were fitted to 853 steady-state dose : serum concentration pairs. 
The results indicate that patient variables such as body weight, smoking, ethnicity and age 
(~ 65 years), in descending order of importance, significantly influenced Vm (the maximum 
metabolic rate)(p < 0.05). Although a significant difference (p = 0.03) in Km (the Michaelis 
- Menten constant, a constant equal to the serum concentration at which the rate of 
metabolism is one-half the maximum) between black and coloured patients was found, 
incorporating the influence of ethnicity in Km in the final regression model did not improve 
the fit of the model to the data. This indicated that the variability in Km was accounted for 
xx 
by Vm. The scaling factors for smoking, coloured patients and 65 years of age or older in 
Vm were 1.12, 1.06 and 0.968, respectively. 
The parallel Michaelis-Menten and first-order elimination model fitted the data better than 
when the Michaelis-Menten model was considered alone. \/\,Uh the former model either 
dose or steady-state serum concentration was used as the dependent variable whereas 
with the latter model only dose was used as the dependent variable. Three structural 
models were therefore tested in this study. The results indicated that linear clearance (Cl) 
of phenytoin should be taken into account, especially when predicting steady-state 
concentrations. Wien using the parallel Michaelis-Menten and first-order elimination model 
with steady-state serum concentrations as the dependent variable, the mean population 
parameter estimates (standard error in brackets) for Vm, Km and Cl were 5.27 (0.59) 
mg/kg/day, 6.81 (1.30) mg/I and 2.68 (0.78) I/day, respectively. The inter-individual 
variability in these parameters was 12.5, 67.9 and 46.3% respectively, and the intra-
individual variability was 20.1 %. Using this model, Vm values for subpopulation groups 
were reported. The mean population estimates for Vm and Km obtained with the 
Michaelis-Menten model were 5.71 (0.10) mg/kg/day and 3.45 (0.24) mg/I, respectively. 
The inter-individual variability in these parameters was 13.2 and 49.1 %, respectively, and 
the intra-individual variability was 5%. The Vm and Km estimates obtained in this study 
were generally lower than those reported in the literature. 
Each model was evaluated for relative predictive performance using the measures of bias 
and precision, i.e. mean prediction error and the root mean squared error respectively. 
Three sets of population parameter estimates, i.e. one set for each model, were tested. 
The methods of cross-validation and naive feedback were employed. Predictions obtained 
with the first-order and first-order conditional estimates were compared. The results 
indicated that the parallel Michaelis-Menten and first-order elimination model was not much 
better than the Michaelis-Menten model when predicting dose. However, when predicting 
steady-state serum concentration, the former model was clearly superior to the latter. This 
study has also confirmed that when using representative parameter estimates (taking into 
account factors shown to influence these parameters) for a population, predictive 
performance improved. All predictions using the estimates obtained with the first-order 
method were biased. Wien using the estimates obtained with the first-order conditional 
estimation rrethod, the bias improved without an improvement in the precision of the predictions. 
XXI 
Although the Bayesian feedback technique has proved superior to all other currently 
available techniques for phenytoin dosage design, prerequisites for obtaining accurate 
results with this method are good initial estimates of the pharmacokinetic parameters and 
their variances. The greater the confidence in the prior information, the better will be the 
performance of the associated Bayesian system. This study has provided estimates of 
Vm, Km and linear dearance, and their inter- and intra-individual variability, for use in a 




Phenytoin is one of the most effective drugs against partial and generalized tonic-clonic 
seizures. It is also used for the control of status epilepticus. 
Few thorough evaluations of the influence of demographic factors on phenytoin kinetics 
have been performed. A number of investigators have studied the pharmacokinetics of 
phenytoin in different population groups and it has been well documented that this may 
differ in the different population groups. To prescribe phenytoin optimally it is necessary 
to investigate its pharmacokinetics in the respective population groups (Breimer, 1983). 
Most often, these studies have involved a small number of patients, a limited number of 
serum phenytoin concentrations, and they have been retrospective in nature. The 
pharmacokinetic methods of analysis are also often suboptimal. 
In the individualization of phenytoin dosage, it is important to use estimates of the 
pharmacokinetic parameters (Vm - the maximum metabolic rate and Km - the Michaelis-
Menten constant, a constant which reflects the serum concentration at which the rate of 
metabolism is one-half the maximum) that are representative of the population concerned 
or, even better, the individual for whom the drug is prescribed (Miller et al., 1987). The 
determination of representative Vm and Km values, their inter- and intra-individual 
variability, and knowledge of which factors influence these values in a population will allow 
rapid establishment of a patient's parameter values (Sheiner and Beal, 1982). This, in tum, 
will allow optimal maintenance dosage to be determined early in the course of therapy 
(Vozeh et al, 1981). Proper characterization of pharmacokinetic behaviour is also a 
prerequisite for the rational interpretation of dose-response relationships. Studies of this 
nature should preferably be performed prospectively (Vesell and Penna, 1983). 
The influence of various factors ( ethnicity, gender, age, mass and body surface area) on 
Vm and Km has been previously investigated, but not in South African patients. The 
influence of these factors needed investigation in a carefully controlled and prospective 
manner in the South African population. An understanding of how patient characteristics 
may influence dosage requirements is particularly important for drugs with a narrow 
2 
therapeutic range e.g. phenytoin. Miller et al. (1987), in a retrospective study, 
demonstrated that the Vm and Km values representative of the black population attending 
Baragwanath Hospital, Johannesburg, South Africa, were lower than those reported in the 
literature. V\mether this difference also applies to the coloured populatior, of South Africa 
was one of the aspects investigated in this study. 
The inter-individual variability in Vm and Km is large and using average Vm and Km 
values, as is commonly done despite the wide inter-patient variability in these parameters, 
may lead to large prediction errors. To prevent this, the determination of Vm and Km 
values for subpopulation groups will enable the clinical pharmacist to choose Vm and Km 
values most appropriate for a selected patient. 
Knowledge of representative Vm and Km values for the South African population should: 
(a) allow calculation of an accurate initial dosage regimen; (b) provide a good indication 
of when the serum phenytoin concentration will be at steady state, and when blood 
samples should ideally be drawn; (c) improve the accuracy of the prediction of 
steady-state serum concentrations; ( d) allow estimation of the maximum dosage that 
should initially not be exceeded in patient subgroups; (e) facilitate construction of 
applicable nomograms for the South African population; (f) allow identification of patients 
who are likely to be more sensitive to phenytoin dosage adjustment; and (g) in the case 
of toxicity, allow more accurate calculation of how long a patient should be withdrawn 
from therapy so that the serum level might fall to a targeted level, and when therapy 
should be reinstituted. 
All the methods that have been used clinically to predict phenytoin dose or serum 
concentration have traditionally taken into account Vm and Km values only. The influence 
of parallel Michaelis-Menten metabolism and first-order kinetics (i.e. linea: clearance, Cl, 
of phenytoin) on prediction outcome has not been tested. In other words, the incorporation 
of linear clearance of phenytoin in a model with Vm and Km has not been validated in 
patients routinely taking phenytoin. The estimates of Vm, Km and Cl in such a model are 
also not available. 
The population parameter estimates and their inter- and intra-subject variances obtained 
from this analysis will be used in a Bayesian forecasting computer programme for the 
optimization of individual dosage regimens for the population under investigation. The 
3 
accuracy and precision of Bayesian regression based on limited feedback is dependent 
on accurate initial population parameter estimates (Killilea et al., 1989; Nonaka et al., 
1993). Since the Bayesian method relies on previous estimates of population parameters 
(means and standard deviations), it may be necessary to adjust these population values 
for different groups of patients (Yuen et al., 1983a). 
The objectives of this study were: 
(a) to evaluate the influence of ethnicity, gender, age, mass, body surface 
area, smoking status and mild to moderate alcohol consumption on the 
population pharmacokinetic parameters (Vm and Km) of phenytoin using 
the NONMEM approach; 
(b) to determine the mean population pharmacokinetic parameter estimates of 
phenytoin (Vm, Km and Cl) and their inter- and intra-individual variability 
in representative patient populations; 
(c) to determine whether the population pharmacokinetic parameters of 
phenytoin applicable to South African patients are different from those 
reported in the literature for patients elsewhere; 
( d) to assess whether the parallel Michaelis-Menten and first-order elimination 
model fits the data better than the Michaelis-Menten model; 
( e) to establish a set of valid Vm and Km value combinations for subpopulation 
groups; 
(f) to validate the applicability of the estimated Vm, Km and Cl values; 
(g) to assess and compare the reliability of 3 steady-state pharmacokinetic 





Numerous investigators have shown the benefit of monitoring phenytoin (formerly called 
diphenylhydantoin) serum concentrations to maximize efficacy and minimize drug-related 
toxicity. The optimal therapy with this drug requires that its administration be tailored to 
the needs of each individual (Klein et al., 1987; Miller et al., 1982; Lund, 1974). This is 
necessary as the therapeutic concentration of phenytoin is dose to that which causes 
toxicity; i.e., it has a narrovv therapeutic index, and its elimination is saturable within the 
therapeutic range. Phenytoin is one of the few drugs that, at dinical doses, can saturate 
hydroxylation by the hepatic microsomal enzymatic system that metabolizes the drug. P-s 
a result, serum phenytoin concentrations do not change in proportion to dose but, instead, 
a relatively small increase in phenytoin dose can cause a disproportionately large increase 
in the serum phenytoin concentration (Bochner et al., 1972; Richens and Dunlop, 1975; 
Martin et al., 1977; Mawer et al., 1974; Schiller and Buchthal, 1958). Even a small change 
in the bioavailability of phenytoin may dramatically affect steady-state serum 
concentrations and dinical response (Gugler et al., 1976; Sawchuk et al., 1982). The 
half-life of phenytoin changes with dose and serum concentration. The higher the dose 
and serum concentration of phenytoin, the longer the half-life (Arnold and Gerber, 1969; 
Dodson, 1980; Houghton and Richens, 1974). Thus, the time required to reach a new 
steady state is difficult to predict as it depends on the dose and the patient's 
pharmacokinetic parameters (Allen et al., 1979). Phenytoin is, therefore, said to exhibit 
nonlinear pharmacokinetics. The saturation of the microsomal enzymes varies widely 
among individuals. Wde inter-patient variations in serum phenytoin concentrations also 
occur (Buchthal and Svensmark, 1959; Lascelles et al., 1970; Ludden et al., 1978). The 
serum concentration of phenytoin is for this reason undoubtedly difficult to interpret 
pharmacokinetically (Ludden et al., 1977). This justifies therapeutic drug monitoring of 
phenytoin (Morrow and Richens, 1989). 
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2.1 POPULATION PHARMACOKINETICS 
Population pharmacokinetics is defined as the study of the variability in serum drug 
concentrations between individuals in a target population when conventional dosage 
regimens are administered. This variability within the population is measured and 
accounted for by patient variables such as ethnicity, age, sex, mass or disease states 
(Aarons, 1991; Wliting et al., 1986). Good therapeutic practice should ideally be based 
on an understanding of pharmacokinetic variability. This ensures that dosage adjustments 
can be made to accommodate differences in pharmacokinetics (\Mliting et al., 1986). 
Population pharmacokinetic methods focus on the central tendency of a response across 
an entire population and account for deviations from the central tendency in 
subpopulations or among individual patients (Colburn, 1989). A nomogram designed from 
data obtained from a particular population may not be suitable for another patient 
population group. More recently, population pharmacokinetics has also been defined as 
the design, execution and analysis of sparsely collected data (Aarons, 1991). 
Population pharmacokinetics is especially useful in patients where only one or two blood 
samples for drug assay can be obtained. In this case, population pharmacokinetic 
parameters can be used together with therapeutic drug monitoring programmes that apply 
Bayesian feedback techniques (Sheiner and Beal, 1982; Vozeh et al., 1981, 1985) for the 
adjustment of dosage regimens. A prerequisite for the satisfactory performance of this 
technique of drug dosage optimization is good estimates of the population parameter 
distributions. If these are accurate, then the performance of the Bayesian system is 
improved (\M1iting et al., 1986). 
Population pharmacokinetic parameters quantify population mean kinetics, inter- and intra-
individual kinetic variability, and measurement error (Sheiner and Beal, 1983). A 
knowledge of the magnitude of the inter- and intra-individual variability should enable one 
to place a certain level of confidence on the predicted dose or concentration. 
2.1.1. POPULATION PARANIElcR ESTIMATION IN PHARMACOKINEllC 
STUDIES 
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The most commonly used methods of analysing pharmacokinetic data are the Naive 
Pooled Data (Sheiner, 1984; Sheiner and Beal, 1981), Standard Two Stage (Sheiner and 
Beal, 1981) and the Nonlinear Mixed-Effects fv1odelling (NONMEM) methods. 
The NONMEM method has been studied in detail and is applied throughout this study. The 
NONMEM approach is currently considered to be the most satisfactory method for 
population pharmacokinetic data analysis (Sheiner et al., 1972; 1977). Wth the Naive 
Pooled Data method, the averaging procedure may mask the most appropriate model and 
allow a different model to be justified. No estimate of inter- or intra-individual variability is 
possible with this method (Sheiner, 1984; Sheiner and Beal, 1981 ). NONMEM estimates 
are as good as those of the Standard Two Stage method for mean parameters and for 
residual variability and they are considerably better for inter-individual variability (Sheiner 
and Beal, 1981). Other approaches include a nonparametric maximum likelihood method 
(Mallet, 1986), Bayesian methods (Racine-Poon and Smith, 1990), and variants of 
NONMEM (Amisaki, and Tatsuhara, 1988; Lindstrom and Bates, 1990). 
2.1.2. DESCRIPTION OF NONIVEM 
NONMEM is a sophisticated computer programme and complex data analysis technique 
that concentrates on the central tendency of the pharmacokinetic information, and it is 
designed for the calculation of population pharmacokinetic parameters from sparsely 
collected data (Aarons, 1991). This programme uses the extended least squares method 
to estimate population pharmacokinetic parameters. Nonlinear mixed-effects regression 
recognizes two sources of deviation from a predicted response, i.e. inter- and intra-
individual variation. 
The introduction of the NONMEM computer programme has facilitated the identification 
of factors which influence pharmacokinetics, and it has enabled the quantification of 
pharmacokinetic variability using routine clinical data (Sheiner et al., 1972). The ability of 
NONMEM to use routine clinical data is a distinct advantage compared with other methods 
of population pharmacokinetic data analysis. 
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NONMEM describes the available data in terms of a number of fixed and random effect 
parameters. Fixed effects are population average values of parameters such as dearance, 
volume of distribution, maximum metabolic rate and Michaelis-Menten constants. Random 
effects quantify the amount of pharmacokinetic variability which is not explained by the 
fixed effects i.e. inter- and intra-subject variability. The NONMEM programme 
simultaneously derives fixed effects and random effects - hence the name 'mixed-effects 
modelling'. The fixed effect parameters measure central tendency in the values of the 
parameters and/or a number of parameters which describe these mean values as 
functions of various patient characteristics or pathophysiology, e.g. age, sex, height, body 
mass, underlying pathology, and other influences on drug disposition such as concomitant 
drug therapy, smoking habits and alcohol intake. The inter-individual random effects 
parameter describes a probability distribution about a particular mean value for a fixed 
effect parameter. The difference between an individual's parameter and population mean 
values is referred to as the inter-individual variability. On the other hand, the intra-
individual random effects parameter explains all the sources of variability that cannot be 
accounted for on the basis of the fixed effects and the inter-individual variability. The intra-
individual pharmacokinetic variability involves the change in response of an individual to 
drug treatment with time. Examples indude inhibition or induction of metabolic elimination 
(changes in dearance), variable absorption due to intestinal flora or gut wall metabolism, 
diurnal variation due to circadian rhythms, assay error and model misspecification error. 
(Sheiner, 1984; Sheiner and Grasela, 1984; Vozeh et al., 1984). 
Data analyzed by NONMEM need not be from a homogeneous population since NONMEM 
can be used to determine the pharmacokinetic characteristics of specific patient 
subpopulations such as smokers, the elderly, patients with renal or liver impairment, and 
others. NONMEMs estimation of population parameters do not require the data to be 
restricted to special types of routine data such as those obtained only at steady state, or 
only at peak or trough, nor do estimates improve with such data. NONMEMs estimates 
do improve, however, when a data set is enhanced by the addition of many observations 
from many individuals. In addition, the number of samples per individual need not be the 
same. NONMEM is particularly useful when the data collection design varies considerably 
between individuals (Boeckmann et al., 1991). 
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Besides being used to develop a pharmacokinetic model, NONMEM is also used to 
develop a statistical model. The NONMEM approach uses a statistical model in which the 
individual patient's pharmacokinetic parameters are assumed to arise from a distribution 
which has a population mean and a particular quantifiable deviation from this mean. The 
emphasis is, therefore, shifted away from the individual patient to a system in which the 
population is treated as a unit of analysis, thus allowing the simultaneous analysis of data 
from all individuals in the study. Observations are pooled to characterise a central 
tendency for the population rather than the individual subject. Fewer samples are needed 
from each individual because the individual is no longer of central interest (Sheiner and 
Beal, 1983). 
Minimization of the NONMEM objective function is equal to twice the negative 
log-likelihood of the data (-21oglmax) which is equivalent to maximizing the probability 
(likelihood) of the data. Thus, the monitoring of changes in the minimum objective function 
(MOF) can serve as a statistical test to show which parameter values render the data most 
probable. The MOF is a goodness-of-fit statistic. Hypothesis testing is done by noting the 
changes in the MOF when 1 (reduced) or 2 (full) compartment pharmacokinetic models 
are fitted to the data. The difference in the MOF values obtained for the full versus the 
restricted models is approximately chi-square distributed, with degrees of freedom equal 
to the number of parameters set equal to a fixed value in the restricted model. This 
approach is used to estimate the significance of various patient characteristics, usually 
referred to as fixed effects or covariates, as predictors of pharmacokinetic parameters 
(Sheiner et al., 1977). 
NONMEM provides estimates of the standard errors for all parameters estimated and 
these can be used to construct confidence intervals for the parameter values, thereby 
allowing hypothesis testing. Under the assumptions of normality for distributions of random 
variables, NONMEM provides another method of testing hypotheses, the likelihood ratio 
test which is used in comparing models. The NONMEM computer package is supplied with 
a powerful scattergram subroutine which enables the user, for example, to plot variables 
against residuals and weighted residuals. One can detect trends which can subsequently 
be formally tested in an additional run (Vozeh et al., 1984). 
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Three input files are required to run NONMEM: (a) the data file which contains the 
concentration - time data, (b) the PRED file, a FORTRAN subroutine which defines the 
structural and variance models, and (c) the control file which details information on the 
organization of data in the data file, initial estimates of parameters with upper and lower 
limits, and instruction for presentation of results, tables and graphs. 
The NONMEM approach has proved itself in the human clinical setting (Vozeh et al., 1982; 
Grasela et al., 1983; Grasela and Sheiner, 1984; Grevel et al., 1988) and has accordingly 
been chosen for this study. 
2.2. CLINICAL PHARMACOKINETIC CONSIDERATIONS FOR PHENYTOIN 
The clinical pharmacokinetics of phenytoin has been reviewed in the literature (Aronson 
et al., 1992; Levine and Chang, 1990; Wnter and Tozer, 1986; Richens, 1979), and 
therefore only the basic concepts and essential information which have a bearing on this 
study are presented here. 
2.2.1. CHARACTERISTICS OF CAPACITY-UNITED NETAOOLJSM 
Detailed investigation has demonstrated the complex nature of phenytoin elimination, 
which can be explained in terms of the Michaelis-Menten equation (Gerber and Wagner, 
1972; Glazko et al., 1969). 
The Michaelis-Menten model was developed to individualize phenytoin therapy based on 
serum concentrations obtained at steady state. The Michaelis-Menten equation for the rate 
of phenytoin elimination ( dAe/dt) is represented as follows: 
d.Ae/ dt = Vm x CPss 
Km + CPss 
(1) 
where Vm is the maximum metabolic rate (mg/day), Km is the Michaelis-Menten constant 
(mg/I) and Cpss is the steady-state phenytoin concentration in serum or plasma (mg/I). By 
analogy with enzyme kinetics, the reaction velocity is the phenytoin elimination rate which, 
at steady state, is equal to the daily dose (Dodson, 1982). 
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From the steady-state serum concentration values, phenytoin pharmacokinetic parameters 
(Vm and Km) are determined in each patient to allow the calculation of dose (Ludden et 
a/., 1977). Vm is calculated using the following equation: 
Vm = S.F.R Km+ S.F.R 
CPss 
(2) 
where R is the dosing rate (mg/day), S - the salt form factor, and F the bioavailability 
factor. The other variables have been defined above. This method fixes Km to the 
population mean value and uses one Cpss - dosage pair to solve for Vm. This Vm value, 
the population mean Km, and the target serum concentration can be used to solve 







) (S) (F) 
where -r is the dosing interval. 
(3) 
Estimates of Vm and Km can also be obtained graphically if at least 2 reliable steady-state 
serum phenytoin levels at different daily doses are available (Ludden et al., 1977). Briefly, 
R {mg/day phenytoin sodium) is plotted on the y-axis against R/Cp55 on the x-axis. The 
y-intercept is the value of Vm and the slope is the negative value of Km. The graphic 
method is necessary only if at least 3 reliable steady-state serum phenytoin concentrations 
at different daily doses are available. Wien steady-state phenytoin concentrations are 
known for only 2 dosage regimens, there is no need to use the graphic method. Km could 
be calculated from the following equation: 
Km= (4) 
where Cp551 and Cp552 are the steady-state serum phenytoin concentrations obtained after 
doses 1 and 2 respectively, and R1 and R:z are the first and second dosing rates 
respectively. The Km value is substituted in equation 2 and Vm is calculated. N. this 
stage, the Vm and Km values specifically pertaining to the individual have been calculated. 
Now that estimates of the individual's Vm and Km are known, the appropriate dosing rate 
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required to produce a desired steady-state serum concentration can be predicted more 
accurately using equation 3 (Driessen et al., 1980; Ludden et al., 1976). 
If no estimates of Vm and Km are available for a particular patient as a result of having 
no Cp55-dosage pairs, then the population values of Vm and Km obtained from the 
literature are used. 
The serum phenytoin concentration that will be obtained at steady state (Cp55) on a 
particular dose can be calculated by rearranging equations 2 or 3 (Ludden et al., 1976): 
C _ Km x ( S) ( F) ( R) 
Pss - Vm - (S) (F) (R) 
(5} 
Phenytoin dosage regimens derived from individually calculated pharmacokinetic 
parameters (Vm and Km) have been shown to be superior to conventional regimens, 
more accurate and effective clinically without increasing the risk of toxicity. It has been 
shown that there is no significant difference between predicted and observed mean 
steady-state phenytoin concentrations using individual values of these apparent 
Michaelis-lVlenten parameters (Blain et al., 1981). 
The Michaelis-lVlenten model predicts that, when the serum phenytoin concentration is 
greater than the Km value and the dose of phenytoin is increased, the serum phenytoin 
concentration will increase disproportionately. This causes a nonlinear relationship 
between the maintenance dose administered and the resulting serum concentration 
(Richens and Dunlop, 1975a). The most important clinical consequence of this is that 
increments in dose need to be progressively smaller as the upper limit of the therapeutic 
range is approached. If this is not so, phenytoin intoxication is likely to develop. fos a 
result, there is a tendency among clinicians who have knowledge of Michaelis-Menten 
pharmacokinetics or the nonlinear pharmacokinetics of phenytoin to administer small and 
therapeutically inadequate doses (Rambeck et al., 1979). Conversely, a small decrease 
in phenytoin dose will result in a disproportionately large decrease in the serum phenytoin 
level. 
A large change in serum level after a small change in dose may reflect a low Km value. 
Careful adjustment of phenytoin dosage is necessary for all patients with low Km values. 
A low Km value indicates a high percentage of enzyme saturation operating at low serum 
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concentrations of phenytoin, and the risk of phenytoin accumulation on dosage adjustment 
increases as the body's maximum capacity to metabolize phenytoin is approached (Taylor 
et al., 1983). Wien serum phenytoin concentrations are well below the apparent Km, a 
linear relationship between dose and serum concentration exists in the lower part of the 
therapeutic range. 
Wien the rate of phenytoin administration exceeds the individual's Vm, accumulation of 
the drug is rapid and this further contributes to the sudden appearance of toxicity after a 
small increase in dose. In this case, the drug accumulates continuously and the serum 
concentration never reaches steady state (Chiba et al., 1980; Garrettson and Jusko, 
1974). Appreciation of the variability in the rate of phenytoin accumulation is extremely 
important for the pharrnacokinetic interpretation of serum phenytoin concentrations 
(Ludden et al., 1978). The time of onset of phenytoin toxicity is related to the magnitude 
by which the rate of phenytoin administration exceeds the Vm values (Garrettson and 
Jusko, 1974). A high Vm value should reduce the risk of drug accumulation. 
Km values may vary from 1.5to24 mg/I (Maweret al., 1974; Richens and Dunlop, 1975a). 
Mean values have been found to range from 2.3 to 9.4 mg/I. Rambeck et al. (1979) 
reported that Vm ranged from 155 to 818 mg/day, the mean being 355 ± 106 mg/day. A 
drawback of this study was that all patients received one or more other antiepileptic drugs 
in addition to chronic phenytoin therapy. Ludden et al. (1977) estimated individual 
Michaelis-Menten pharrnacokinetic parameters for phenytoin from two reliable steady-state 
serum concentrations resulting from different daily doses in 12 patients. They reported Vm 
and Km values of 8.53 (range 5.25 to 12.4) mg/kg/day and 8.42 (range 1.03 to 16.2) mg/I, 
respectively. Estimates of Vm and Km values obtained by other investigators are reported 
in Table 1 (page 13). 
Km and Vm vary substantially from person to person, but remain constant in the individual 
provided the pathological and physiological status of the patient remains stable (Rambeck 
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LITERATURE REVIEW OF Vm AND Km VALUES IN ADULTS AND 
CHILDREN 
Vm Km AGE NO.OF NO. ETHNIC NON-
(ng'I) (Yl1 PATIENTS OFR: GROUP MEM 
rrgday rrgkg Cp. 
day PAIRS 
7.5± 5.7± 20-39 26 - - No 
2.2 2.2 
6.6± 5.4 ± 40-59 32 
1.8 2.4 
6.0± 5.8 ± 6CH9 34 
1.9 2.3 
13.5 6.59 0.~3.0 42 432 Caucasian No 
10.93 6.82 4-6 28 
10.05 6.51 7-9 33 
8.25 5.69 10-16 32 
238± 20.4 ± 7.5± 0.67- 40 159 English No 
25.5 2.1 1.2 2.75 
542.2± 8.7± 9.4± 18-66 21 
37 0.7 2.3 
13.8 ± 4.1 ± 0.~3.0 34 236 Japanese No 
4.3 5.6 
11.2 ± 4.1 ± 4-6 24 
3.0 3.6 
9.5± 3.6± 7-9 24 
1.5 4.11 
8.0 ± 3.0± 10-16 22 
1.7 2.51 
499 2.307 2-76 66 174 Singa1X)l'e Yes 
Chinese 
10.9 <15 23 64 
8.05 >15 43 110 
17.9 ± 4.54± 0:'.:;1 9 - - No 
5.67 2.19 
12.0 ± 5.23± 1s:4 8 
2.33 2.09 
10.4 ± 3.85± 4'.:13 9 
3.68 1.63 
11.1 ± 5.69± 8:"::::12 14 
2.97 4.51 
7.85± 5.14 ± 12:'5:16 11 
2.31 4.08 
9.57± 7.15 ± 16:'5:22 7 
5.04 4.02 
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TAB£ 1: Continued 
Vm Km AGE NO.OF NO. ETHNIC NON-
REFERENCE (nql} (yry PATIENTS OF R: GROUP MEM 
rrgt'ay rrgkrj Cp. 
my PAIRS 
Eacie et al., 8.1 5.8 Adults 21 - - No 
1976 12.5 5.3 Children 15 
Grasela et al., 415 5.93 5.7 Adults European Yes 
1983 
355 6.53 5.7 29.5± 178 385 German 
15.2 
208 9.08 2.2 6.05± 104 236 Japanese 
3.94 
138 11.69 3.2 1.33± 40 159 English 
0.52 
Mav.er et al., 435 0.8- 3.8 15 No 
1974 13.2 
11/iller et al., 455 6.5 3.43 11-60 37 100 Black Yes 
1987 South 
Africans 
RarriJeck et al., 355± 6.01 ± 6-n 127 German No 
1979 100 3.71 
Tayla et al., 550± 7.1 ± 7.14± 43.2 ± 30 - American No 
1983 168 2.2 4.6 18.9 
Vazeh et al., 7.22 4.44 22-78 49 124 S'Mss Yes 
1981 
YIJ<awa et al., 325 5.42 2.41 0.6-71.1 101 - Japanese Yes 
1990 
N. lower serum concentrations of phenytoin the decline in serum concentration is a 
first-order process, but at higher serum concentrations, the decline in serum concentration 
approximates more dosely a zero-order process, suggesting saturation of phenytoin 
metabolizing mechanisms (Arnold and Gerber, 1969). The decline from a toxic level is at 
first slow, but it becomes more rapid as the concentration falls. Thus, a gradual change 
from zero- to first-order kinetics occurs as the concentration decreases. The time of 
decline of the serum concentration to control values varies from 1 to at least 6 days 
(Loeser, 1960). 
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2.2.2. PARAl..l.EL MCHAEUS-IVENTEN AND FIRST-ORDER EUMNATION 
Since virtually all drugs are likely to have at least a small parallel first-order pathway, an 
appropriate expression for the rate of phenytoin elimination would be: 
I Vm X Cp 55 ( l ) d.Ae dt = + C X Cp55 
Km+ Cpss 
{6) 
where Cl is the clearance for the linear pathway(s). 
PJ. low concentrations relative to Km, the elimination of the drug is first-order with constant 
clearance, i.e. 
d.Ae/ dt = (: + CL) x Cp {7) 
Nonlinear pharmacokinetic behaviour will be most evident when concentrations are close 
to or above the Km value. PJ. high concentrations relative to Km, the rate of elimination 
approaches 
d.Ae/dt - Vm + Cl X Cp {8) 
PJ. very high concentrations, the rate of elimination may again be first-order when the rate 
of elimination via the linear pathway greatly exceeds the Vm value for the saturable 
pathway: 
d.Ae/dt - Cl X Cp {9) 
Even a minimal linear pathway can have a marked effect on predicted steady-state 
concentrations at high dosing rates (Ludden, 1991). Unchanged phenytoin is excreted in 
the urine in amounts ranging from 1 to 5% of the dose (Butler, 1957; Glazko et al., 1982). 
Bochner et al. ( 1973) reported that the renal clearance of phenytoin ranged from 0.18 to 
1.381/h. This would involve a total urinary loss of approximately 15 mg/day of phenytoin. 
This is small compared with an average total clearance of approximately 25 I/day at a 
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concentration of 15 mg/I. However, it is possible that the total of all parallel linear 
pathways, including the minor metabolic ones, could be much greater. N. rates of 
administration approaching Vm, renal elimination of unchanged phenytoin can significantly 
influence the steady-state serum phenytoin concentration and the time required to achieve 
steady state. AA equation which takes parallel Michaelis-Menten metabolism and 
first-order kinetics of phenytoin into account has been described (Ludden et al., 1978; 
Ludden, 1991). This equation predicts steady-state phenytoin concentration as follows: 
[ 
~ 2 l {10} Cp = _ _! ( Vm + Km _ _B__) _ ( Vm + Km _ _B__) + 4 . R. Km 
ss 2 Cl Cl Cl Cl Cl 
where Cl is the first-order (linear) clearance value for phenytoin in I/day. The population 
pharmacokinetic parameters used in this model, i.e. Vm, Km and Cl, have not been 
quantified. This model, as far as can be determined, has also not been clinically 
validated. 
Computer simulations have shown that the time required to reach a particular fraction of 
the steady state is a function of the individual pharmacokinetic parameters, the rate of 
administration (the higher the dose, the longer the time required to achieve a percentage 
of steady state), and the magnitude of the parallel first-order elimination pathway (Ludden 
et al., 1978; Wagner, 1978). Even a first-order pathway that is only 1 to 2% of the 
maximum clearance (which occurs at low concentrations) can be an important determinant 
of steady-state concentration and cumulation rate when serum concentrations are high 
(Ludden, 1991). 
2.2.3. ALTERED PHARMACOKINETICS 
A wide variation in the disposition of phenytoin occurs. This may be due to differences in 
liver drug-metabolizing activity, in the plasma concentration of phenytoin at which enzyme 
induction may occur or in the level at which rate-limiting enzyme reactions become 
saturated (Arnold and Gerber, 1969). 
Demographic factors such as age, height (Houghton et al., 1975), weight (Eadie et al., 
1973; Hooper et al., 1974; Houghton et al., 1975; Mawer et al., 1974), body surface area 
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(Barot et al., 1978; Sherwin, 1974) and sex (Eadie et al., 1973; Hooper et al., 1974; 
Houghton et al., 1975) have been studied with regard to the serum phenytoin 
concentration. A number of factors and conditions that have been reported to alter the 
pharmacokinetics of phenytoin are discussed below: 
2.2.3.1. AlJTO-INDUCllON 
This phenomenon occurs with phenytoin and has been reported in mice (Gerber and 
Arnold, 1969) and humans (Miller et al., 1989a; Yuen et al., 1983). It may result in 
therapeutic failure, and an upward adjustment in dose may be required. Reynolds et al. 
(1981) reported that declining phenytoin levels on a constant dose occurred in 39% of 
patients during the first few months of therapy. Although there was no evidence of poor 
compliance in this study, they could not entirely rule out this possibility. 
2.2.3.2. HEPATIC DISEASE 
In hepatic disease there is an increase in the unbound fraction of phenytoin. This may be 
due to a decrease in the serum albumin concentration or a decrease in the protein 
binding of phenytoin. The latter may be due to elevated levels of bilirubin, which 
competitively displaces phenytoin from its protein binding sites. In severe hepatic failure, 
a total serum phenytoin concentration that is apparently either subtherapeutic or 
therapeutic may actually be associated with phenytoin toxicity. In this context, effective 
antiepileptic therapy may be achieved with total phenytoin concentrations that are lower 
than the normal therapeutic range (Hooper et al., 1973). 
2.2.3.3. RENAL DISEASE 
In the presence of uraemia the percentage of bound phenytoin is reduced (Hooper et al., 
1973). This is most probably due to a change in the conformation of the albumin 
molecule, rather than a decrease in albumin concentration. An altered metabolic 
disposition of phenytoin in uraemia has also been suggested (Letteri, 1971). The higher 
free serum levels of phenytoin result in a shorter half-life (Odar-Cederlof and Borga, 1974) 
and this may necessitate more frequent dosing to prevent wide fluctuations in serum 
phenytoin concentrations. The therapeutic range may decrease in uraemia to 4-10 mg/I. 
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No change in the daily dose of phenytoin may be necessary in uraemic patients despite 
the lower total serum concentrations. In nephrotic syndrome the reduced protein binding 
of phenytoin should be taken into account. 
2.2.3.4. FEBRILE lu.NESS 
During febrile illness (body temperature> 38.3° C for more than 24 hours), the phenytoin 
concentration in blood decreases by more than 40% from the pre-illness baseline. Neither 
phenytoin binding nor absorption is altered by the febrile illness, so the most probable 
cause of the fall in phenytoin levels was considered to be induction of hepatic oxidative 
enzymes (Leppik et al., 1986). 
2.2.3.5. INFECTIOUS IVIONONUCL.EOSIS 
One case report on a hospitalized patient indicated a marked decrease in phenytoin levels 
in a 22-year old woman. It was suggested that an increase in the capacity of the phenytoin 
hepatic oxidation pathway might have occurred during infectious mononudeosis (Leppik 
et al., 1979). 
2.2.3.6. DIABE I ES NEWlUS 
Steady-state phenytoin concentrations were shown to be significantly lower in type 1 and 
type II diabetic patients compared with controls. The Vm and Vm/Km of phenytoin were 
significantly increased in type 1 diabetics. Vm was unaltered in type II diabetics, but the 
Vm/Km was higher. Protein binding of phenytoin decreased in both groups (Adithan et al., 
1991). 
2.2.3.7. CRITICALLY ILL AND HEAD TRAUMA PATIENTS 
Preliminary data have suggested that phenytoin systemic clearance increases during initial 
therapy in critically ill (Boucher et al., 1988) and head trauma (Bauer et al., 1983) patients. 
This may be a consequence of changes in protein binding, induction of metabolism, or 
influence of stress on hepatic metabolic capacity (Boucher et al., 1988). 
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2.2.3.8. AGE 
It has been suggested that age plays an important role in determining the phenytoin 
dosage required, particularly in paediatric patients (Dawson and Jamieson, 1975), who 
have a higher rapid metabolic rate. 
2.2.3.8.1. PRETERM NEONATES, NEVVB:>RNS, INFANTS AND CHILDREN 
Preterm neonates younger than 2 weeks have a prolonged half-life because of a larger 
volume of distribution (1.2 I/kg) and incomplete maturation of the hepatic enzymes. 
Children 6 months to 6 years of age have a higher body clearance and a shorter 
elimination half-life than adults. The daily dose in mg/kg of phenytoin from 2 weeks to 6 
years of age is generally higher than in neonates, older children and adults because of a 
higher basal metabolic rate. In this age group, a shorter dosing interval is required to 
minimize large fluctuations in serum phenytoin concentrations (Dodson, 1982; Sherwin et 
al., 1974; Svensmark and Buchthal, 1964). 
2.2.3.8.2. THE ELDERLY 
The elderly have a lower body clearance of phenytoin compared with adolescents and 
younger adults (Bach et al., 1981; Hayes et al., 1975; Houghton et al., 1975; Sherwin et 
al., 1974). The influence of age on the dose and plasma concentrations of phenytoin was 
studied in 223 adult patients (Sherwin et al., 1974). There was a marked increase in 
plasma phenytoin concentration in female patients over 65 years of age (when doses were 
normalized to 5.1 mg/kg/day) compared with women under 45 years of age receiving 
equivalent doses. 
2.2.3.9. GENETIC FACTORS 
Genetic variation is considered to be responsible for individual differences in the rate of 
phenytoin metabolism (Andreasen et al., 1973; Kutt, 1971). The inter-individual variation 
in the saturability of the hydroxylase enzyme is genetically determined. The actual 
proportion of the drug which is metabolized by liver enzymes is determined by the 
prevailing steady-state serum phenytoin concentration (Houghton and Richens, 1974). It 
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seems likely that genetic differences are more important in determining a patient's 
steady-state plasma phenytoin concentration than age, weight and height (Houghton et 
al., 1975). 
The treatment of patients of different ethnic groups may create problems if clinicians are 
unaware of kinetic differences. From studies of negroes and Ghanaians compared with 
Caucasians (Andoh et al., 1979; Arnold and Gerber, 1969), and black South Africans 
(Buchanan et al., 1977), it is recognized that phenytoin may cause such problems. 
Inter-ethnic and inter-phenotype differences among Ghanaians and Caucasians in the 
metabolic hydroxylation of phenytoin have been found (Andoh et al., 1979). 
A pronounced difference in the mean plasma half-life of phenytoin in Caucasian (18.5, 
range 7 - 42 hours) and negro (26.5, range 11.5 - 38.5 hours) males was found, although 
the ranges did overlap (Arnold and Gerber, 1969). Haerer and Grace ( 1969) reported that 
the mean serum phenytoin concentration in white patients (8.6 mg/I) was lower than that 
in negro patients (10.3 mg/I). \/\hie there was a small difference in the mean weights 
between these groups, this did not sufficiently account for the differences in the mean drug 
levels. 
Phenytoin disposition was studied in Greenland Eskimos and in Caucasian Danes in order 
to discover possible ethnic differences in pharmacokinetics. The total body clearance of 
phenytoin per kg body weight was nearly twice as high in Eskimos, irrespective of the 
place of residence, diet or sex, compared with the Danes. The volume of distribution was 
larger in the Eskimo group but protein binding did not differ. The reason for these 
differences is not clear, but the results emphasize that ethnic differences in 
pharmacokinetics can be of significance (Kromann et al., 1981). In another study of 
Eskimo patients from Greenland (Dam et al., 1977), the dose/plasma concentration ratio 
for phenytoin was higher in this ethnic group than in Danes treated with the same dosage. 
Furthermore, the 24-hour urine samples of the Greenlanders contained more 
5-(p-hydroxyphenyl)-5-phenylhydantoin than that of the Danes, indicating more rapid 
metabolism of phenytoin in Greenlanders. 
Kutt et al. (1964) were the first to describe a group of individuals who apparently had an 
inherited defective ability to oxidise phenytoin. Subsequently, a genetically determined 
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polymorphism of drug oxidation was described which influences the ability to oxidise a 
number of drugs, including phenytoin (Sloan et al., 1978). A family with an inheritance of 
phenytoin hypometabolism has been described by Vasko et al. (1980). 
2.2.3.10. GENDER 
\/\bmen receiving the same daily dose of phenytoin as men had lower mean serum 
phenytoin concentrations (Gallagher and Baumel, 1971; Houghton et al., 1975; Sherwin 
et al., 1974; Travers et al., 1972). In the study by Houghton et al. (1975) the difference 
was not statistically significant. Other investigators have suggested that gender itself does 
not alter the relationship between plasma phenytoin concentration and dose in adults or 
children (Eadie et al., 1973; Galdames et al., 1980; Hooper et al., 1974). Richens (1975) 
found that after allowing for weight (women were lighter than men), women had slightly, 
but not significantly, lower serum concentrations. No marked differences in plasma protein 
binding of phenytoin between the sexes were found (Lunde et al., 1970) 
2.2.3.11. PREGNANCY 
Serum phenytoin levels decrease during pregnancy and increase in the postpartum period 
(Lander et al., 1977). Pregnancy is associated with altered phenytoin absorption or 
metabolism or both (Lander et al., 1984), and periodic measurement of serum phenytoin 
concentration is necessary when managing a pregnant epileptic patient (Kochenour et al., 
1980; Levy and Yerby, 1985). Ezquer et al. (1992) reported that Vm during pregnancy 
was barely modified while the Km decreased. 
2.2.3.12. POSlURE 
An average increase of 10% in total plasma phenytoin concentration caused by standing 
for 45 minutes has been demonstrated (Albalan et al., 1990). 
22 
2.2.3.13. OODY SURFACE AREA 
Barot et al. (1978) found that dosage requirements correlated most strongly (r = 0.57, p 
< 0.001) with body surface area. This relationship (approximately 200 mg/day per m2) 
accounted for about one-third of the total dosage variance. A limitation of this study was 
that only 3 of the 90 patients studied were receiving phenytoin monotherapy. 
2.2.3.14. MISCELLANEOUS FACTORS 
Other conditions in which altered pharrnacokinetics of phenytoin have been reported are 
extensive bums, cystic fibrosis, AIDS and malnutrition. All influence the pharrnacokinetics 
of phenytoin as a result of reduced protein binding of phenytoin (Bauer et al., 1983; 
Boucher et al., 1988; Ehmebo et al., 1971; Ehmebo and Odar-Cederlof, 1975; Perrucca, 
1980; Toler et al., 1990). 
2.2.4. FACTORS INFWENCING Vm AND Km VALUES 
Blain et al. (1981) estimated the Vm and Km from 159 dose-serum concentration pairs in 
English children (40 patients, aged 8-33 months) and adults (21 patients, aged 18-66 
years) and found that Vm {mg/day) was significantly greater in adults than in children, but 
the apparent Km was similar in children and adults. In relation to body weight (mg/kg/day), 
however, the Vm was significantly greater in children than adults. The Vm and Km values 
were estimated using the method of Mullen (1978) and Ludden et al. (1977). Limitations 
of this study were that it did not investigate differences in Vm and Km within the wide 
range of ages in the adult patients. This study also did not control for gender. The merit 
of this study was that patients were receiving phenytoin monotherapy. The plasma 
.concentrations of phenytoin reported were actually adjusted saliva concentrations and this 
created uncertainty about the mean value of Km for the data set. 
Chiba et al. (1980), in a retrospective study, estimated Vm and Km values from 385 
dose-serum concentration pairs in 104 Japanese paediatric patients aged 0.5 to 16 years. 
Their results indicated that Vm is inversely related to age but that there is no relationship 
between age and Km. The Vm in mg/kg/day decreased from a mean value of 13. 8 to 8. 0 
as age increased from 3 years to more than 10 years. The method of Ludden et al. ( 1977) 
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was used to estimate the values of Vm and Km. A drawback of this study was that only 
17 of the 104 patients were taking phenytoin as the only anticonvulsant. Subsequently, the 
same authors (Chiba et al., 1980a) published a paper on the same patients in which they 
stated that Km tended to increase and become more variable as the number of 
co-administered anticonvulsants increased. This made the previous results questionable. 
Rambeck et al. ( 1979) studied retrospectively 127 German patients aged 6-72 years who 
were receiving long-term phenytoin therapy. They found that Km was independent of age 
and body surface area, but Vm correlated positively with both. This study, however, did 
not control for gender. A further limitation of the study was that in addition to phenytoin, 
one or more anticonvulsant drugs (phenobarbitone, primidone, carbamazepine, sodium 
valproate, succinimides or benzodiazepines) were prescribed. 
Grasela et al (1983) re-analysed retrospectively the phenytoin data of Blain et al. (1981), 
Chiba et al. (1980) and Rambeck et al. (1979) using NONMEM. The influence of age, 
gender, ethnicity, height and weight on Vm and Km were investigated. Their results, 
contrary to some of the initial condusions, showed that Vm was not influenced by 
ethnicity, gender, height or age, but was influenced by weight; a nonlinear function of 
weight, (weight)06, was used to reflect this relationship. Km, on the other hand, was 43% 
lower for patients under 15 years of age than for older patients. Ethnicity was shown to 
influence the Km value, as the Km for Japanese patients was 23% lower than for 
European patients. The apparent effect of age on Km, especially in the Europeans, may 
be in part due to the uneven distribution in age between the age groups in the patients 
from the different countries. In the Japanese group the majority of patients were under 
15 years of age, but in the Europeans, those under 15 years were mainly from England 
and those older than 15 years mainly from Germany. The estimates of Vm and Km values, 
as reported by Grasela et al. (1983), were lower than those reported in the original 
studies. The assumptions made regarding compliance and the absence of any effect of 
other co-medication limit the confidence that can be placed in the Vm and Km estimates. 
Bauer et al., (1983) demonstrated in 135 Caucasian paediatric patients that Vm values 
were significantly different for different age groups (0.5 - 3; 4- 6; 7 - 9 and 10- 16 years), 
but not the Km values. Linear regression analysis of Vm against age revealed a significant 
dedine in Vm with increasing age. The plotting of Km against age showed a poor 
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correlation and large variability. No differences were found in either parameters between 
boys and girls in each age group. Patients received phenytoin as their only anticonvulsant 
therapy. The results of Bauer et al. (1983), in comparison with those of Chiba et al. (1980), 
showed that for each age group, the Km values (mg/ml) were higher in Caucasian children 
(5.69 - 6.59) than in Japanese children (3.0 - 4.1 ). The Vm values did not differ 
substantially between the two ethnic groups when like age groups were compared. Bauer 
and Blouin (1982), in a similar study, investigated the influence of age on phenytoin 
kinetics in adult epileptics. They reported Vm values for 3 age groups: 7.5 ± 2.2; 6.6 ± 
1.8; and 6.0 ± 1.9 mg/kg/day for the 20 to 39, 40 to 59 and 60 to 79-year-old subjects, 
respectively. Values of Vm for the geriatric patients were substantially lower than those 
for the younger adults (20 to 39 year olds, p < 0.05). As a result, it was calculated that the 
geriatric group would require an average of 21 % less phenytoin daily than the younger 
adults to maintain a steady-state concentration of 15 mg/I. However, the Km values did 
not appear to be influenced by age. The mean values for Km ranged from 5.4 to 5.8 mg/I. 
No gender difference was noted for Vm and Km. 
Dodson (1982) reported Vm and Km values for phenytoin in 54 children, of whom 39 
received other drug therapy in addition to phenytoin. The ethnic background was not 
reported. The mean Vm values declined with increasing age, while mean Km values 
remained nearly constant. The Km was influenced primarily by drug interactions. These 
results of the relationship of Vm and Km with age were similar to those of Bauer et al. 
(1983). Both studies used linear regression analysis to study these relationships. 
Chan and Lee ( 1990) studied retrospectively the population pharmacokinetics of phenytoin 
in 66 (43 > 15 years and 23 < 15 years) epileptic Singapore Chinese children and adults. 
Using NONMEM, they found that there were no age- or gender-related effects on Vm or 
Km. Vm was estimated to be 30.72 mg.kg-0 656 and Km 2.307 mg/I. They reported that the 
Km value obtained was much lower than those reported in studies of European patients. 
Vm was influenced by mass (p < 0.001) and the relationship between the two variables 
was nonlinear, as had previously been reported by Grasela et al. (1983). The estimate of 
the power parameter of mass for Chinese patients (0.656) was similar to that of 0.625 
obtained by Grasela et al. ( 1983). In another study, Lee and Chan ( 1981) reported that the 
low serum phenytoin versus daily dose ratio obtained in Chinese paediatric patients 
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compared with that obtained in other population groups could be due to ethnic differences 
e.g. a fast rate of hydroxylation of phenytoin. 
The retrospective study of Taylor et al. (1983) yielded no significant correlation between 
patient physical data (age, sex, weight, body surface area) and pharmacokinetic values 
of Vm and Km. Twenty of the 69 patients received other anticonvulsants. The study was 
limited by the small number of patients. The method of Ludden et al. (1977), with the 
Bayesian forecasting technique, was used. 
From this literature review, it is dear that most of the Vm and Km values reported in the 
literature were derived from retrospective studies and routine data and are not precise 
(W,iting et al., 1986). The information in the literature is also conflicting. The method of 
analysis also has a significant influence on the results (Grasela et al., 1983). Wlether, and 
to what extent, ethnicity, gender, age, mass, body surface area and smoking influence the 
Vm and Km values of South Africans requires investigation in a controlled and prospective 
manner. 
Table 1 (page 13) presents a literature review of studies reporting Vm and Km values in 




/ls this study was the first pharmacokinetic service of its kind to be established in the 
Western Cape, a detailed description of the procedures involved in this service is given. 
3.1. SELECTION OF HOSPITALS 
The hospitals were selected on the basis of the following criteria: the size of the hospital 
(i.e. number of patients attending the hospital for all ailments), the existence of an epilepsy 
clinic (club), and day of the week on which the epilepsy clinic was usually held. The 
hospitals were chosen so that a pharmacokinetic consulting service could be offered by 
the investigator every day with minimal interference with the regular epilepsy clinics held 
at some of the hospitals. The following hospitals and institutions were chosen for this 
study: the Heideveld, Guguletu, Khayelitsha, Dr. Abdurahman, Lotus River and Elsies 
River Day Hospitals, the Neurology Outpatient Clinic at Groote Schuur Hospital, the South 
African National Epileptic League Protective \/Vorkshop (SANEL) and Betel School for 
Epilepsy. All of the clinics were situated in the Western Cape. It was arranged that the 
smaller clinics, i.e. Dr. Abdurahman Day Hospital, SANEL and Betel School for Epilepsy, 
would take place on the same day as a larger clinic. The Day Hospital Organization 
serving the greater Cape Town area consists of health care centres for outpatients, 
providing primary health care to lower-income groups not covered by medical aid (health 
insurance). Patients were registered after confirmation of the diagnosis by and referral 
from a neurology department. Although this was a multi-site study, only one clinic per 
week was initially offered to identify and minimize problems in the clinical pharmacokinetic 
consulting service. 
3.2. INITIATION OF CLINICAL PHARMACOKINETIC CONSULTING 
SERVICE 
Before commencing the service at some of the hospitals, the availability of patients for 
enrolment in this study was determined. In order to assess patient numbers, the 
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pharmacists working at the dispensary were requested to list all patients taking phenytoin 
as the only anticonvulsant. They were also requested to list respective ages and folder 
numbers so that the patients could be traced, if necessary. This was usually done two to 
three months before the planned commencement date of the pharmacokinetic service. 
Before the initiation of a dinical pharmacokinetic consulting service for phenytoin at the 
various hospitals, a briefing on phenytoin pharmacokinetics and the proposal of this study 
was presented to the doctors, nurses and pharmacists at the respective hospitals. AA 
information brochure written by the investigator and entitled 'Pharmacokinetic guidelines 
for oral phenytoin use' (Mnexure 1) was provided at this lecture. 1\/lonotherapy for the 
treatment of epilepsy was encouraged. A continual, informal in-service education 
programme was provided throughout this study. The investigator requested that only one 
doctor be responsible for the dinic at each hospital so that better communication might 
exist between the doctor and the investigator. A starting date for the service was usually 
arranged a month after the presentation of the project to the hospital staff. This was to 
allow the doctors and primary health care nurses sufficient time to make appointments and 
to inform the patients of the service. 
Before the initiation of the pharmacokinetic services, the two nurses who were employed 
at separate dinics to assist the investigator, were trained in phenytoin usage and 
encouragement of patient compliance. Special emphasis was placed on explanation to the 
patient of how to fill in the patient diary. 
Certain of the guidelines published by Robinson et al. (1984) on how to establish a 
pharmacokinetic consulting service for ambulatory patients were followed. 
3.3. PATIENT SELECTION 
The patients were chosen consecutively with regard to the time of presentation at the 
hospital, and it was assumed that they represented typical patients receiving phenytoin. 
All ambulatory patients routinely taking phenytoin as the only anticonvulsant were 
screened for entry into the study. Of these patients those who satisfied the entry criteria 
were selected for this study. All patients were seen personally by the investigator and 
treated on an outpatient basis. 
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3.3.1. ENTRY CRITERIA 
All patients satisfied the following entry criteria: 
(a) compliant with drug therapy and able to understand the instructions 
(b) above 15 years of age 
(c) no hepatic or renal disease 
( d) no evidence or history of alcohol or drug abuse 
(e) no major depressive or psychiatric diseases 
(f) no intake of medicines that might interfere with phenytoin serum levels within two 
weeks of entering the study 
(g) taking phenytoin routinely as the only anticonvulsant 
(h) taking phenytoin by oral administration only 
(i) not pregnant or breastfeeding 
0) subjective judgement of the likelihood that the patient would comply with the 
treatment protocol, for example, by assessment of the patient's attitude to 
treatment, and 
(k) a constant weight during the treatment period under consideration. 
3.3.2. EXCWSION CRITERIA 
It was decided in the study plan that patients would be withdrawn from the study if they: 
(a) were non-compliant with the prescribed dosage regimen 
(b) developed renal, hepatic, major depressive or other psychiatric diseases 
subsequent to entering the study 
(c) showed evidence of alcohol or drug abuse subsequent to entering the study. 
Consumption of alcohol more than thrice weekly and of more the 750 ml of beer 
or 125 ml of spirits was regarded as alcohol abuse. Ally habit-forming drug not 
taken for therapeutic reasons was regarded as drug abuse. 
( d) became pregnant 
(e) developed significant adverse effects to the medication during the course of the 
study 
(f) developed abnormalities of laboratory examinations which were judged to be 
clinically significant; namely, liver and renal function tests, and full blood count 
(g) failed to respond to treatment 
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(h) took other medications that might interfere with phenytoin pharmacokinetics 
subsequent to entering the study, and 
(i) failed to adhere to the protocol and reduced patient exroperation. 
A full account was made of each withdrawal from the study. 
3.4. LA8)RATORY TESTS 
Laboratory tests were performed with special attention to liver (alkaline phosphatase, 
alanine transaminase, aspartate transaminase, glutamyltransferase, total bilirubin) and 
renal (serum creatinine and urea) function tests. Plasma albumin concentration 
determinations were also done. These tests were performed for all patients at SANEL and 
Groote Schuur Hospital as they were required by the neurologist. PJ. the other clinics these 
laboratory tests were especially performed for geriatric patients and those who previously 
abused or were suspected of abusing alcohol. Laboratory tests were also done when 
there was difficulty in interpreting the serum phenytoin concentrations. 
3.5. THE CLINICAL PHARMACOKINEllC CONSULTING SERVICE 
3.5.1. DOCTOR-PATIENT CONSULTATION 
It was requested that the doctor screen the patient initially and that if he/she satisfied the 
inclusion criteria that the patient be referred to the investigator for a pharmacokinetic 
consultation. For a new patient, the doctor prescribed the 'standard' dose of phenytoin, if 
indicated, and referred the patient to the investigator for counselling. 
3.5.2. NURSE - PATIENT INTERVIEW 
PJ. Guguletu and Elsies River Day Hospitals the patients were usually screened initially by 
the primary health care nurses before being referred for a pharmacokinetic consultation. 
The primary health care nurses were asked to refer all patients who were taking phenytoin 
as the only anticonvulsant. If the patient attended the hospital on a day other than the 
fixed day of the week designated for the epilepsy clinic, an appointment was made for the 
patient by the doctor or primary health care nurse to see the investigator. 
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explained. The hospital folder was carefully perused for information such as the seizure 
type, the cause of the seizures, present dosage regimen and adverse effects. Medical 
records were, however, usually incomplete. All information collected was confirmed, where 
possible, by the hospital records. If the seizure type was not recorded in the hospital 
folder, an attempt was made by the investigator to dassify the seizures into generalized 
tonic-clonic, tonic, myoclonic, simple or complex partial, or partial seizures with secondary 
generalization. If the seizures were due to an identifiable reason then the date of such 
cause ( e.g. head injury due to a motor vehide accident or assault) was noted. The date 
of the first seizure (if known) and/or the approximate duration of the epilepsy were also 
recorded. The patient was asked to describe the seizure, and if a family member or friend 
was present he/she was asked to describe the seizure/s. Much time was spent acquiring 
information regarding the frequency of the seizures. The number of seizures, if any, 
experienced in the past week, month, 3 months and year was recorded. The patient's 
statement on seizure frequency was compared with the doctor's or with the primary health 
care nurse's notes in the hospital folder. AA attempt was made to count the number of 
seizures experienced during the past year, as reported in the folder. The prescription chart 
was checked to determine if any other anticonvulsant besides phenytoin had previously 
been used and whether the dose of phenytoin had been different from the present dose. 
Previous results of serum phenytoin concentrations reported in the folder were not used 
in this study as compliance in the taking of phenytoin was not known. Drug compliance 
was carefully evaluated by questioning the patient. The compliance status was 
documented as follows: 'daims compliant', 'poor compliance' or 'tendency to run out of 
medication'. If the patient had run out of phenytoin, the length of time without medication 
was documented. Questions such as 'when last did you forget to take your tablets?', 'do 
you sometimes forget to take your tablets?', 'do you still have tablets left?' or 'when did 
you finish your tablets?' were asked. A careful inquiry into adverse effects was made and, 
if applicable, the frequency and severity of the adverse effects were noted. 
The patient was given a diary designed by the investigator (Mnexure 3) to record when 
phenytoin was taken, the occurrence of seizures and the date of the next appointment. 
The cover of the diary contained the following information: name and telephone numbers 
of the investigator; name, address and folder number of the patient, and the name of 
hospital attended by the patient. The diary was valid for 3 months and those particular 
months were written in the diary by the investigator. The patient was asked to make a 
cross for every 100 mg tablet, a filled circle for every 50 mg tablet (both manufactured by 
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Lennon Pty Ltd), and an empty circle for half an Epanutin lnfatabR (manufactured by 
Warner-Lambert Pty Ltd) taken on a daily basis in the appropriate column (morning, 
afternoon or night) corresponding with the date when the tablets were taken. The patient 
was also asked to make a cross for every seizure that occurred and to record any 
side-effects or comments corresponding with the date when the events occurred. The next 
appointment, which was usually a month later, was recorded by circling the date in the 
diary and by writing 'appointment' in the appropriate column. This date was also filled in 
the hospital's appointment card. Patients were usually consulted once a month, except 
for selected patients who attended more frequently. Poorly controlled patients were 
reviewed more frequently, either to obtain a duplicate blood sample for phenytoin 
concentration or to adjust the dose. If a possibility existed that the patient might not be 
able to fill in the diary correctly, then the patient was requested to return a week or two 
later to check on how the diary was being filled in. The importance of filling in the diary 
accurately was stressed. It was requested that the diary and the phenytoin tablets be 
brought to every visit at the hospital. This was written prominently on the cover of the diary 
as a reminder. The patient was counselled about phenytoin use and this advice was 
reinforced by written instructions in the language (English, Afrikaans, Xhosa) of his/her 
choice. A copy of these instructions in English is given in Annexure 4. 
The initial dose was decided empirically by the attendant doctor. In most cases, the dose 
was prescribed by a doctor in a neurology department at a tertiary hospital and repeated 
by the doctor at the day hospital. No attempt was made by the investigator to influence 
the initial dose prescribed. 
It was stressed to the patient that if phenytoin was being taken once a day, then the 
missed dose ought to be taken as soon as remembered, as long as it was taken at least 
12 hours before the next dose. If the missed dose was remembered within 12 hours of 
the next dose, then the missed dose was to be omitted altogether. It was also stressed 
that double the daily dose was never to be taken as a single dose. If phenytoin was taken 
twice a day and the morning dose was missed, then the missed dose was to be taken as 
soon as remembered or with the evening dose. The patient was advised that this might 
lead to sid&effects; if this occurred the investigator was to be informed at the next visit 
and the daily dose never to be taken as a single dose again. If a dose was missed at 
night, then it was to be taken with the morning dose the following day. If phenytoin was 
taken thrice daily and the morning dose was missed, then it was to be taken in the 
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afternoon; if the afternoon dose was also missed, then the missed doses were to be taken 
with the evening dose. If the evening dose was missed, then it was to be taken with the 
morning dose the following day. If any signs or symptoms of transient toxicity were 
observed with the dosage regimens, the patient was requested not to take the missed 
dose within four hours of the next dose. In order to darify the patient's understanding of 
the dosage regimen, he/she was asked to explain what was to be done in the event of 
a missed dose. The patient was also asked to show how he/she would fill in the diary 
every day, especially in the case of a missed dose. The patient was also briefly advised 
about the other information contained in the brochure (Annexure 4). 
Patients and their escorts were informed that a few dosage adjustments might be 
necessary during the course of therapy to establish an effective dose with minimal 
side-effects. In this way, the patient and relatives were prepared for later changes without 
doubting the competence of the investigator, if change became necessary. The patient 
was also informed that the full therapeutic response of phenytoin might only be obtained 
four to six weeks after the initiation of therapy or following a change in dose. Every effort 
was made to secure the understanding and confidence of the patient and the family and 
thus improve the chance of obtaining successful seizure control. Adequate time was spent 
with the patient to ensure the best understanding of the therapy. The idea that medication 
controls rather than cures seizures was strongly reinforced. Patients and their families 
were educated about epilepsy and the signs and symptoms of phenytoin toxicity, and 
were requested to contact the investigator if toxicity occurred. The importance of drug 
compliance was stressed, and patients were encouraged to have a relative or dose friend 
accompany them, supervise medication and assist in keeping a record of seizures. It was 
also preferred that such a person should personally observe the patient having a seizure. 
They were encouraged to visit any time they wished, and were informed that it was not 
always necessary to draw the hospital folder and pay the hospital fees. The only time they 
needed to draw the hospital folder was when more medication was required. The patient 
was also encouraged to telephone the investigator at any time for advice or with any query 
that he/she may have. A copy of the informed consent (Annexure 5) was also given to the 
patient in the language of his/her choice. 
The first consultation usually took 45 to 60 minutes. N. the end of the interview, a formal 
consultation note was written in the patient's hospital folder. 
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3.5.3. FIRST INVESTIGATOR-PATIENT INTERVIEW 
The first interview usually took place immediately after the doctor or primary health care 
nurse had consulted with the patient. The main purpose of the first interview was to screen 
the patient for inclusion in the study, to gather information about the patient, and to 
establish a baseline regarding seizure frequency and adverse effects. 
Once the investigator had ensured that the patient satisfied all the inclusion criteria, the 
patient was entered into the study. A red identification sticker was then placed on the 
cover of the patient's folder and the word 'phenytoin' was written on the sticker. If the 
inclusion criteria were not satisfied, the patient was counselled regarding phenytoin usage 
and then asked to consult the doctor or primary health care nurse at the following visit. A 
note was written in the hospital folder stating the reason for the patient not being included 
in the study. Witten informed consent was obtained before entry into the study. 
During the first interview, demographic and medical data were collected which included 
the patient's name, address, folder number, telephone number, occupation, age, date of 
birth, gender, race, mass, height, frame size, social class, concurrent medication, duration 
of therapy and dosages, smoking history, alcohol intake, previous history of other 
diseases, history of seizures and frequency, description of seizures, present clinical 
status, previous admissions to hospital and drug history with emphasis on the history of 
anticonvulsant therapy. The patient was questioned about previous experiences with 
phenytoin to discover any known problems with the drug. A data collection form (Annexure 
2) was used to facilitate the interview. Patients were interviewed according to a 
standardised detailed format. 
The patient's height and mass were recorded. Body mass was measured to the nearest 
0.1 kg using a calibrated scale with the patient in light clothing. Height was measured to 
the nearest 0.5 cm with a vertical ruler. 
During the interview the following information was also carefully acquired and documented: 
if the patient consumed alcohol, the type, frequency and amount of alcohol was recorded. 
N. this point, the relationship between alcohol intake and the severity and frequency of 
seizures, and the influence that alcohol intake has on phenytoin pharmacokinetics, were 
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A folder for the investigator's personal use was opened for each patient. Each folder 
contained the data collection form (Annexure 2), signed copy of the informed consent 
(Annexure 5), blank 'request for taking of blood sample' forms (Annexure 6) and 
'phenytoin assay results and recommendations' forms (Annexure 7). The completed 
diaries that the patients were requested to return were also placed in this folder. 
3.5.4. SECOND INVESTIGATOR-PATIENT CONSULTATION 
The investigator's diary was examined to determine the reason for the patient's visit. The 
patient's diary was checked to determine if it had been filled in correctly. The patient was 
questioned about compliance and occurrence of seizures since the preceding visit and this 
information was compared with that in the patient's diary. The diary was evaluated for 
completeness, and this was recorded on the data collection form. The patient was again 
questioned about the correct completion of the diary. The events recorded in the diary 
were then discussed. 
Wiether any phenytoin tablets were left over was assessed. If the answer was affirmative, 
the number of tablets left over was assessed. If the tablets were brought to the hospital, 
they were counted, and the following details noted on the data collection form: the number 
of tablets remaining, date of dispensing as indicated on the tablet packet or container, and 
the date of the tablet count. It was requested that the old tablets be placed in a safe place 
and that the new lot of phenytoin tablets be started on the day dispensed. The tablet 
counts were performed as far as possible without the knowledge of the patients. 
If the patient was compliant and at steady state, a request form (Annexure 6) for blood 
collection was filled out by the investigator. A month was usually considered sufficient time 
for steady state to be reached (Barot et al., 1978; Ludden et al., 1978; Rambeck, 1979; 
V\/elty et al., 1986; Yukawa et al., 1991). Steady state was defined as the same dosage 
being maintained for at least 30 days without a trend toward an increasing or decreasing 
serum concentration after that time (Bourgeois and Wad, 1985; Yuen et al., 1983a). 
Good compliance was again encouraged and reinforced. The patient was then sent to the 
nurse for blood collection. If it was suspected that compliance was less than optimal, 
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blood sampling was delayed until compliance could be assumed and steady-state serum 
concentrations were reached. 
3.5.5. BLOOD SANPLE COLLECTION 
The time of the last dose and the time when the blood sample was collected were 
documented on the request form for blood collection. This information was filled in by the 
investigator or the nurse. The time the samples were taken did not bear a fixed 
relationship to the time of the previous dose of phenytoin (Aronson et al., 1992; Bryson 
et al., 1988; Miller at al., 1987). Variation of serum concentration from this source was 
found to be negligible by comparison with variation due to progressive accumulation or 
elimination extending over several weeks (Haerer and Buchanan, 1972; Mawer et al., 
1974). The blood samples were collected by the nurse by direct venipuncture in plain 
red-top tubes without anticoagulant (Mauro and Mauro, 1991; Parish and Alexander, 
1990). These samples were fetched by the investigator at the end of the clinical session. 
All the blood samples were then stored in a cool place and delivered by the investigator 
to the analytical laboratory of the Department of Pharmacology, University of Cape Town. 
All the blood samples for serum phenytoin assay were accompanied by the 'request for 
taking of blood sample' form (Annexure 6). The assay procedure is discussed in section 
3.6. 
3.5.6. PHENYTOIN /JSSAY RESULTS 
The phenytoin assay results were carefully checked by the investigator the day after the 
collection of blood. The results were reported on the 'request for taking of blood sample' 
forms (Annexure 6). A copy of the result was filed in the patient's folder kept by the 
investigator and a second copy was placed in the patient's hospital folder. 
If a phenytoin level confirmed toxicity, the doctor was informed immediately. The patient 
was informed telephonically of the result, where possible, and was asked either to stop 
the medication for a certain period or to return to the hospital on the next clinic day. In 
some instances, the patient was telephonically advised how to reduce the daily dose until 
the next visit. For example, if a dose of 350 mg/day phenytoin sodium was being taken 
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and it was decided that the dose should be reduced to 325 mg/day, then 300 and 350 
mg/day phenytoin on alternate days were prescribed until the next epilepsy clinic. 
3.5.7. DOSE CALCULATION 
If the serum phenytoin level was subtherapeutic, as indicated by inadequate seizure 
control, then there was a need to adjust the dose. It was preferred not to use the first 
serum phenytoin concentration obtained to adjust to a new dose without the concentration 
being confirmed with a second measurement. If a new dose was to be calculated at that 
stage, equations 2 and 3 in Chapter 2 (page 10) were used. A Km value of 4.4 mg/I was 
assumed, and Vm was calculated using equation 2. The Vm and Km values were then 
substituted in equation 3. 
Serum phenytoin concentrations were initially targeted to either 15 mg/I or 20 mg/I, as 
these values represented the midpoint and uppermost point of the usual therapeutic 
range. Wien necessary, the time for the phenytoin level to reach steady state on the new 
dose was calculated using equation 11 (page 41) described later in this chapter. If the 
serum phenytoin level was below the therapeutic range and the patient was seizure free, 
no adjustment of dose was made. Phenytoin doses were modified according to clinical 
response. 
Throughout this thesis, doses are expressed as phenytoin sodium and complete 
bioavailability has been assumed. Wien Epanutin lnfatabsR (phenytoin acid) were used 
for small increments or decrements of dose, the equivalent dose expressed as phenytoin 
sodium was calculated. This was done by dividing the dose of phenytoin acid by 0.92. The 
latter figure represents the fraction of phenytoin sodium that is free acid. The Epanutin 
lnfatabsR contain 50 mg phenytoin acid per tablet, and the phenytoin sodium tablets are 
available in 50 mg and 100 mg strengths. 
In order to interpret the serum concentrations and to make recommendations on dosage 
design for individual patients, the Bayesian technique of drug dose optimization was used. 
OP~. version 4.1 b (Clydesoft Statistical and Scientific Software), is an interactive, 
user-friendly, personal computer software package used for this purpose (Kelman et al., 
1982). A laptop computer was used at the clinics to run OP~. The patient's mass, height, 
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gender, ideal body mass and steady-state phenytoin concentrations were entered into the 
programme and the most likely estimates of Vm, Km and dose were derived. Wien no 
serum phenytoin concentration feedback was available, the assigned constants in the 
programme for phenytoin were taken as 7.22 mg/kg/day and 4.44 mg/I for Vm and Km, 
respectively. Doses were often calculated for two target serum phenytoin concentrations. 
The nearest practical dose attainable with 100 mg, 50 mg and 27 mg (i.e. half an 
Epanutin lnfatabR) phenytoin sodium was entered and the corresponding target phenytoin 
concentration was calculated and reported. Dosing recommendations based on the 
pharmacokinetic calculations were decided on by the clinical judgement of the investigator. 
The recommended dose and the corresponding target serum concentration were then 
entered on the data collection form. The daily dose was normally prescribed as a single 
dose (Strandjord and Johannessen, 1974). The dose was prescribed twice daily only if 
there was a special reason to do so, or in selected cases where the daily dose exceeded 
400 to 450 mg daily. The patient's data were recorded in an OP~ file which could be 
updated by adding details of subsequent doses and concentration measurements. OP~ 
allowed only steady-state serum phenytoin concentrations to be used, and only 
steady-state concentrations could be predicted. Wien OP~ was not available at the clinic, 
the equations described in Chapter 2 were employed. 
3.5.8. REPORT TO DOCTOR 
A verbal and/or written report (Annexure 7) of the measured serum phenytoin 
concentration and recommendation of the dose was given to the doctor at the patient's 
next clinic visit. This report also stated the targeted serum concentration, estimates of Vm 
and Km values, and an estimate of when the serum level would be at steady state. Each 
written report was discussed personally with the doctor to ensure that the contents of the 
report were fully understood. A copy of the written report, if one had been prepared, was 
then placed in the patient's folder. The doctor made the final decision about the necessity 
of a dosage adjustment. A prescription for the new dosage regimen was always written 
by the doctor. 
The pharmacokinetic service also evaluated the serum phenytoin concentration, patient 
response (e.g. seizure frequency and adverse effects), compliance with dosage regimen 
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and concomitant drug administration. The report included, where possible, any explanation 
for a large discrepancy between predicted and measured drug concentrations. 
3.5.9. SUBSEQUENT INVESTIGATOR-PATIENT INTERVIEVVS 
A routine consultation was conducted with emphasis on the number and description of 
seizures since the last visit, the date when the last seizure was experienced, and the 
presence of sid~ffects to phenytoin. The phenytoin assay result was explained to the 
patient and the result recorded on the data collection form. 
If there was no urgency to adjust the dose, a second assay while the patient was on the 
same dose was performed to confirm the result. Initial serum phenytoin concentrations 
below 10 mg/I were seldom used to adjust the dose before confirming the result. This 
served as a test for compliance. If two serum phenytoin levels were available on the same 
dose then the average of the two levels was used in the calculation of the new dose. If 
at least two reliable steady-state phenytoin serum levels on different daily doses were 
available, the patient's individual Vm and Km could be calculated using equations 2 and 
4 in Chapter 2 (page 10), respectively. These parameter estimates were used to calculate 
a new dose by means of equation 3 in Chapter 2. 
If more than one phenytoin dosage form was prescribed, the dosage forms were always 
shown to the patient. For example, if a dose of 377 mg phenytoin sodium was prescribed, 
three 100 mg phenytoin tablets, one 50 mg phenytoin tablet and half an Epanutin lnfatabR 
were shown to the patient. This was done to ensure that no mistakes in the dosage 
regimen occurred, given that many patients were illiterate. If a new dose was prescribed, 
the patient was counselled regarding the new dosage regimen. Decision to change therapy 
was a co-operative effort between the patient, investigator and the doctor. 
The next appointment was scheduled by recording the date in the patient's diary provided 
by the investigator. The appointment was, as far as possible, scheduled to coincide with 
the patient's return to the hospital to collect his/her medication. The patient was then 
shown how to fill in the diary, with the new dose, if a new dose had been prescribed. If 
a complex dosage regimen had been prescribed the patient was often requested to return 
to our clinic after obtaining the phenytoin from the dispensary. This was to ensure that the 
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correct dosage forms had been dispensed and that the directions on the tablet packets 
or containers were correct. All the important principles of phenytoin use and compliance 
were reinforced at every visit. The patient was advised of drug-related precautions. Letters 
were written to patients who defaulted on clinic attendance to offer them another 
appointment date. 
The patient was followed up for as long as possible to obtain more blood samples or to 
check on progress. The more dose-concentration pairs available, the more accurate the 
estimation of Vm and Km would be. The patient was continually reassessed to ensure 
optimal therapy. Towards the end of the study, many patients were discharged from the 
pharmacokinetic service if they had been seizure free for at least six months. 
3.5.10. SANEL., GROOTE SCHUUR HOSPITAL AND BE I EL SCHOOL FOR 
EPILEPSY 
The clinics held at these institutions are discussed separately because the procedure 
followed differed slightly from that described previously. 
The clinic at SANEL was managed by a nurse. The patient was initially consulted jointly 
by the neurologist and investigator once a week. All electro-encephalogram, full blood 
count and a Sl\,1AC (electrolytes, renal and liver function tests as well as albumin 
concentrations) were performed on all the patients. Besides the patients recording their 
seizures in the patient diary, a record of seizures was kept on a daily basis by a 
supervisor at the protective workshop. The phenytoin medication was obtained from 
Heideveld Day Hospital and distributed at work by the nurse. The investigator was 
promptly kept informed by the nurse of any problems the patients might have experienced. 
N. the outpatient clinic at Groote Schuur Hospital the blood samples were assayed for 
serum phenytoin concentration by a technician at the clinic and the results of the assays 
were available within an hour. This allowed a written report to be generated for the doctor 
during the same clinical session. This also reduced the number of patient visits to the 
hospital relative to all the other clinics where the prompt assay service was not available. 
This clinic was discontinued after 30 clinic sessions because of an insufficient number of 
patients on phenytoin monotherapy. Patients already entered in the study were still 
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followed up at this hospital on an appointment basis for a period of two months after 
officially discontinuing the service. 
The dinic at Betel School for Epilepsy was managed by three full-time nurses and a 
medical officer who visited the dinic once a week. The phenytoin dose was placed in 
labelled bottles daily by the nurses and dispensed to the hostel students. 
3.5.11. GENERAL CONMENTS REGARDING lHE CLINICAL PHARMACO-
KINETIC SERVICE 
If there was a large discrepancy between two measurements of serum phenytoin 
concentrations on the same dose, then a third measurement was taken to assess which 
was most likely to have been correct. The first blood sample for the measurement of 
serum phenytoin concentration was taken after a minimum of 4 weeks on a constant 
maintenance dose. Subsequent samples were taken after intervals of 2 to 4 weeks 
provided that the dosage regimen was the same and compliance was optimal (Barot et 
a/., 1978). 
A dosage increase was only considered when seizures occurred after at least 3 to 4 
weeks following the last dosage increment or when the seizures occurred after the length 
of time required to reach steady state in a compliant patient. 
In cases of suspected phenytoin toxicity, the treatment was stopped for 1 to 7 days before 
the new maintenance dose was started. The size of the dosage reduction was usually 
determined empirically. This depended on the degree of toxicity, seizure control and the 
serum phenytoin level, if available. The patient was telephoned, where possible, the next 
day to confirm toxicity and the dose was re-evaluated in the light of the available serum 
phenytoin level. 
Doses were often adjusted empirically without any pharmacokinetic calculations. This was 
usually done in compliant patients with serum phenytoin levels of less than 15 mg/I. If the 
steady-state serum level was lower than 6 mg/I, an increase of 100 mg in the daily dose 
was recommended. If the serum phenytoin level ranged from 6 to 10 mg/I - a 50 mg/day 
increase was recommended, and if the level was between 10 and 15 mg/I, an increase 
41 
of 27 to 50 mg phenytoin sodium per day was recommended. A modification of the 
recommendations of Mawer et al. (1974) and Aronson et al. (1992) was used. Even an 
increase of 27 mg/day phenytoin sodium in a few instances was too large and it was 
necessary to prescribe e.g. 400 mg and 427 mg on alternate days. An extra 50 mg 
phenytoin tablet twice per week was also occasionally recommended. Given the lack of 
knowledge of the population pharmacokinetic parameters of phenytoin in the South African 
population, conservative increases in dosage were recommended. The number of doses 
prescribed daily were kept to a minimum to improve compliance. If the seizures were 
observed to occur at a time corresponding to the trough serum concentration or if adverse 
effects were experienced at a peak concentration, then it was advised that phenytoin be 
taken twice daily without changing the size of the daily dose. The only changes that were 
made were alterations in the phenytoin dosage regimen, substitution of drugs interfering 
with phenytoin or discontinuation of drugs not required by the patient. 
The time taken for the serum concentration of phenytoin to reach 90% of steady state was 
often calculated using the following equation: 
Km X Vd x (2.303 Vm - 0.9 S.F.R) (11) 
( Vm - S. F. R) 2 
where tooa10 is the time (days) taken to reach 90% of steady state, Vd (I) is the volume of 
distribution. The other parameters have previously been explained in Chapter 2 (Levine 
et al., 1987). A few days to a week were allowed between the time taken to reach steady 
state as calculated above and the time of blood collection to ensure that a steady state 
had indeed been achieved. Vm was calculated using equation 2 in Chapter 2 (page 10) 
and Km was assumed to be 4.4 mg/I (Vozeh et al., 1981). Vd was assumed to be 0.65 
I/kg (Wnter and Tozer, 1986). If individualized parameters were available then these 
values were used in the calculation (Allen et al., 1979; Vozeh and Follath, 1980). 
In the case of frequent seizures caused by non-compliance, an oral loading dose (LO) was 
calculated using the following equation: 
LD = Vd x Cp
55 
(12) 




) was usually 20 mg/I. If a reliable feedback serum level was available, 
then the following equation was used: 
LD = Vd ( Cpdesired - CPachieved) (13} 
The oral loading dose was administered by giving an immediate dose of 400 mg followed 
by 200 mg every 2 hours over a period of 4 to 6 hours. The usual or new maintenance 
dose was also prescribed on that day. 
A nurse or interpreter was always present for Xhosa-speaking patients. Nurses were 
employed at Guguletu, Khayelitsha, Lotus River and Elsies River Day Hospitals to assist 
with obtaining routine information concerning the patient. Other functions of the nurse 
included the drawing of the patient's hospital folder (if required for inserting information or 
prescribing of a new dose), escorting the patient to the utility room for blood collection, 
taking the folder to the doctor for a repeat prescription of phenytoin and requesting the 
doctor to examine the patient for other complaints. 
The individual patient's clinical response in terms of seizure frequency and severity was 
used as the major monitoring parameter for the efficacy of the phenytoin therapy. 
3.5.12. COIVPUANCE CHECKS 
Compliance was assessed by an extensive patient interview, tablet counts (Blain et al., 
1981), correct filling in of the patient's diary and variation between two measured serial 
serum phenytoin concentrations taken at different times on the same dose (Ludden et al., 
1977; Wison and Wlkinson, 1974). After steady state was attained and if the variation 
between two serum phenytoin concentrations on the same dose was less than 20%, then 
the patient was considered to be compliant (Yuen et al., 1983a; 1989). This method allows 
direct measurement of compliance. 
A large variation between predicted and measured serum phenytoin concentrations was 
sometimes used as a measure of non-compliance. The accuracy of this method depends 
on the accuracy of the estimates of Vm and Km used in the calculation (Miller et al., 
1982). The accuracy of the method improved when more feedback serum phenytoin 
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concentrations were available. The accuracy of the prediction was categorized as good, 
average or poor. A good prediction was considered to be within 20% of the measured 
concentration, an average prediction between 20 and 40%, and poor prediction greater 
than 40% of the measured concentration. A good and average accuracy of prediction were 
considered acceptable. 
Compliance was also assessed by checking the hospital prescription cards. Patients 
collecting medication more than 28 days after the date of dispensing were suspected of 
being non-compliant as they were never supplied with more than 28 days medication 
unless otherwise arranged with the investigator. The number of tablets left over at the 
previous visit was taken into account in the assessment of compliance. All possible 
reasons for default were also sought. W1ere possible, the patient was telephoned to 
check on status and to encourage compliance. 
A good investigator-patient relationship was sought in order to improve compliance. The 
patient was not made to feel guilty about poor compliance and a feedback on all laboratory 
results was provided to all patients. The patient's spouse, family and/or support group 
were involved as active participants in the planning of the treatment programme. P-s far 
as possible, phenytoin was prescribed as a single daily dose at night to improve 
compliance. Some patients were informed that their compliance in taking phenytoin could 
be verified by serum concentration determinations. The latter two procedures have been 
reported by Miller et al. (1982) to improve patient compliance. 
3.5.13. ADVERSE EFFECTS 
M.. every visit, the adverse effects to phenytoin were assessed by direct enquiry or by 
clinical examination. The main adverse effects investigated were dizziness, double vision, 
blurred vision, nystagmus, tremor, slurred speech and ataxia. Nystagmus was classified 
as horizontal and/or vertical; on straightforward gaze, at 45° or 180° deviation and 
unilateral or bilateral. Lower limb ataxia was assessed at every visit but upper limb ataxia 
was only assessed if deemed necessary by the investigator. The patient and family or 
close friends were questioned about whether the patient staggered or had an ataxic gait. 
The time of the day when the adverse effects occurred was noted. W1ether the adverse 
effects occurred simultaneously was also taken into account. Other less frequent and 
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serious adverse effects of phenytoin were also noted. The relationship between the 
adverse effect/sand the serum phenytoin concentration was recorded (Buchthal et al., 
1960; Gerber et al., 1972; Kutt et al., 1964). 
3.6. ASSAY 
3.6.1. CALIBRATION OF MACHINE 
The TDx and TDxFL.x analyzers (Abbott Laboratories, Diagnostic Division, North Chicago) 
were calibrated by the technical staff of the Department of Pharmacology, University of 
Cape Town every four to six months. This was done in accordance with the manufacturer's 
specifications. Six phenytoin calibrator vials supplied by Abbott Laboratories were used 
in the calibration procedure. The first vial contained no phenytoin while the remaining five 
vials contained accurately measured amounts of phenytoin ( 2.5, 5.0, 10.0, 20.0 and 40.0 
µg/ml) in human serum. This was done to establish linearity over the specified range of 
phenytoin concentrations. 
3.6.2. QUALITY CONTROL 
3.6.2.1. EXlERNAL QUALITY CONlROL 
External quality control was performed once a month by Cardiff Bioanalytical Services Ltd., 
Cardiff Business Technology Centre, Senghenyold Road, Cardiff, Wales, CF2 4A7, United 
Kingdom. 
3.6.2.2. INTERNAL QUALITY CONTROL 
Internal quality control procedures were performed daily with the phenytoin controls 
supplied by Abbott Laboratories. Each vial labelled L, M or H read within the following 
ranges 6.75 - 8.25, 13.5 - 16.5, and 27.0 - 33.0 mg/I, respectively. Only one of these 
phenytoin controls was used daily for the batch analysis of the phenytoin samples. 
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3.6.2.3. INTER-ASSAY COEFFICIENT OF VARIATION 
Six phenytoin duplicate blood samples obtained routinely from patients were used to 
determine the inter-assay coefficient of variation. During the quality control procedure the 
duplicate samples were labelled with fictitious patient names. 
3.6.2.4. ADSORPTION OF PHENYTOIN TO RUBBER STOPPERS 
Six duplicate phenytoin blood samples obtained routinely from patients were used to 
determine whether adsorption of phenytoin to the rubber stoppers of the blood collection 
tubes occurred. Six phenytoin blood samples were stored upright and the other six 
duplicate samples were stored in an inverted position. Samples were stored as described 
above for 6 hours before assay. A paired t test1 was used to determine whether a 
significant difference between the two groups existed. A significant difference was 
indicated when a p value was~ 0.05. The coefficient of variation in the serum phenytoin 
concentration was calculated. 
3.6.2.5. STABILITY OF PHENYTOIN IN WHOLE ELOOD SANPLES 
The effect of storage on the phenytoin concentration in the blood samples at room 
temperature was investigated. Six triplicate samples obtained routinely from patients were 
used. The first, second and third batch were assayed 2, 6 and 26 hours after blood 
collection. All samples were stored as whole blood samples. A paired ttest1 was used to 
determine whether a significant difference between the samples stored for 2 and 6, and 
6 and 26 hours existed. A significant difference was indicated when a p value was~ 0.05. 
The coefficient of variation between the serum phenytoin concentrations was also 
calculated. 
3.6.3. M!>SAY PROCEDURE 
The assays were performed on the same day when the blood was collected from the 
patient. On rare occasions, the serum was stored overnight at -2D° C. The interval 
1the Wilcoxon signed rank test was also performed 
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between the time when the blood was collected from the patient and the time of 
centrifugation was kept as short as possible. This time seldom exceeded 6 to 8 hours, 
although phenytoin has been shown to be stable in serum for at least 24 hours at 
temperatures up to 32° C (Parish and Alexander, 1990). The blood samples were 
centrifuged at 3000 rpm for 15 minutes and 80 µI of the serum were transferred to a TDxR 
CLNette using a micropipette. Although 50 µI of serum were required, an excess was 
pipetted to allow for the presence of any air bubbles. The TDxR CLNettes were then placed 
in a carousel which had the capacity to accommodate 20 such TD>f CLNettes. The 
carousel and a phenytoin reagent pack were placed in the TD>f Analyzer and the batch 
assay process was started. Total serum phenytoin concentrations were thus measured 
with a fluorescent polarization immunoassay. The assays were performed with an 
automated TD>f or TDxFLJcR system. All assays were performed in accordance with the 
manufacturer's specifications and quality control procedures. The drug assays were 
performed by the technical staff at the Department of Pharmacology, University of Cape 
Town. 
3.7. DATA ANALYSIS 
3.7.1. DATA ORGANIZATION 
All information on the patients was recorded on 4 spreadsheets by means of the LOTUS 
123 computer programme: 
spreadsheet 1 : coloured patients excluded from the study 
spreadsheet 2: black patients excluded from study 
spreadsheet 3: coloured patients included in study 
spreadsheet 4: black patients included in study 
Spreadsheets 3 and 4 were used for the NONMEM analysis. 
3.7.2. NONIVEM DATA ANALYSIS 
The unnecessary information contained in spreadsheets 3 and 4 was deleted and the 
remaining information was reorganised into a format suitable for NONMEM. The 
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information was then coded according to NONMEMs specifications. The 2 spreadsheets 
were then combined and converted into an ASCII format to form a NONMEM data input 
file. Inputs to NONMEM cons;sted of a data file, control files and user-coded subroutines. 
Double precision NONMEM version Ill level 1.2 and version IV level 1.0 (NONMEM 
Project Group, University of California, San Francisco) were used in this study (Beal et al., 
1988 - 1992; Sheiner et al., 1977, 1979). The NONMEM version Ill and IV programmes 
were run on a 486 computer at the University of Durban-VVestville, South Africa. Version 
IV was also run on a Spare StationR and UNIX was used as the operating system at the 
Food and Drug Administration, United States of America. 
The posthoc option allows the estimation of individual parameters and associated 
individual predictions of the dependent variable given the population parameters. It does 
this through a Bayesian regression and uses all the data in the data set for each 
individual. The usual purpose of the posthoc option is to obtain individual parameter 
estimates. The conditional estimation method, an option of NONMEM version IV level 1.0, 
uses an E-M algorithm to derive improved estimates of the population pharmacokinetic 
parameters. This is an iterative procedure that involves multiple, sequential estimation of 
individual parameters, then population parameters, then individual parameters etc. until 
convergence is achieved for the population values. By combining data on population 
pharmacokinetic parameters (prior distributions of the parameters) with information from 
sampled concentrations in an individual patient, an optimal estimate of this individual's 
pharmacokinetic parameters (posterior distribution of the parameters) was obtained. The 
procedure therefore makes use of the Bayesian principle (Frakes et al., 1986; Peck et al., 
1980; Sheiner and Beal, 1982; Sheiner et al., 1979; Vozeh et al., 1981). The main purpose 
of the conditional estimation method is to obtain population parameter estimates. The 
estimates obtained with the conditional estimation method were given greater credence 
(Beal et al., 1988-1992). 
3. 7.3. PHARMACOKINETIC MODELS 
A one compartment model with either Michaelis-Menten or parallel Michaelis-Menten and 
first-order elimination was used. 
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3.7.3.1. STRUCTIJRAL MODELS 
Three pharmacokinetic models, termed structural models S1, S2 and S3, were used. 
3.7.3.1.1. STRUCTIJRAL MODEL S1 (NICHAEUS-I\IENTEN MODEL) 
In this model, dose rather than Cp55 as the dependent variable was chosen to ensure 
stability during data fitting (Vozeh et al., 1981). This model was represented as follows: 
_ Vmj X Cpssij 
R .. - -~--~ 
1.J Kmj + Cpssij 
(14) 
where Rij is the ith dosing rate of phenytoin in mg/day predicted to achieve the ith Cp55 in 
the jth patient; Vmj and Kmj are the maximum metabolic rate (mg/day) and 
Michaelis-l\i1enten constant (mg/I) of phenytoin respectively in the jth patient and Cpssii is 
the steady-state serum phenytoin concentration measured in the jth patient receiving 
dosage Rij. Vmj and Kmj are assumed to be constant over time within a patient, but may 
differ between patients (Grasela et al., 1983; Sheiner and Beal, 1980; Yukawa et al., 
1990). 
3.7.3.1.2. STRUCTIJRAL MODEL S2 (PARAUJ:L MCHAEUS-IVENTEN AND 
FIRST-ORDER EUNINATION MODEL VVITH DOSE /JS THE 
DEPENDENT VARIABLE) 
Since a small amount of phenytoin is eliminated unchanged in the urine, the contribution 
of a parallel first-order elimination pathway was considered. In this model, dose was used 
as the dependent variable and was represented as follows (Ludden et al., 1991) : 
vm. x Cp .. 
R .. = J SS1.J + (Cl. X Cp .. ) 
1.J Km . + Cp . . J SS1.J 
] SS1.J 
(15) 
where C~ is the linear dearance of phenytoin for the jth patient in I/day. 
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3.7.3.1.3. STRUCTURAL MODEL S3 (PARAU..EL NICHAEUS-NENTEN 
AND FIRST-ORDER EUNINATION MODEL V\lllH STEADY- STATE 
SERUM CONCENTRATION AS lHE DEPENDENT VARIABLE) 
Wien using equation 15 and solving for Cpss, the following equation was derived: 
1[( Vm · R .. ) 
CPssiJ = - 2 Cl; + KmJ - c~: - _J + Km . - ____!2 + ( vm. R .. ) 2 ClJ 1 Cl J 4.RiJ"KmJ ClJ 
{16) 
The derivation of this equation has been described by Ludden et al. (1978). Our equation 
differed from that of Ludden et al. (1978) in that linear clearance (Cl) was substituted for 
the product of Vd (volume of distribution) and Ka (first-order elimination rate constant). 
3.7.3.2. PARAIVETER MODELS 
Wth NONMEM, the influence of various demographic or patient factors (fixed effects, FE) 
was tested by relating them to the pharmacokinetic parameters (P) using parameter 
models of the type: 
P = 8 (FE) {17) 
where P is the expected value of the pharmacokinetic parameter ( e.g. Vm or Km) in any 
individual, FE is an identifiable patient factor (e.g. mass), and 8 is a regression coefficient. 
Wien quantifying the influence of a discontinuous variable such as smoking status, the 
model was of the type: 
{18) 
where SMK equals 1 for non-smokers and 8SMK for smokers. 
3.7.4. STATISTICAL MODELS 
The statistical model takes into account the inter-individual variation and intra-individual 
error. The inter-subject variability in Vm, Km and Cl, as well as the intra-subject error, 
were modelled with additive and proportional error models. Wth the conditional estimation 
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method, the proportional error model was used to avoid obtaining negative values for the 
parameters. In the first set of analysis, only the additive and multiplicative error models 
were tested. The intra-individual variability in the dose : serum concentration relationship 
can be modelled as follows: 
R.1.
1
. = R .. + e.. (additive error) m.11 .IJ 
R ij = Rmij exp e ij (proportional error) 
= c .. + e . . (additive error) m.11 .IJ 






~ is the actual dosage rate for the ith R-Cp55 pair in the .fth individual (mg/kg). ~j 
is the predicted dosage rate to obtain the ith Cp55 in the .fth patient. This value 
includes the contribution of the Tl 'f1, Tl f and Tl J1 terms; 
Cij is the ith actual concentration for the .fth individual, Cnij is the ith concentration 
predicted by the model for the .fth individual. This value includes the contribution 
of the Tl 'f1, Tl f and Tl J1 terms; 
E,i is assumed to represent independent normally distributed statistical errors 
(intra-subject or residual error) with mean zero and variance cr2 (Yukawa et al., 
1990). The variable t;j models all sources of error or deviation of the actual 
dosage or steady-state phenytoin concentrations from those that are predicted 
from the model. The models given above by equations 19-22 should be regarded 
as only an approximation of what are undoubtedly more complex error models, 
since t;j must represent all uncertainty caused by, e.g. pharmacokinetic model 
misspecification, analytical error in measuring serum phenytoin concentrations, 
sampling error and non-compliance. 
It is, however, more convenient for the numerical aspects of fitting data to the 
Michaelis-Menten model to cast the statistical model in the form of the equation above (i.e. 
~ = ~ + t;j) where dose is predicted. Otherwise, infinitely large residuals occur when 
Vm (or Vmi) values are less than some values of R. In this model, the dosage rate is 
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regressed on Cp55, and it is therefore regarded as a random variable whose distribution 
is conditional on Cp55• This is contrary to usual pharmacokinetic practice, although it is 
commonplace when fitting phenytoin data (Sheiner and Beal., 1980). 
The statistical models for individual pharmacokinetic parameters were as follows (Driscoll, 
1989; Grevel et al., 1988; Miller and Ludden, 1993; Mungall et al., 1985; Sheiner and Beal, 
1980; 1981 ): 
vm 1 = vm + 11? ( additive error) (23) 
(24) Vm 1 = vm exp 11? (proportional error) 
Km 1 = Km + 11 J ( additive error) (25) 
(26) Km1 = Km exp 11J (proportional error) 
Cl 1 = cl + 11J1 (additive error) (27) 
(28) Cl 1 = Cl exp 11J
1 (proportional error) 
where 
Vmj, Kmj and Clj are the true pharmacokinetic parameters for the individual as 
predicted by the regression model; 
Vm, Km and Cl are the population means of the maximum metabolic rate, 
Michaelis-Menten constant and linear clearance, respectively; 
11 ;m, 11 J and 11 J1 are assumed to represent random normally distributed 
terms with zero means and variances; 
atm, a~, a~1 , respectively distinguish the fth individual's Vm, Km and Cl from 
those predicted by the regression model; 
a vm• a Km• a cl are approximately the coefficients of variation of Vm, Km and Cl, 
respectively. 
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3.7.5. VALIDATION OF POPULATION PHARMACOKINETIC PARAIVETERS 
AND SlRUCTURAL IVIODELS 
3.7.5.1. THE NAIVE FEEDBACKNETHOD USING ESTIMATES OBTAINED 
VVITH THE FIRST-ORDER AND THE FIRST-ORDER 
CONDITIONAL ESTIMATION NETHODS 
The validity of the estimated population parameter values and pharmacokinetic models 
was tested using the naive prediction method (i.e. a method that uses the mean population 
estimates of Vm, Km and Cl but no patient-specific phenytoin concentration data). All the 
steady-state phenytoin concentrations obtained during treatment with the initial and 
adjusted dosage regimens were used. For models S1 and S2, the estimated population 
parameters ( obtained from the NONMEM outputs and calculated from the parameter 
models) were used to predict the dosage of phenytoin that would achieve the measured 
concentration. For model S3, the estimated population parameters were used to predict 
the steady-state serum concentration that would be achieved when a particular dosing rate 
was administered. The predictions obtained with the mean population estimates derived 
with the first-order (FO) and the first-order conditional estimation (FOCE) methods were 
compared. 
The same patient population used in the NONMEM analysis was used in this validation 
procedure. To minimize possible bias in favour of the model by predicting dose or serum 
concentrations for patients whose data were used for the estimation of the population 
parameters, the estimation and validation of the pharmacokinetic parameters were 
undertaken in separate patient groups. A method of cross-validation was used. All patients 
producing only one steady-state concentration on a single dose of phenytoin were 
excluded from this analysis. The reason for this was to exclude the possibility of non-
compliance influencing the predictive performances of the models. The remaining patients 
were then randomly allocated to two equally matched groups (1 and 2) stratified according 
to the factors ( ethnicity; smoking - non-smoker, smoking less than 10 cigarettes per day, 
10 to 20 cigarettes per day, or more than 20 cigarettes per day; and age - less than 65 
or 65 years or older) demonstrated to influence the pharmacokinetics of phenytoin. 
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The NONMEM fixed-effects parameter estimates obtained in Group 1 (81, 82 etc.) 
were validated or constrained to their estimated values in Group 2. Similarly, the NONMEM 
estimates obtained in Group 2 were validated in Group 1. A similar validation procedure was 
used by Vozeh et al. (1982) when studying population pharmacokinetics of oral mexiletine. 
The predictive performances of the 3 final models were compared. The fixed effects obtained 
by a NONMEM first-order method in Group 1 was validated in Group 2 by fixing these values 
in the PRED file and the MAXEVAL option of the $ESTIMATION command omitted by typing 
'$EST OMITTED'. This step calculated the Vm using the final parameter models determined 
in Set 1 and Set 2 analysis for each patient. A fixed FO or FOCE Km and Cl values were 
used for each of the 3 structural models evaluated. The output tables (ID, vrv1, KM, CL, RI (or 
CP), PRED, RES and V\RES were imported into LOTUS 123 spreadsheets. The DV - PRED 
which is equal to RES was used in the prediction error analysis as discussed in section 
3.7.6.6 was performed. Thereafter the fixed effects obtained by the NONMEM first-order 
method in Group 2 were validated in Group 1 and the same procedure as described above 
was followed. The fixed effects obtained by a NONMEM first-orderconditional estimation 
method were validated as described for the FO method. 
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A method of cross-validation was used to validate the results in preference to the method 
where a separate validation population is used, for the follO\Ning reasons: 
(1) The NONMEM estimates were determined in a larger patient population; 
(2) The stability of the NONMEM predictions was determined, e.g. if the bias obtained 
in the two matched groups for each of the structural models was significantly 
different, then either the NONMEM parameter estimates were unstable or the 
models used were inadequate; 
(3) The validation of the results was based on a larger population; 
(4) k, more bias values were available, this method provided a better comparative 
method. This method of cross-validation also ascertained the variability in the bias 
between the two groups; 
(5) The validation population was representative of the patient population routinely 
attending the epilepsy clinics. 
3.7.5.2. PREDICTIONS OF STEADY-STATE SERUM CONCENTRATIONS 
USING THE MICHAEUS-NENTEN IVIODEL (S4) 
The purpose of this part of the study was to compare the predictive performance of model 
S4 with that of model S3, and indicate the importance of Cl in the latter model. The 
estimates of Vm and Km obtained with model S1 were used in model S4. The latter 
model, which has been discussed previously (section 2.2.1) is represented as follows: 
3.7.5.3. 
Km x (S) (F) (R) 
CPss = Vm - (S) (F) (R) 
(5) 
PREDICTIONS OF OOSE AND STEADY-STATE SERUM 
CONCENTRATION USING ESTIMATES OBTAINED FROM THE 
STUDY OF VOZEH eta/. (1981) IN MODELS S1 and S4 
The purpose of this part of the study was to compare the predictive performance of our 
estimates of Vm and Km with those obtained by Vozeh et al. (1981) using the 
Michaelis-Menten models S1 and S4. The values of 7.22 mg/kg/day and 4.44 mg/I for Vm 
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and Km respectively obtained from the study ofVozeh et al. (1981) were also programme-
assigned values used in the OP~ pharmacokinetic computer programme. 
The correlation between the predicted dose or serum concentration and the actual dose 
or serum concentration was determined by calculating the mean prediction error (MPE) 
and the mean squared prediction error (RMSE) (Miller and Rheeders, 1989). 
3.7.6. STATISTICAL ANALYSIS 
3.7.6.1. SUMVIAR.Y AND FREQUENCY ANALYSIS 
The spreadsheets were imported into the StatgraphicsR computer package (Statistical 
Graphics Corporation) for summary and frequency statistical analysis. The level of 
significance was set at p = 0.05. 
3.7.6.2. NONIVEM ANALYSIS 
To test the hypothesis of whether the fit of the model to the data was significantly different, 
the value of the MOF determined in the NONMEM fitting routine was used. Minimizing the 
objective function is equivalent to maximizing the probability (likelihood) of the data, and 
monitoring changes in the MOF can thus provide a statistical test as to which parameter 
values render the data most probable. Assuming that inter- and intra-individual variances 
were normally distributed, a difference in the minimum objective function (DOBF) of more 
than 3.8 indicated statistical significance (p < 0.05, assuming chi-square distribution) in the 
improvement or worsening of the fit of the model to the data when the restricted model 
had one regression parameter less than the full model, i.e. one degree of freedom 
(Sheiner et al., 1977). In order to identify potentially significant factors, a DOBF of> 7.9 
for one degree of freedom associated with a p value of 0.005 was required. The validity 
of the p - value rests in the validity of the underlying model. This approach was only used 
when comparing nested models. Wien building a final model from a simple model in a 
forward procedure, a decrease in the MOF indicated an improvement in the fit of the 
model to the data. Conversely, when fixed-effect parameters were removed from a model, 
an increase in the MOF indicated an improvement in the fit of the model to the data. 
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Wien two models that were not restricted in terms of each other (i.e. zero degree of 
freedom) were compared, the likelihood ratio (Lmax ratio) was used to estimate the 
relative probability of the two models (Mungall et al., 1985; Sheiner and Grasela, 1984). 
The following equation was used to calculate the Lmax ratio: 
L1 oc e-[MoF,1> - MoF(2J10.s 
L2 
{29) 
All estimate of 10 or more was regarded to indicate a difference between two models. 
In this study, either the OOBF or Lmax ratio was regarded as a sufficient criterion on the 
basis of which to select the most appropriate model to describe the data. If the DOBF was 
not sufficiently decisive, then the following criteria were considered in addition to the DOBF 
(Fattinger et al., 1991; Grevel et al., 1988): 
( 1) inspection of the correlation matrix of the parameter estimates to indicate whether 
a minimum correlation between the parameters existed; 
(2) whether the scatterplot of weighted residuals versus predicted concentration was 
randomly scattered around zero. All other residual plots were also examined; 
(3) whether smaller standard errors for the estimates were obtained. 
(4) whether a decrease in the size of the inter-individual variance of the 
pharmacokinetic parameters and residual error were obtained. 
3.7.6.3. CORRELATION ANALYSIS 
Model parameters were not estimated independently but as an interrelated set giving rise 
to the generation of a correlation matrix for parameters. In the course of this thesis, the 
incidence of 'high' correlation between parameter estimates was used to examine the 
reliability of the parameter estimates. Two parameters were judged to be highly correlated 
if the pairwise correlation was~ 0.752, otherwise it was termed low. Inspection of the 
correlation matrix should indicate a minimum correlation between the parameters. 
2this value has been used by the FDA, no reference is available 
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3.7.6.4. CONFIDENCE INTERVALS 
The reliability of the fixed effect parameter (8) estimates is important in parameter 
estimation. This statistical problem was approached through the construction of 
'confidence intervals' for the parameter estimates. The standard error of the parameter 
estimates (SEE) produced by NONMEM can be used to calculate confidence intervals for 
the true parameter values, thereby allowing hypothesis tests for these (Sheiner and Beal, 
1980). The approximate 95% confidence interval for (8) was given by 8 ± 1.96(SEE) 
(Miller and Ludden, 1993). Efficient parameter estimation required low standard errors for 
the parameters. 
The width of the confidence interval depends on the precision of the current parameter 
estimates. To a certain extent, it indicates the degree of caution the dinician should 
exercise in adjusting the dose. The reliability of the reported confidence interval thus 
determines the safety and the efficacy of the algorithm (Vozeh and Steimer, 1985). 
3.7.6.4.1. CALCULATION OF 11-IE 95°/o CONFIDENCE INTERVAL FOR RMSE 
Because of the large number of observations used in this study (i.e. a large number of 
degrees of freedom - 768), the t distribution tables presented in the standard textbooks 
on statistics could not be used. The t percentage points in terms of the standard normal 
percentage points were calculated using the following formula: 
X~,p = v [1 - 2 + zpJ 2 ] 
9v 9v 
(30) 
where v = the degrees of freedom, p = the tail area and Zp = 1.645 - the ordinate of the 
standard normal which gives the tail area p. The upper percentage point was then 
calculated by symmetry (Abrahamowitz and Stegun, 1972). The upper and lower limits of 








where x ~ . 97 5 and x ~ . 0 2 5 represent the lower and upper percentage points 
respectively, determined using equation 30 (Larsen and Marx, 1990). 
3.7.6.5. CALCULATION OF THE STANDARD ERROR FOR THE 
ESTIMATED AVERAGE Vm VALUE 
The parameter model used in this calculation was Vm = 81 wt + 83 where wt was 
considered the mean weight value for the population. The mean weight of 64 kg was used 
in this calculation. Although the variance of Vm would have to take the variance of weight 
into account, for this study where the interest was in the precision with which Vm was 
estimated at average weight, this was not needed. 
The following standard theorem was used to calculate the stardard error for Vm: 
var(aX + bY) = a 2 varX + 2ab cov(X, Y) + b 2 var(Y) (32) 




(Chatfield and Collins, 1980; Johnson and Wchem, 1988) 
Therefore, 
var ( Vm) = wt 2 var((\) + 2wt cov(8l' 83 ) + var (83 ) (33) 
Therefore, 
SE ( Vm) = ,/var ( Vm) (34) 
The values for var (81), cov (81, ~) and var (83} were obtained from the NONMEM output 
for each structural model. 
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3.7.6.6. PREDICTION ERROR ANALYSIS 
Given that the actual dose or the measured concentration was known, the efficiency with 
which each model predicted dose or concentration could be judged. Prediction error 
analysis involved the calculation of the MPE and the RMSE (Rhoney et al., 1992; Vozeh 
et al., 1981). 
The MPE described the bias that may be present, a positive bias indicated that the 
prediction method overpredicted the actual dose or concentration and a negative bias 
indicated that the prediction method underpredicted the actual dose or concentration. The 
MPE was determined by calculating the prediction error, which is the predicted dose or 
concentration minus the actual dose or concentration for each patient. The result was then 
applied to the following equations (Beck et al., 1987; Privitera et al., 1989; Sheiner and 
Beal, 1981) : 
n 
MPE = l. L (PE) 
n i=1 
(35} 
where n is the number of dose and serum concentration pairs and PE the prediction error. 
In order to express the predictions on the same scale, percentage error was computed for 
dosage prediction: 
% MPE = MPE for dose x 100 
mean actual dose 
(36} 
and for concentration prediction : 
% MPE = MPE for concentration x 100 (37} 
mean measured concentration 
The percentage MPE obtained with each of the matched groups for each of the 3 models 
were compared. The average percentage MPE for each of the 3 sets of matched groups 
was then calculated and compared. Since the MPE has a sign associated with it, it was 
not a measure of the absolute magnitude of error. To remove the sign, the prediction error 
was therefore squared and the mean taken; this gave the mean squared error (MSE) 
(Graves et al., 1986): 
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n 
MSE = _±_ L (PE) 2 
n i=1 
(38} 
The precision of the prediction method was evaluated by calculating the RMSE: 
n 
RMSE = _±_ L (PE) 2 
n i=1 
(39} 
The RMSE was expressed as a percentage of the actual dose or serum phenytoin 
concentration (Yuen et al., 1983a; 1989). The smaller the RMSE, the greater the precision 
of the model with its associated population estimates in predicting the actual dose or 
serum phenytoin concentration. Bias and precision were further evaluated by constructing 
the 95% confidence intervals about the MPE and RMSE for each method (Flint et al., 
1985). 
In summary, the following factors were taken into account when making comparisons of 
predictive performance: 
(1) magnitude of MPE (bias) 
(2) magnitude of RMSE (precision) 
(3) 95% confidence interval of MPE 
(4) standard deviation of MPE 
(5) 95% confidence interval of RMSE 
(6) comparison of mean predicted dose or serum concentration with the mean actual 
dose or measured concentration 
(7) comparison of the standard deviation of the predicted dose or serum concentration 
with that of the actual dose or measured serum concentration. 
(8) statistical difference between the actual and predicted dose or serum 
concentration using Student's t-test. The level of significance was set at p < 0.05 
(9) percentage of under- or overpredictions 
( 10) percentage of prediction errors of more than 10% for dose and of more than 20% 
for serum concentrations 
(11) number of dose : serum concentrations pairs excluded due to the dosage rate 
being greater than Vm 
(12) number of highly unrealistic serum phenytoin predictions greater than 75 mg/I. 
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3.8. ETHICS 
Informed written consent was obtained from each patient included in this study. The study 
was carried out with prior approval of the Ethics Committee of the Medical School, 
University of Gape Town and it was conducted strictly in accordance with the Helsinki 
Declaration. The choice of phenytoin for the patient was based on clinical grounds by the 
doctor attending to the patient. A dose was changed for therapeutic reasons only, and 




The data for this study were collected between August 1990 and July 1992 during routine 
clinical consultations at the various epilepsy clinics. 
4.1. PATIENT CHARACTERISTICS 
A total of 538 (233 black and 305 coloured) adult epileptic patients residing in the VVestem 
Cape were entered in the study. Of these patients, 332 were included in the data analysis 
as they were considered to have produced reliable phenytoin levels. Of the 332 patients 
included in the data analysis, 226 were male and 106 were female, 149 were black and 
183 coloured (Table 2, page 62). Of the patients classified as coloured, 67 were of Cape 
malay origin. 
The demographic characteristics of patients included in the NONMEM analysis are 
recorded in Table 3 (page 63). Details of the latter are given separately for black and 
coloured patients and the two ethnic groups combined. The age distribution of patients is 
shown in Table 4 (page 63). Only 24 patients in the age group 60 - 79 were available for 
inclusion in the study. 
Of the 206 patients not included in the data analysis, 78.2% produced no phenytoin 
levels. The remainder (21.8%) produced unreliable levels, i.e. a large variation between 
two levels on the same dose. Ps a result of this, 89 phenytoin levels were excluded from 
the study. The details of the demographic characteristics of patients who defaulted or were 
excluded from the study are shown in Table 5 (page 64). These patients experienced an 
average of 1.08 ± 1.22 seizures per month, ranging from Oto 8 seizures per month. 
Some patients spent as much as 14 months in the study without producing any reliable 
serum phenytoin level for inclusion in the data analysis. The demographic characteristics 








Total patients entered in study 538 
Black patients entered in study 233 
Coloured patients entered in study 305 
Black patients included in NONMEM analysis 149 
Coloured patients included in NONMEM analysis 183 
Malay patients included in NONMEM analysis 67 
Total nurmer of patients included in NONMEM analysis 332 
Black male patients included in NONMEM analysis 100 
Black female patients included in NONMEM analysis 49 
Coloured male patients included in NONMEM analysis 126 
Coloured female patients included in NONMEM analysis 57 
Black patients who were exduded or defaulted from dinic 84 
Coloured patients who were exduded or defaulted from dinic 122 
A further description of patients who produced no phenytoin levels, either because of 
defaulting or being excluded from the study, is given in Table 6 (page 64). The majority 
of these patients were unemployed (88.7%) and only 23.8% had their epilepsy controlled. 
The reasons for excluding patients from the study are outlined in Table 7 (page 65). The 
most common reason was non-compliance as determined by comparison of at least two 
serum phenytoin levels obtained on the same dose. Most patients who were excluded 
from the study were excluded for more than one reason. 
TA81..E 3: 
63 
DEMOGRAPHIC CHARACTERISTICS OF PATIENTS INCLUDED IN THE 
NONMEM ANALYSIS 
El.ACK COLOURED COM81NED 
Mean Rarge Mean Rarge Mean Ral'}Je 
(SD) (SD) (SD) 
Age (yr1 33.5 15.0- 38.7 15.0- 36.4 15.0-
(12.3) 82.0 (15.0) 78.0 (14.1) 82.0 
Heig"t(an) 167.2 147.0- 165.2 142.5- 166.2 142.5-
(9.2) 190.0 (9.6) 197.0 (9.4) 197.0 
Mass (kg) 66.4 44.0- 61.9 36.9- 64.0 36.9-
(13.2) 135.0 (12.0) 113.1 (12.7) 135.0 
8oct,' suface area (m2) 1.7 1.3- 1.7 1.2- 1.7 1.2 -
(0.2) 2.6 (0.8) 2.5 (0.2) 2.6 
Duatia1 in shrlf 9.0 1.0- 6.6 1.0- 7.7 1.0-
(nmhs) (4.7) 19.0 (5.5) 22.0 (5.3) 22.0 
Duatia1 cl e~lepsy 10.4 1.0 - 12.2 1.0- 11.3 1.0-
(yr1 (8.5) 48.0 (9.0) 34.0 (8.8) 48.0 
Pher?ftdn dosage at 295.3 200.0- 302.1 100.0- 299.1 100.0-
start cl sb.rlf (ngday) (38.3) 450.0 (63.1) 500.0 (53.4) 500.0 
Dosage at ero c1 sb.rlf 307.1 150.0- 313.1 100.0- 310.4 100.0-
(ngday) (57.0) 500.0 (70.8) 500.0 (64.9) 500.0 
~ p,el'1floin 308.8 150.0- 302.4 100.0- 305.8 100.0-
ctJse (ngday) (56.6) 500.0 (66.4) 500.0 (60.7) 500.0 
~ p,el'1floin 65.3 15.0- 58.3 22.0- o2.7 15.0-
level (µmoUI) (26.4) 133.0 (20.9) 115.0 '23.9) 133.0 
TA81..E 4: NUMBER OF PATIENTS IN SELECTED AGE CATEGORIES 
NUMEER OF PATIENTS 
AGE GROUPS 
15 -19 20- 39 40-59 60- 79 
El.ACK 13 90 44 2 
COLOURED 11 95 55 22 
TOTAL 24 185 99 24 
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TAEl.E 5: DEMOGRAPHIC CHARACTERISTICS OF PATIENTS \M-10 
DEFAULTED OR \/\ERE SUBSEQUENTLY EXCLUDED FROM 
THE STUDY 
BLACK COLOURED COMBNED 
Mean RanJe n Mean RanJe n Mean RanJe n 
(SD) (SD) (SD) 
~(yr) 32.91 15- 79 41.35 16- 119 37.98 15- 198 
(11.46) 73 (14.86) 74 (14.19) 74 
Heigt(an) 168.26 144- 36 166.78 149.5 ± 43 167.44 144- 79 
(11.01) 189 (8.76) 179.5 (9.8) 189 
Mass (kg) 64.74 41.6- 37 60.73 34.3- 51 62.41 34.3- 88 
(14.04) 113 (12.60) 85.0 (13.3) 113 
Cuatialdeplepsy 11.34 1- 56 11.77 1- 112 11.58 1- 168 
(yr) (9.71) 50 (11.36) 50 (10.64) 50 
~ndose 291.78 200- 76 295.09 100- 112 293.75 100- 188 
(nqday) (47.68) 400 (47.91) 500 (47.72) 500 
No. d seizt.res 2.49 0- 78 3.35 0- 116 3.24 0- 194 
experien:ed cuirg (3.15) 14 (3.80) 24 (3.65) 24 
the 3 m:nl1s befae 
ermrirg the st1d/ 
Cuatial in st1.dJ 1.81 0- 81 2.64 0- 107 2.28 0- 188 
(m:nlls) (2.64) 13 (3.52) 14 (3.20) 14 
TAEl.E 6: DESCRIPTION OF PATIENTS \M-10 DEFAULTED OR \/\ERE 
EXCLUDED FROM THE STUDY 
BLACK COLOURED COMEINED 
DESCRIPTION % % % 
Total patients who defaulted or were exduded 36.1 40.0 38.3 
Exduded from study 3.9 12.5 20.9 
Defaulted from study 32.2 27.5 79.1 
Males 67.5 84.5 76.0 
Females 32.5 15.5 24.0 
Efll)loyed 7.4 12.4 9.9 
Unerr1)1oyed 91.4 86.0 88.7 
Scholars 1.2 1.6 1.4 
Seizures apparently controlled 28.6 18.9 23.8 
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TAB..E 7: REASONS FOR EXCLUSION FROM THE STUDY 




Alcohol abuse (suspected or confinned) 44.4 15.8 
Irregular attendance at dinic 22.2 15.8 
Abnormal laboratory finding 11.1 7.9 
Non-corrl)liance 
33.3 
(a) Detemined by phenytoin levels and, 
1.1 
63.2 
(b) Tablet counts/rrissing phenytoin closes -
Adverse/hypersensitivity reactions - 2.6 
Wong anticonvulsant presaibed - 2.6 
Anticonvulsant changed or added 11.1 10.5 
Interfering drugs presaibed 11.1 5.3 
Patient or farrily merroers unable to fill in diary - 5.3 
Patient or farrily merroers uncooperative 22.2 15.8 
Unable to obtain blood for phenytoin levels - 2.6 
Phenytoin stopped - 5.3 
Became pregnant subsequent to entering study 22.2 7.9 
Deceased - 2.6 
Of the patients, 49. 7% smoked cigarettes; 40. 7% of black patients smoked whereas a 
significantly greater proportion (58.7%) of coloured patients smoked. Black patients 
smoked 9.1 ± 6.6 (range 1 - 30) cigarettes per day whereas coloured patients smoked 
10.6 ± 7.6 (range 1 - 40) cigarettes per day. Of black and coloured patients, 27.4% and 
27.5% respectively reported mild-to-moderate alcohol consumption. Alcohol abusers were 
not included in the study. A large proportion of patients (67.8%) were unemployed and this 
contributed to patients defaulting on clinic attendance, given the lack of finances for 
transport costs and hospital fees. 
Most of the patients were from Heideveld (HOH), Elsies River (ERO), Lotus River (LRD), 
Khayelitsha (KOH) and Guguletu Day Hospitals (GOH) and fewer patients were from the 
Outpatients Neurology Clinic at Groote Schuur Hospital (GSH), Dr Abdurahman Day 
(DAD) Hospital, Betel School for Epilepsy and the South African National Epileptic League 
(SANEL) (Table 8, page 66). Details of the clinical pharmacokinetic services offered at the 
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various hospitals and institutions are given in Table 8. The duration of the study at each 
clinic, the number of clinic sessions held, the number of patients producing results, and 
the percentage of defaulting patients at each of the hospitals and institutions are shown 
















SUMMARY OF CLINICAL PHARMACOKINETIC SERVICES OFFERED 
AT THE VARIOUS HOSPITALS AND INSTITUTIONS IN THE \/\£STERN 
CAPE 
DURATION NO.OF NO.OF NO.OF DEFAULTERS 
OF STUDY CLINIC PATIENTS PATIENTS (%) 
(monts) SESSIONS PRODIJCING 
RESULTS 
21.0 91 110 66 40.0 
22.0 46 24 16 33.3 
5.0 30 12 10 16.7 
19.8 83 129 81 37.2 
18.0 74 70 42 40.0 
15.0 67 94 68 27.7 
8.3 6 7 7 0.0 
6.7 30 60 26 56.7 
7.6 36 32 16 50.0 
463 538 332 
61.7 
• the full narres of the hospitals and institutions are reported in the text 
Altogether 3341 consultations were conducted by the investigator. Further details of these 
are given in Table 9 (page 67). The number of repeat consultations depended on the 
severity of the epilepsy, the presence of adverse reactions and the need for dose 
adjustments. 
TAB..E9: NUMBER OF CONSULTATIONS CONDUCTED BY THE 
INVESTIGATOR 
NUMEER OF CONSULTATIONS 
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El.ACK COLOURED COMBNED 
Patients included in study 1459 1289 2748 
Patients who defaulted or were exduded from study 198 395 593 
Total nurmer of consultations 3341 
A total of 1095 serum phenytoin levels were taken during this study. As serum phenytoin 
concentrations are not routinely measured at the hospitals concerned, the number of 
measured serum phenytoin concentrations per individual is greater than would routinely 
be available. The 332 patients included in the study produced a total of 1006 serum 
phenytoin levels. Only 853 of these levels were judged reliable for inclusion in the study. 
A minimum of two serum phenytoin concentrations at steady state on one dosage regimen 
was preferred for each patient to permit adequate analysis and assessment of reliability 
of the data. The characterization of serum phenytoin levels to dose relationship is shown 
in Table 10 (page 68). In 81 (24.4%) patients, only one serum phenytoin level was 
obtained. Even one data point per individual obtained during routine treatment can be 
used by NONMEM and can contribute useful information (Sheiner and Beal, 1983). In 48 
(14.5%) patients, one level on each of 2 to 4 doses of phenytoin was obtained. Because 
of the prospective nature of the study, patients who produced a single dose : serum 
concentration were included in the analysis provided they claimed good compliance, the 
tablet counts were correct and the diaries correctly filled in. If a single level was lower than 
30 µmol/1 such a level was not included in the analysis. In the balance of 203 (61.1 %) 
patients at least 2 serum phenytoin levels on one or more doses of phenytoin was 
obtained. The average number of serum phenytoin concentration measurements obtained 
per patient was 2.6, range 1 to 8. These samples were obtained as part of the therapeutic 
drug monitoring programme. 
On admission, 235 patients were taking phenytoin alone, while 140 (40 black and 100 
coloured) patients were taking other medication concurrently with phenytoin. The 
concurrent medications are reported in the literature not to interfere with phenytoin 
pharmacokinetics. In this study, paracetamol (PanadoR) was the most frequently 
prescribed drug used concurrently with phenytoin (Table 11, page 69). However, all 
patients were taking phenytoin as the only drug for the treatment of their epilepsy. In 52 
(15.7%) patients, other disease states besides epilepsy were present. A list and the 
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occurrence of these diseases are reported in Table 12 (page 71). Hypertension was the 
most frequent disease (4.8% of patients) occurring concurrently with the epilepsy. 
TAEI..E 10: 
CODES: 
1 CONC : 1 OOSE 
2 CONCS : 1 OOSE 
CHARACTERIZATION OF SERUM PHENYTOIN CONCENTRATION: 
DOSE RELATIONSHIPS 
NUMBER OF PATIENTS 
El.ACK COLOURED TOTAL 
1 CONC : 1 DOSE 31 50 81 
2 CONCS : 1 DOSE 46 61 107 
3 CONCS : 1 DOSE 5 4 9 
4 CONCS : 1 DOSE - 2 2 
2 CONCS : 2 DOSES(2) 4 13 17 
2 CONCS : 2 DOSES (3) 21 19 40 
2 CONCS: 2 DOSES (4) 19 21 40 
2 CONCS : 2 DOSES (5) 4 1 5 
3 CONCS : 3 DOSES 14 8 22 
4 CONCS : 4 DOSES 5 4 9 
= 1 serum phenytoin concentration obtained on a single dose of phenytoin 
= 2 concentrations obtained on a single dose of phenytoin. 
2 CONCS : 2 OOSES (2) 
2 CONCS : 2 OOSES (3) 
= total of 2 concentrations, 1 concentration obtained on each of 2 doses. 
= total of 3 or more concentrations obtained on 2 doses of phenytoin; 2 or more 
concentrations obtained on one dose and 1 concentration on another dose. 
2 CONCS : 2 OOSES (4) = total of 4 or more concentrations obtained on 2 doses; 2 levels on 1 dose and at least 2 
levels on another dose, etc. 
Phenytoin was initially prescribed in 91.0, 7.1 and 1.9% of the patients once, twice or 
thrice daily, respectively. Two hundred and sixty-five dosage adjustments were made 
during this study in 156 patients. The phenytoin dose was increased in 31. 9% and reduced 
in 15.1 % of patients taking phenytoin. Altogether, dose adjustments were made in 47.0% 
of patients. No change in dose therefore represented the most common therapeutic 
decision in patients on phenytoin (Table 13, page 72). Wien considering only the patients 
in whom dosage adjustments were made - one, two or three dosage adjustments were 
made in 69.8, 24.4 and 5.8% of patients, respectively. Similarly, if only patients optimized 
on phenytoin were considered, the results differ little. 
TAB.E 11: 
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FREQUENCY OF DRUGS ADMINISTERED CONCURRENTLY \J\ATH 
PHENYTOIN AT THE TIME OF BLOOD COLLECTION FOR 
PHENYTOIN LEVELS 
NUMEER OF PATIENTS 
GENERIC NAME TRADE NAME 
El.ACK COLOURED 
n=40 n= 100 
Anitriptyline Tryptanol - 2 
Aspirin Disprin - 1 
Atenolol Tenoonin - 1 
Astenizole Hismanal - 1 
Clonidine Dixarit - 1 
Diclofenac Voltaren - 1 
Digoxin - 1 
Ferrous gluconate - 1 
Felic acid 2 -
Furosemde - 1 
Glibendamde 2 -
Glicazide Diamicron - 1 
Ibuprofen Brufen 3 6 
lndomethacin lndodd - 4 
lsosorbide lsordil - 2 
dinitrate 
lspaghula Fybogel 1 -
Medroxy- Provera, Depo-Provera 1 1 
progesterone 
Methyldopa Aldomet 3 3 
Naproxen Naprosyn - 1 
Norethisterone Nur-lsterate 2 -
Oxazepam Serepax - 1 
Paracetamol Panado 13 40 
Potassium chloride Slo.v-K - 1 
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T A8LE 11: cootinued 
GENERIC NAME TRADE NAME NUMBER OF PATIENTS 
Bl.ACK COLOURED 
Prazosin Minipress - 1 
Promethazine Phenergan - 1 
Propranolol lnderal - 1 
Pyridoxine - 1 
Salbutarrol Ventolin - 2 
Sodium bicarbonate - 1 
Vrtanin B. Co. - 6 
Vitanin 81 - 1 
Aspirin, CX>deine Codis 1 -
Paracetarrol, CX>deine Panadeine 2 -
Diphenhydrarrine, Benylin 1 -
amronium chloride, 
sodium citrate 
Alurrinium hydroxide Ml)hojel - 2 
Alurrinium hydroxide, Propan Gel-S 1 2 
magnesium oxide, 




Triarrterene, hydrochloro- Dyazide - 1 
thiazide 
Arriloride, hydrochloro- Moduretic 8 8 
thiazide 




FREQUENCY OF THE OCCURRENCE OF OTHER DISEASE STATES 
BESIDES EPILEPSY 




Alcoholic carcliomyopathy - 1 
Anaerria - 1 
Arthritis 1 1 
Asthma - 3 
Bronchiectasis - 1 
Bronchitis - 1 
Cerebral palsy 2 1 
Diabetes 1 1 
Endometriosis - 1 
Cerebral granuloma 1 -
Herriplegia 2 1 
Hydrocoele 1 -
Hypertension 6 10 
Lung abscess 1 -
Mental retardation 1 1 
Neurocysticercosis 2 -
Peripheral neuropathy - 1 
Pleurisy - 1 
Poliomyelitis - 1 
Psoriasis - 1 
Rickets 1 -
Schizophrenia - 1 
Sinusitis - 1 
Stroke 1 1 
Venereal disease - 2 
72 
TA81..E 13: PERCENTAGE OF PATIENTS IN \/\,HOM THE PHENYTOIN DOSE 
WAS EITHER INCREASED, DECREASED OR UNCI-IANGED 
PERCENTAGE OF PATIENTS 
El.ACK COLOURED COMBINED 
n= 149 n= 183 n=332 
Doseirueased 34.2 30.1 31.9 
Dose cleaeased 17.5 13.1 15.1 
No~inoose 48.3 56.8 53.0 
Dose aqusted 51.7 43.2 47.0 
Patients were considered to be optimized on phenytoin if they experienced one seizure 
in 3 months or were seizure free for this period. One hundred and ninety-four (58.4%) 
patients were optimized on phenytoin at the end of the study. In 13.34% of patients, 
dosage adjustments were made without obtaining a subsequent serum phenytoin level at 
steady state at that dose because of defaulting. One hundred and ninety-nine patients 
were studied on 1 dose, 102 patients on 2 different doses, 22 patients on 3 different doses 
and 9 patients on 4 different doses. The average optimized dose of phenytoin was 305.8 
mg/day, range 100- 500 mg/day. This value may be biased as the calculation thereof did 
not take into account the lowest dose necessary to control the seizure. Many of the 
patients were started on 300 mg phenytoin and the small increments and decrements in 
doses made by the investigator were probably overshadowed by the large number of 
patients on 300 mg phenytoin. The number of prescriptions for 50 mg and 27 mg 
phenytoin sodium (half an Epanutin lnfatabR) increased from 20 to 116 and from zero to 
51, respectively. The following doses of phenytoin sodium in mg/day were prescribed 
during this study: 100, 150, 171, 200, 227, 250, 277, 286, 300, 307, 314, 327, 334, 341, 
350, 364, 377,384,400,414,427, 450 and 500. 
In 55.6% of patients no cause for their epilepsy could be determined by questioning the 
patient or perusing the folder. Head trauma due to motor vehide accidents or assault was 
the cause of the epilepsy in 34. 7% of patients. The other causes of epilepsy are available, 
but not reported here. 
Forty-four percent of patients experienced adverse effects resembling those of phenytoin 
at the first visit, of whom 23.5% had experienced adverse effects not related to phenytoin. 
N. the first visit, 20.5% of patients had experienced adverse effects probably related to 
phenytoin. N. the last visit, 3.2% of patients experienced adverse effects to phenytoin. 
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The decision whether the adverse effects were related or unrelated to phenytoin was 
based on serum phenytoin concentrations and the clinical judgement of the investigator. 
The correlation of serum concentration with the adverse effects of dizziness, diplopia, 
nystagmus and ataxia are outlined in Table 14. These adverse effects were experienced 
at the time when the blood samples were taken for the determination of serum phenytoin 
concentrations. 
T.AEI.E 14: SERUM PHENYTOIN CONCENTRATION VERSUS ADVERSE EFFECT 
RELATIONSHIPS 
SERUM PHENYTOIN CONCENTRATIONS (µmol/l) 
ADVERSE 
REACTlON Bl.ACK COLOURED COMBINED 
II/lean Rarge n Mean Rarge n Mean Rarge n 
(SD) (SD) (SD) 
Dizziress 119.5 66- 22 121.9 00-208 31 120.7 5S- 53 
(34.8) 205 (40.4) (37.9) 208 
Dipqja 121.0 73- 19 129.8 65-208 16 125.4 65- 35 
(38.0) 205 (56.8) (47.0) 208 
Nystagrus 110.7 61- 18 118.6 52-208 23 114.7 52- 41 
(36.7) 205 (48.5) (43.4) 208 
Ataxia 130.9 80- 19 137.3 79-200 21 134.1 79- 40 
(31.6) 205 (36.0) (33.7) 200 
One hundred and fourteen (53 black and 61 coloured) patients defaulted on clinic 
attendance after producing levels that were used in the NONMEM analysis. Of these, 47 
(27 black and 20 coloured) were optimized on phenytoin and the balance of the patients 
defaulted on attendance, even though they were not optimally controlled. Sixty-three (42 
black and 21 coloured) patients were discharged from the pharmacokinetic consulting 
service prior to termination of the study as they had been optimally controlled on 
phenytoin. 
4.2. THERAPEUTIC CONCENTRATIONS OF PHENYTOIN 
The relationship between the therapeutic concentration ranges of phenytoin and the 
number of patients optimized in the specific range is given in Table 15 (page 74). Most 
patients (61.9%) were optimized in the therapeutic range of 40 to 79 µmol/1. A significant 
number of patients (21.1 %) were optimized on phenytoin at serum concentrations above 
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that range and 1.6% of patients were optimized at serum concentrations above 120 µmol/1. 
Conversely, 17% of patients were optimized at serum levels below 40 µmol/1. This serves 
to emphasize the need to view the therapeutic range as a statistical concept with regard 
to group means, within which individuals differ both in efficacy and side-effects. 
TABI..E 15: RELATIONSHIP BETV\EEN THERAPEUTIC CONCENTRATION OF 
PHENYTOIN AND THE PERCENTAGE OF PATIENTS OPTIMIZED AT 
THAT CONCENTRATION RANGE 
PERCENTAGE OF PATIENTS 
THERAPEUTIC 
CONCENTRATION Bl.ACK COLOURED COMBNED 
(µnd/1) n=93 n=78 n= 171 
0.0 - 19 0.0 0.0 0.0 
20 - 39 16.1 18.0 17.0 
40 - 59 22.6 39.7 31.2 
60 - 79 34.4 26.9 30.7 
80 - 99 12.9 9.0 10.9 
100 -119 10.8 6.4 8.6 
120 - 139 3.2 0.0 1.6 
4.3. SEIZURE FREQUENCY REDUCTION 
The response to treatment was based on an assessment over a minimum period of 3 
months (Callaghan et al., 1985). A total of 1202 seizures during the 3 months before 
entering the study (1st baseline period) were reported by the 332 patients. A total of 1070 
seizures were reported by the same patients during the 3 months after entering the study 
(2nd baseline period). The same patients reported 643 seizures 3 months before 
termination of the study (test period). These results were not used to determine the benefit 
of the dinical pharmacokinetic service (i.e. a reduction in seizure frequency) as many of 
these patients were in the study for less than 3 months. This makes comparison of the 
number of seizures occurring during the 1st baseline with those occurring during the test 
period difficult as an overlap between these periods existed. In this case, a second 
baseline period was also not available. 
To determine the benefit of our service, the following criteria were set: (a) the patient had 
to participate in the study for at least 6 months so that the second baseline and the test 
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periods did not overlap, and (b) the patient had to attend the clinic for at least 6 
consultations. One hundred and ninety-five (113 black and 82 coloured) patients satisfied 
these criteria. The total number of seizures experienced by these patients during the 1st 
and 2nd baseline periods and the test period are reported in Table 16. The percentage 
reduction in seizure frequency was determined by comparing the number of seizures 
during the 1st and 2nd baseline periods with those occurring during the test period. The 
average of the number of seizures occurring during the 1st and 2nd baseline periods was 
considered as the initial frequency. The results of this analysis are reported in Table 17 
(page 76). A 60.1 and 69.5% reduction in seizure frequency were obtained in black and 
coloured patients, respectively. In 29 black and 50 coloured patients, the dose of 
phenytoin was adjusted within 3 months of their entering the study. Ps the seizure 
frequency during this period was used as the 2nd baseline period, the percentage 
reduction in seizure frequency stated above as a result of the clinical pharmacokinetic 
service is most probably an underestimate. 
TAB...E 16: TOTAL NUMBER OF SEIZURES EXPERIENCED DURING THE FIRST 
AND SECOND BASELINE PERIODS AND THE TEST PERIOD1 
NUMBER OF SEIZURES 
PERIOD 
Bl.ACK COLOURED COMBINED 
n= 113 n=82 n= 195 
First baseline period 273 394 007 
Seard baseline period 284 304 588 
Test period 111 105 216 
1 Only patients who participated in the study for at least six roonths and attended the dinic for at least 6 consultations were 
induded in this analysis. 
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TA8l...E 17: PERCENTAGE REDUCTION IN SEIZURE FREQUENCY 
PERCENTAGE IMPROVEMENT IN SBZURES 
PERIOD 
El.ACK COLOURED COMBNED 
n= 113 n=82 n= 195 
Based on tt-e first baselire period 59.3 73.4 66.4 
Based on tt-e secaid baselire period 60.9 65.5 63.2 
Based on tt-e average d tt-e first and 60.1 69.5 64.8 
secaid baselire periods 
The percentage reduction in seizure frequency was grouped into 5 categories as indicated 
in Table 18. Of the 195 patients who satisfied the indusion criteria in this analysis, 127 
experienced a reduction in seizure frequency. This represented 64.9% of patients. The 
seizure frequencies per month (mean and range) for specific time periods before and after 
entering the study are reported in Table 19 (page 77). The patients in this analysis were 
evaluated according to the same criteria as above. 
TAEI..E 18: PERCENTAGE REDUCTION IN SEIZURE FREQUENCY GROUPED 
INTO VARIOUS CATEGORIES1 
PERCENTAGE OF PATIENTS 
REDUCTION IN SBZURE 
FREQUENCY(%) 
El.ACK COLOURED COMBNED 
n= 113 n=82 n= 195 
0 37.2 32.9 35.1 
1 - 24 0.9 0.0 0.5 
25-49 5.3 6.1 5.7 
50- 74 12.4 12.2 12.3 
75- 99 3.5 12.0 7.2 
100 40.7 37.8 39.2 
1Patients who were already optirrizecl on phenytoin are included in this analysis. 
TA81..E 19: 
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MEAN SEIZURE FREQUENCY PER MONTH FOR SPECIFIC PERIODS 
BEFORE AND AFTER THE INITIATION OF THE STUDY 
SEIZURE FREQUENCY PER MONTH 
PERIOD Bl.ACK COLOURED COMBINED 
N'ean Rarg3 N'ean Rarg3 N'ean Rarg3 
1st baselire period 2.44 0-15 4.80 0-48 3.62 0-48 
2nd baselire period 2.54 0-29 3.75 0-22 3.15 0-29 
Test period 1.0 0-16 1.36 0-14 1.18 0-16 
Patients whose seizure frequency had fallen from baseline level by 50% or more in the 
test period were considered to have a 'good improvement' in seizure control. A reduction 
of less than 50% was categorized as 'poor to intermediate improvement' in seizure control 
(Travers et al., 1972). After this categorization, 58.7% of patients exhibited a good 
improvement in their seizure control. This analysis included patients who were 
well-controlled or seizure-free on phenytoin. 
The decrease in seizure frequency reported in this study may be greater than that 
indicated by the results. The seizure frequency for the first baseline period was in most 
cases obtained from the patient and/or the family, and often from the scant information in 
the hospital folder. Epileptic patients tend to be forgetful or unaware that they had a 
seizure and this may result in the number of seizures occurring being under-reported. Also 
the compliance during this time was in question. The second baseline period was taken 
into consideration to minimize the influence of non-compliance on the interpretation of the 
results. 
4.4. CLINICAL PHARMACOKINETIC SERVICE 
There was a high degree of acceptance of the service judged by the requests for advice 
from the doctors on the management of epilepsy, even for patients not included in this 
study. The extent to which the advice was followed was a further indicator of this. For the 
332 patients included in this study, only 7 dosage recommendations were not accepted, 
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for the following reasons: (a) a dose increment of 27 mg instead 100 mg of phenytoin 
sodium was considered too conservative. The doctor wanted to follow the standard 
practice of increasing the dose of phenytoin by 100 mg. The patient subsequently became 
toxic, and the recommendation of a 27 mg increase in dose was then accepted; (b) 
resistance to increasing the dose so that the serum concentration would not exceed the 
therapeutic range: this occurred in 2 patients although they were still experiencing seizures 
and showed no signs of toxicity; (c) the regimen recommended was too complex, and it 
was feared the patient would not comply with the proposed regimen. This happened in 4 
cases. All of the above rejections of the recommendations happened at the start of the 
pharmacokinetic consultation service. 
As this study was conducted among outpatients, compliance was critical. Many patients 
were compliant as long as they possessed phenytoin, but they defaulted when they ran 
out of medication. Other patients defaulted in keeping their clinic appointments. These 
patients were also regarded as non-compliant. In the majority of patients, more than one 
phenytoin level was obtained and this greatly assisted the assessment of patient 
compliance. In most patients, at least two levels on a particular dose were taken before 
further adjustment. It was found in numerous instances that 2 blood samples obtained on 
the same dose in the same subject showed markedly differing values. If non-compliance 
was suspected, a third level was taken on the same dose. Thereafter, the two levels that 
differed the least from each other were used. For these reasons, non-compliance was not 
considered to be a major problem in this study. As phenytoin is used prophylactically in 
the management of epilepsy, one could expect occasional under-compliance in a patient 
who had good epileptic control. A number of patients remained obstinately non-compliant 
despite the best efforts of the investigator. Frequent visits, good relationships with the 
patients and their families, and the regular checking of the serum phenytoin levels 
contributed greatly to improved compliance (Gibberd et al., 1970). Patient morale also 
appeared to improve. 
4.5. UMTATIONS OF THE STUDY 
The following limitations and drawbacks were experienced in offering a clinical 
pharmacokinetic service: 
(1) Non-compliance posed a problem, especially during the initial period after the 
patient entered the study. As a result, 242 serum phenytoin samples were not 
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used in this analysis. A number of patients who claimed to be taking their 
phenytoin every day had a zero or near zero serum phenytoin level. 
(2) As most of the patients involved in this study were from the lower socio-economic 
group, they were often not able to keep an appointment because of lack of finance 
for transport or hospital fees. 
(3) The frequent change of doctors at the Outpatient Neurology Clinic at Groote 
Schuur Hospital often led to doctors being unaware that the service was being 
offered and resulted in confusion as to the follow-up treatment of the patient. The 
short duration (approximately two and a half hours) of the clinic posed a problem. 
Some patients were sent for X-rays and other investigations and only returned at 
the end of the clinic session. By the time the necessary calculations had been 
completed and a report written, the doctor had often left and the recommendations 
were not acted on. If the patient was seen by the doctor close to the end of the 
clinic session there was often no time for the pharmacokinetic consultation. As this 
was the last clinic of the day, the clinic was closed at the end of the clinic session 
and the investigator was unable to consult with the patient. 
(4) Patients were taken off phenytoin or another anticonvulsant which had been 
added before the dose of phenytoin was optimized. However, it must be stated 
that the latter seldom occurred once the doctors were fully aware of the service 
that was being offered. \/\Alen this happened, it was most often when the patient 
attended the hospital on a day other than that on which the epilepsy clinic was 
held. 
(5) The frequent change of doctors at some of the hospitals presented a problem. 
This required regular discussions of the project and phenytoin pharmacokinetics 
throughout the study. 
(6) Patients were being treated for epilepsy at more than one hospital, for example, 
a neurology clinic at a major hospital and a day hospital. This often resulted in the 
patient obtaining an extra supply of phenytoin. This led to patients missing the 
appointment with the investigator if they had enough medication. It made the 
assessment of compliance based on tablet counts difficult. Doses were also 
changed without a follow-up report. 
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(7) Patients may have falsely reported seizures in order to obtain a disability grant. 
~ far as could be determined this seldom occurred in our clinic, as most patients 
reported an improvement. 
(8) Pharmacists often supplied phenytoin acid instead of phenytoin sodium. This 
occurred especially when the dispensary had no stock of phenytoin sodium 50 mg 
tablets. In such cases, the serum phenytoin concentration measurements were 
usually delayed for a month. 
(9) On numerous occasions a drug which interfered with the pharmacokinetics of 
phenytoin was concurrently prescribed by the doctor or primary health care nurse. 
The most common interfering drugs prescribed were theophylline and 
co-trimoxazole. The patients affected were temporarily or permanently withdrawn 
from the study. Otherwise, the doctor or primary health care nurse was advised 
to consider prescribing an alternative drug, if possible. 
( 10) The possibility of the patients taking extra doses of phenytoin before attending the 
clinic, after experiencing a seizure or when having a feeling that a seizure was 
imminent, was always borne in mind. If this happened, blood collection for 
assessment of serum phenytoin concentration was deferred, usually for a month. 
(11) The initial reluctance of a doctor to prescribe complex dosage regimens of 
phenytoin, e.g. 3 different dosage forms of phenytoin at the same time, presented 
a problem. 
(12) A policy of the hospital authorities that entailed rotation of the nurses to different 
hospitals every three months presented a problem in that some of the incoming 
nurses were unaware of the pharmacokinetic service and therefore did not refer 
the patients to our clinic, but instead requested the patients to collect their 
medication at the dispensary. If the repeat prescription of phenytoin was written 
up by the nurse, the patients often defaulted on attendance at the pharmacokinetic 
service as they thought it unnecessary to consult the investigator, or were 
reluctant to wait in a queue. The incoming nurses often erroneously sent the 
phenytoin blood sample to the state laboratory instead of keeping the blood 
samples aside for collection by the investigator at the end of the clinic session. 
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(13) V\bmen of child-bearing age were taken off phenytoin by the doctor and 
prescribed carbamazepine in the erroneous belief that carbamazepine is safer in 
pregnancy. 
(14) The high number of defaulters was partly due to lack of interest on the part of the 
patients. Epilepsy is such a common condition in the communities in which this 
study was performed that having a seizure was acceptable to the patient and 
his/her family. A typical initial response from the patient was "I have only had two 
or three fits the past month." Some patients mistakenly felt that nothing could be 
done to improve their epilepsy as they had previously consulted many doctors. 
(15) It was often difficult to obtain a phenytoin level after the first dose adjustment as 
many patients defaulted on attendance at the pharrnacokinetic service once better 
seizure control was achieved. 
(16) Iv. two of the hospitals, most of the patients were Xhosa-speaking and this 
required the assistance of an interpreter. Consultations with these patients tended 
to be prolonged. 
( 17) The old age home organisation which manages almost all the old age homes in 
Cape Town refused to allow access to their epileptic residents taking phenytoin. 
No reason was given, and this was a major limiting factor in the study as few 
geriatric patients were seen at the hospitals. In Cape Town, there are two old age 
homes which care for approximately 40 black geriatrics. Of these residents, 3 
were on phenytoin therapy of whom 2 were suitable for the study. 
(18) Wdespread alcohol abuse excluded many patients from the study. 
(19) Illiteracy was high among the target patient population, and some patients were 
unable to fill in the diary or understand the instructions. If family assistance could 
not be found, these patients were excluded from the study. It should be stressed 
that although many patients were illiterate they nevertheless were capable of filling 
in the diary by making crosses when taking phenytoin and when seizures 
occurred. This required the instructions to be repeated many times. 
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(20) Hunger and stress due to financial problems were common trigger factors for 
seizures. The patients' perception that they should not take phenytoin if they had 
not eaten added to the problem of non-compliance. 
(21) Wiile the information gained in this study has been most useful for understanding 
population pharmacokinetics, the clinical pharmacokinetic consulting services 
which had to be offered to obtain data were labour intensive, and required the 
cooperation of many patients over a prolonged period of time. 
4.6. INTER-ASSAY COEFFICIENT OF VARIATION 
An inter-assay coefficient of variation of 2.21% was obtained in this study (n = 12). The 
level of acceptance was set at 5% (Abbott Laboratories). 
4.7. ADSORPTION OF PHENYTOIN TO RUBBER STOPPERS 
In the samples (n = 6) used to determined whether adsorption of phenytoin to the rubber 
stoppers occurred, no significant difference2 (t = 0.20, p > 0.05) between the samples 
was found. The estimate of the mean difference (95% CI in brackets) was found to 0.17 
(-1.95 to 2.3) µmol/1. The median difference was 1,5 (range 4,0) µmol/1. The coefficient 
of variation was 0.5 %. 
4.8. STABILITY OF PHENYTOIN IN WHOLE BLOOD SANPLES 
In the samples (n = 6) used to determine the effect of storage on the phenytoin serum 
concentration, no significant difference2 (t = 0.273, p > 0.05) was found between the 
samples stored for 2 hours and 6 hours. The estimate of the mean difference (95% CI in 
brackets) was 0.2 (-1.83 to 2.23) µmol/1. The median difference was 1 (range 5) µmol/1. 
However, a significant difference2 (t = 7.07, p ~ 0.05) was found between the samples (n 
= 6) stored for 6 and 26 hours. The estimate of the mean difference (95% CI in brackets) 
was 5.8 (1.61 to 9.99) µmol/1. The median difference was 5 (range 4) µmol/1. The 
coefficient of variation was 2.4 % between the samples assayed t.·10 hours after blood 
collection and the samples stored as whole blood for six hours. The coefficient of variation 
between the samples assayed 6 and 26 hours after blood collection was 7.6 %. 
2pararretric and nonpararretric tests produced the sarre results 
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4.9. NONIVEM ANALYSIS 
A total of 74 NONMEM runs were performed in this study, 20 runs on NONMEM version 
Ill level 1.2 and 54 runs on version IV level 1.0. Only 61 of the important runs are reported 
in this study. The results of this study are reported as 3 sets of analysis. Set 1 analysis 
was performed at the University of Durban-V\/estville, South Africa, under the supervision 
of Prof. R Miller. In this analysis, the influence of various patient factors on Vm and Km 
values was investigated using the Michaelis-Menten model. Population estimates of Vm 
and Km and their inter- and intra-individual variability were also obtained. Set 2 analysis 
was performed at the Food and Drug Administration of the United States of America under 
the supervision of Dr T. Ludden, and investigated primarily with regard to whether the 
parallel Michaelis-Menten and first-order elimination model fitted the data better than the 
Michaelis-Menten model. Population parameter estimates of Vm, Km and Cl and their 
inter- and intra-individual variability were obtained using the parallel Michaelis-Menten and 
first-order elimination model with dose or steady-state serum concentration as the 
dependent variables. Set 3 analysis was performed at the University of Durban-VVestville 
and validated the applicability of the determined Vm, Km and Cl values, and assessed and 
compared the reliability of the 3 steady-state pharmacokinetic models in predicting 
phenytoin doses or serum concentrations. 
The abbreviations used in the NONMEM data file (Annexure 8) and the control files 
(Annexures 9 - 11) are reported in the Glossary of Symbols and Abbreviations on pages 
XN- XVII. 
The information was coded as follows (Annexures 8 - 11 ): 
Gender: Female = O 
Male = 1 
Race: Black =O 
Coloured = 1 
Malay =2 
Smoking: Non-smokers =O 
Smokers: 
less than 10 cigarettes/day = 1 
10 to 20 cigarettes/day =2 
more than 20 cigarettes/ day =3 
Alcohol: Non-drinkers =O 
Drinkers =1 
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4.9.1. NONIVEM ESTIMATES 
The following estimates were obtained from the NONMEM output (Driscoll, 1989): 
(a) typical (mean) population pharmacokinetic parameter values of Vm, Km and Cl, 
(b) variances of the population values i.e . a~ , a~, a~1 and inter-individual 
random effects of Vm, Km and Cl i.e. llVm, 11Km and 11°, 
(c) variance of the residual random error, a: i.e. intra-individual differences E, 
( d) standard errors of the parameter estimates, 
(e) correlation matrix of the estimates, and 
(f) value of the MOF 
Estimates of the variance components ( d-, a:) from NONMEM were converted to 
standard deviation by derivation of their square root. 
4.9.2. SET 1 ANALYSIS 
In this set of analysis the structural model S1 was evaluated. The results are presented 
in Tables 20 (page 85) and 21 (page 88). 
After the first NONMEM run, dose : serum concentration pairs with weighted residuals of 
more than three standard deviations from the population mean were identified from the 
scatterplots of identification versus weighted residuals. This indicated that these data 
points were considerably different from the others. Four dose : serum concentration pairs 
were identified to be outliers in four different patients. In three patients, a dose: serum 
concentration pair was omitted for the following reasons: 2 of the dose : serum 
concentration pairs were exduded as the phenytoin samples were possibly taken before 
steady state was reached and the third dose : serum concentration pair was exduded 
because of possible poor compliance. One outlier on the scatterplot was induded in the 
NONMEM data set as the reason for it was attributed to significant enzyme induction of 
phenytoin, given that non-compliance had been ruled out and no error could be found. 
The revised NONMEM data set is presented in Annexure 8. The goodness of fit was 
judged by comparing the scatterplots of the actual dose versus the predicted dose 
obtained with the original and the revised data sets. The scatterplots of the weighted 
residuals versus predicted dose, weight, age, sex, body surface area, smoking or patient's 
identification number were also compared. Less scatter of the data points were obtained 

















DETAILS OF NONMEM PARAMETER MODELS USING THE 
MICHAELIS-MENTEN STRUCTURAL MODEL (S1) - (SET 1 ANALYSIS) 
MNIMUM 
PARAMETER MODEL OBJECTIVE 
FUNCTION 
Vm = 81+TJ1 6792.103 
Km= e.,+lb 
Vm = 81 + TJ1 6714.30 
Km=e.,+lb 
Vm = (81*Wf+El:i}+TJ1 6656.0 
Km=e.,+lb 
Vm = (81 * wr + El:i)(1 +ri1) 6693.575 
Km = e., + lb) 
Vm = (81 * BSA + El:i) + TJ1 6658.213 
Km=e.,+lb 
Vm = (81*Wf+El:i}+TJ1 6651.213 
Km = e., * RACE + lb 
where RACE = 84 if black, otherwise = 1 
Vm = (81*Wf+El:i}+TJ1 6647.681 
Km = e., + lb if black 
= 84 + lb if coloured 
= 85 + lb if malay 
Vm = (81 * wr + El:i) RACE + TJ1 6646.514 
where RACE = 84 if malay and coloured, otherwise = 1 
Km=e.,+lb 
Vm = (81*Wf+El:i)RACE+ri1 6644.701 
where RACE = 84 if coloured, otherwise = 1 
RACE= 85 if malay, otherwise= 1 
Km= e.,+lb 
Vm = (81*Wf+El:i)+ri1 6651.213 
Km = e., + lb if black 
= 84 + lb if malay and coloured 
Vm = 81 * v,.,re3 + T]1 6651.975 
Km = e., + lb if black 
= 84 + lb if coloured 
3the MOF and the pararreter estirrates obtained with rrodel P2 were for the revised NONMEM data set. 
4 for rrodels subsequent to P10, coloured and rralay patients will be grouped together as 'coloured' 
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TAB..E 20: continued 
MODEL MNIMUM 
NO. PARAMETER MODEL OBJECTIVE 
FUNCTION 
P12 Vm = (01 *WT"+SJSEX+TJ1 6649.728 
where SEX = 0s if rrale, otherwise = 1 
Km = 0i + 112 if black 
= 04 + 112 if ooloured 
P13 Vm = (01 •wr+SJ SMK+ri1 6639.44 
where SMK = 05 if srrd<er, otherwise =1 
Km = 0i + 112 if black 
= 04 + 112 if ooloured 
P14 Vm = (01 * wr + SJ ALC + Tl1 6648.200 
where ALC = 05 if drinker, otherwise = 1 
Km = 0i + 112 if black 
= 04 + 112 if ooloured 
P15 Vm = (01*WT"+SJSMK+ri1 6640.915 
where SMK = 05 if srroking ~ 10 cigarettes per day, otherwise 
=1 
Km = 0i + 112 if black 
= 04 + 112 if ooloured 
P16 Vm = (01 •wr+SJ SMK+ri1 6650.632 
where SMK = 05 if srroking ~ 20 cigarettes per day, otherwise 
=1 
Km = 0i + 112 if black 
= 04 + 112 if ooloured 
P17 Vm = (01*WT"+SJSMK*AGE+ri1 6638.596 
where SMK = 05 if smoker, otherwise = 1 
AGE = Se if ~ 60 years, otherwise = 1 
Km = 0i + 112 if black 
= 04 + 112 if ooloured 
P18 Vm = (01 * wr + SJ RACE + Tl1 6646.462 
where RACE = 04 if ooloured, otherwise = 1 
Km = 0i + 112 if black 
= 05 + 112 if ooloured 
P19 Vm = (01 * wr + SJ RACE * SMK + Tl1 6635.893 
where RACE = 04 if ooloured, otherwise = 1 
SMK = 05 if smoker, otherwise = 1 
Km=Si+112 
P20 Vm = (01 * wr + SJ RACE * SMK + Tl1 6634.882 
where RACE = 04 if ooloured, otherwise = 1 
SMK = 05 if smoker, otherwise = 1 
Km = Si + 112 if < 60 years 
= Se + 112 if ~ 60 years 
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4.9.2.1. EVALUATION OF THE MODEL 
To assess which model was the most suitable, the simplest model describing the data was 
analyzed initially (model P1, Table 20, page 85). Thereafter, a stepwise procedure was 
used to find the model that fitted the data best. The influence of various patient variables, 
such as ethnicity, mass, gender, age, body surface area, smoking and mild-to-moderate 
alcohol intake, on Vm was evaluated by including them in the model. The influence of 
ethnicity and age on Km was evaluated. The building of the final regression model from 
the simplest model is outlined in Table 20. In the development of the most suitable model 
to describe the data, only factors that proved to be significant were included in the model. 
A detailed description of each model and the resulting MOF are presented in Table 20. 
The models that were compared, the resulting OOBF and the associated p values 
obtained are presented in Table 21 {page 88). The p values were obtained by 
interpolation, where possible. The NONMEM parameter estimates obtained in Set 1 
analysis are presented in Table 22 (page 90). 
4.9.2.2. SIIVPLEST MODEL 
In the simplest model (model P1, Table 20), it was assumed that all patients had the same 
mean Vm and Km values with differences arising from the random inter- and intra-subject 
variation. A stepwise forward procedure was used to build up an adequate regression 
model from the simplest model. In the screening of fixed effects for a significant influence 
on pharmacokinetic parameters, we chose to begin with a minimum number of parameters 
and then to incorporate additional parameters into the model as necessary to account for 
influential factors. 
4.9.2.3. ERROR MODEL 
The application of a multiplicative error model (P4) for inter-subject variability in Vm and 
Km did not improve the fit of the model to the data when compared with the additive error 
model (P3). No improvement in the goodness of fit was observed when comparing the 
scatterplots of the actual dose versus the predicted dose obtained with the models P3 and 
P4. The scatterplots of weighted residuals versus predicted dose, age, sex, body surface 
area, smoking or patient's identification number obtained with these models were also 
compared and no improvement in the goodness of fit was observed. 
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TAB..E 21: MODELS TESTED FOR FACTORS INFLUENCING VmAND Km VALUES 
OF PHENYTOIN - (SET 1 ANALYSIS) 
TEST RUN MODEL MODEL DOEIF p-Value CCWMENT 
FORCOM-
PARISON 
Initial Vm and Km 1 P1 - - Full data set -
values 
Revised Vm and Km 2 P2 lrTµ"ovement in fit was 
estimates 
P1 
obtained with the edited 
data set. Refer to 
section 4.9.2. 
* 
\/\eight in Vm 3 P3 P2 58.3 <0.CXX>5 Vm is related to weight 
Multiplicative rrodel 4 P4 No irTµ"ovement in fit to 
for inter-subject P3 data. Refer to section 
variation 4.9.2.3 
BSAinVm 5 PS 
P3 
2.213 0.146 BSA provides no 
advantage over weight 
* Race in Km (Race 6 P6 4.787 0.03 Km is related to race 
separated into 2 P3 
groups) 
Race in Km (Race 7 P7 3.532 0.064 No irTµ"ovement in fit 
separated into 3 P6 
groups) 
* Race in Vm (Race 8 P8 9.486 0.003 Vm is related to race 
separated into 2 P3 
groups) 
Race in Vm (Race 9 pg 1.813 0.184 No irTµ"OVement in fit 
separated into 3 P8 
groups) 
* Race in Km 10 P10 
P3 
4.787 0.03 Same as rrodel P6-
2 flags used 
\/\eight raised to a 11 P11 
P10 
0.762 0.385 No irTµ"ovement in fit 
pc,.ver 
GenderinVm 12 P12 
P10 
1.485 0.228 Vm is not related to 
gender 
* Smoking in Vm 13 P13 
P10 
11.773 <0.0007 Vm is influenced by 
srroking 
Mild-to-moderate 14 P14 2.923 0.09 Vm is not influenced by 
alcohol consunl)tion P10 mid-to-moderate 
inVm alcohol consunl)tion 
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T AELE 21: continued 
TEST RUN MODEL MODEL D08F p-Value CCWMENT 
FORCOM-
PARISON 
Srroking in Vm (<10 15 P15 No irrprovement in fit. 
versus ~10 P13 Refer to section 
cigarettes/day) 4.9.2.4.8 
Srroking in Vm (<20 16 P16 No il'Tl)rovement in fit. 
versus~ P13 Refer to section 
cigarettes/day) 4.9.2.4.8. 
NJe in Vm (<60 17 P17 0.844 0.363 Vm is not influenced by 
versus ~ years) P13 a discontinuity at 60 
years of age . 
Race in Vm and Km 18 P18 4.751 0.031 Incorporating the 
P6 influence of race in Vm 
significantly irrproved fit 
18 P18 0.052 0.825 Incorporating the 
influence of race in Km 
did not significantly 
PB il'Tl)rove the fit. 
Therefore only the 
influence of race in Vm 
is incorporated . 
Race and srroking in 19 P19 10.621 0.001 Best rrodel. Influence of 
Vm race and srroking 
PB corrbined in Vm 
provided a better fit than 
race alone in Vm 
NJe in Km (<60 20 P20 1.011 0.317 Km is not influenced by 
versus ~ years) P19 a discontinuity at 60 
years of age 
indicates statistical significance (p :$ 0.05) and il'Tl)rovement in fit of the rrodel to the data 
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TAEI.E 22: PARAMETER ESTIMATES OBTAINED FOR SET 1 ANALYSIS 
IW)[)EL 91 ~ ~ 94 95 9g crv.r,2 crt<rn2 a2 E 
NO. 
P1 382 3.24 3200 3.35 252 
P2 384 3.37 3320 3.33 230 
P3 2.26 3.40 241 2560 3.04 236 
P4 1.95 3.01 253 0.0394 0.296 0.003 
P5 1ffi 3.39 118 2620 2.96 237 
P6 2.30 3.13 237 1.17 2480 3.03 237 
P7 2.24 3.64 241 3.25 2.41 2480 2.96 237 
P8 2.33 3.42 225 1.00 2460 3.0 238 
pg 2.29 3.42 228 1.05 1.10 2450 2.95 238 
P10 2.30 3.66 237 3.13 2480 3.03 237 
P11 74 3.67 0.397 3.13 2500 3.0 237 
P12 2.27 3.66 233 3.13 1.02 2470 3.01 237 
P13 2.39 3.67 222 3.19 1.00 2370 2.89 240 
P14 2.30 3.68 234 3.13 1.04 2450 2.99 238 
P15 2.26 3.64 235 3.16 1.07 2350 3.01 238 
P16 2.30 3.67 237 3.13 1.08 2470 3.03 237 
P17 2.35 3.67 225 3.16 1.00 0.965 2350 2.88 240 
P18 2.33 3.46 226 1.05 3.38 2450 3.01 237 
P19 2.41 3.45 212 1.05 1.00 2350 2.87 241 
P20 2.38 3.42 214 1.05 1.00 3.90 2360 2.85 241 
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4.9.2.4. INFWENCE OF COVARIATES ON Vm AND Km VALUES 
These results are summarized in Table 21 (pages 88 and 89). 
4.9.2.4.1. VVeiglt in Vm 
Incorporation of Vm as a function of weight (model P3) resulted in a decrease of the 
MOF and a DOBF of 58.3 (p < 0.0005) when compared with model P2. This indicated 
that weight significantly influenced Vm. Thus, Vm expressed in proportion to weight is 
more appropriate than to assume the same Vm for all patients. k; weight had a 
significant effect, it was left in the model. In the building of the full model, weight raised 
to a power was tested alone as a scaling function for Vm. No other factors were 
included in the Vm model (model P11 ). This resulted in an increase in the MOF and a 
DOBF of 0.762 (p = 0.385), indicating that this worsened the fit of the model to the 
data. The exponent was estimated as 0.397, and therefore was not expected to make 
a significant difference. 
4.9.2.4.2. Body Sllface area in Vm 
\,l\klen body surface area was incorporated in Vm (model PS), the MOF increased and a 
DOBF of 2.213 (p = 0.146) was obtained when compared with model P3. This indicated 
that body surface area as a function of Vm provided no additional information over weight 
when estimating Vm. Therefore, only the influence of weight in Vm was included in the 
model. 
4.9.2.4.3. Ethricity in Km (2 ethnic groups) 
Incorporating ethnicity in Km when the patients were classified as either black or coloured 
(model P6) resulted in a decrease in the MOF and a DOBF of 4.787 (p = 0.03) compared 
with model P3, which indicated that ethnicity significantly influenced Km and improved the 
fit of the model to the data. Km values of 3.13 and 3.66 mg/I were obtained for coloured 
and black patients, respectively. The Km value of coloured patients was 14.5% lower than 
that of black patients. The influence of ethnicity on Km was therefore included in 
subsequent models. 
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4.9.2.4.4. Ethnicity in Km (3 ethric ~) 
The inclusion of ethnicity in Km when the patients were classified as either black, coloured 
or malay (model P7) resulted in a decrease in the MOF and a DOBF of 3.532 (p = 0.064) 
compared with model P6. This indicated that separating the patients into malay and 
coloured groups did not significantly improve the fit of the model to the data. 
4.9.2.4.5. Ethnicity in Vm (2 ethnic groups) 
Incorporating ethnicity in Vm when the patients were classified as either black or coloured 
(model PB) resulted in a decrease in the MOF and a DOBF of 9.486 (p = 0.003) was 
obtained compared with model P3, which indicated that ethnicity significantly influenced 
Vm and improved the fit of the model to the data. 
4.9.2.4.6. Ethnicity in Vm (3 ethnic groups) 
The inclusion of ethnicity in Vm when the patients were classified as either black, coloured 
or malay (model P9) resulted in a decrease in the MOF and a DOBF of 1.813 (p = 0.184), 
compared with model PB. This, as with the investigation of the influence of ethnicity on 
Km, indicated that separating the patients into malay and coloured groups made no 
significant difference. Therefore, for the purpose of this study, the patients were classified 
either as black or coloured. As coloureds and malays did not significantly differ from each 
other in Vm and Km values, they were grouped together as coloureds. It was decided to 
do this as most of the indigenous malay population are now mixed with the coloured 
population and ethnically 'pure' or 'almost pure' malays are not found in South Africa. 
4.9.2.4.7. Gender in Vm 
Wlen gender was incorporated in Vm (model P12), a decrease in the MOF and a OOBF 
of 1.485 (p = 0.228) resulted, compared with model P10. This showed that Vm was not 
significantly related to gender. 
4.9.2.4.8. Srmking in Vm 
The inclusion of smoking in Vm (model P13) resulted in a decrease in the MOF and a 
DOBF of 11. 773 (p < 0. 0007) compared with model P10. This indicated that smoking 
significantly influenced Vm. Wlen the smokers were separated into those who smoked 
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less than 10 cigarettes and those who smoked 1 O or more cigarettes per day ( model P15), 
no improvement in the fit of the model to the data was obtained compared with model 
P13. Wien the smokers were separated into those who smoked less than 20 cigarettes 
and those who smoked 20 or more cigarettes per day (model P16), no improvement in the 
fit of the model to the data was obtained compared with model P13. No improvement in 
the goodness of fit was obseNed when comparing the scatterplots of the actual dose 
versus the predicted dose obtained with models P13, P15 and P16. The scatterplots of 
weighted residuals versus predicted dose, age, sex, body surface area, smoking or 
patient's identification number obtained with these models were also compared and no 
improvement in the goodness of fit was obseNed. No large decrease in the size of the 
interindividual variance of the pharmacokinetic parameters and residual error were also 
obseNed (Table 22, page 90). Thus, separating smokers into the groups referred to above 
did not improve the fit of the model to the data. Accordingly, the patients were categorized 
as smokers or non-smokers. 
4.9.2.4.9. Alcohol COllSUf1D)l1 in Vm 
The incorporation of mild-to-moderate alcohol consumption in Vm (model P14) resulted 
in a decrease in the MOF and a DOBF of 2.923 (p = 0.09), compared with model P10. 
This indicated that mild-to-moderate alcohol consumption did not influence Vm 
significantly. Because of the homogeneity of the patient population in respect of alcohol 
consumption (abusers excluded), no effect of alcohol consumption on Vm was expected. 
It was found that moderate consumption of alcohol, i.e. week-ends only or once or twice 
per week, did not influence Vm significantly. 
4.9.2.4.10. Age in Vm 
The analysis could not detect a continuous effect of age, and therefore discontinuity at 60 
years of age was tested. A cut-off point of 60 years was arbitrarily chosen. Wien patients 
were separated into 2 groups, i.e. less than 60 years and 60 years of age or older (model 
P17), a decrease in the MOF and a DOBF of 0.844 (p = 0.363) were obtained compared 
with model P13. This indicated that age, in the categories referred to above, did not 
influence Vm significantly. 
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4.9.2.4.11. NJe in Km 
\fvhen patients were separated into 2 groups (less than 60 years and 60 years of age or 
older (model P20), a decrease in the MOF and a OOBF of 1.011 (p = 0.317) were 
obtained compared with model P19. This indicated that discontinuity at 60 years of age 
did not influence Km significantly. 
4.9.2.5. FINAL REGRESSION MODEL FOR SET 1 ANALYSIS 
A stepwise procedure was used to find the model that fitted the data best. On investigating 
the influence of ethnicity alone on the variation in Km (model P6), a OOBF of 4.787 (p = 
0.03) was obtained compared with model P3, indicating that ethnicity produced a 
statistically significant influence on the variation in Km. On investigating the influence of 
ethnicity alone on Vm (model PB), a OOBF of 9.486 (p = 0.003) was obtained compared 
with model P3, indicating that ethnicity produced a statistically significant influence on the 
variation in Vm (Table 21, page 88). This indicated that the influence of ethnicity is greater 
on the variation in Vm than in Km. Incorporating the influence of ethnicity in Vm and Km 
combined (model P18) produced a OOBF of 0.052 (p = 0.825), compared with model PB. 
This indicated virtually no improvement in the fit of the model to the data when Km was 
incorporated in model PB, confirming that ethnicity has a greater influence on the variation 
in Vm. However, when Vm was incorporated in model P6 which only included the 
influence of ethnicity in Km, a OOBF of 4.751 (p = 0.031) was obtained. It can be 
concluded that the final model only needed to account for the influence of ethnicity on the 
variation in Vm. The incorporation of the influence of ethnicity on the variation in Km did 
not significantly improve description of the data. The above is explained schematically in 
Figure 1 (page 95). 
Model P19 (Table 20, page 86) was found to be the model which best described the data 
in this study. In this model, Vm was expressed as a function of ethnicity, weight and 
smoking. No influence of covariates on Km was taken into account. A OOBF of 10.621 (p 
= 0.001), compared with model PB, indicated that the combined influence of ethnicity and 
smoking on the variation in Vm was more significant than ethnicity in Vm alone (Table 21, 
page 89). 
The final population estimates (with the standard error of the estimate in parentheses) are 
presented in Table 27 (page 111). The NONMEM control file for the final model is 
presented in Annexure 9. 
Model PB: 
Improvement in fit 
DOBF = 9.486 
Vm = {01 * 'WT + 03) RACE + Tl, 
where RACE = 0, if coloured, 
otherwise = 1 
Km= 02 + T]2 
MOF = 6646.514 
No improvement in flt 
DOBF = 0.052 
Model P3: 
Vm = (01 * 'WT + 03) + Tl, 
Km= 02 + ll2 
MOF = 6656.0 
Model P18: 
Improvement in fit 
DOBF = 4.787 
Model P6: 
Vm = (01 * 'WT + 03) + T]1 
Km = 02 * RACE + T]2 
where RACE = 0, if black, 
otherwise = 1 
MOF = 6651.213 
Improvement in fit 
DOBF = 4.751 
Vm = {01 * 'WT + 03) RACE + Tl, 
where RACE= 04 if coloured, otherwise= 1 
Km = 02 + T]2 if black 
05 + T]2 if coloured 
MOF = 6646.462 
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FIGURE 1: SCHEMATIC PRESENTATION OF THE INFLUENCE OF ETHNICITY ON 
Vm AND Km ALONE, AND ON Vm AND Km COMBINED 
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4.9.3. SET 2 ANALYSIS 
In Set 2 analysis, the structural models S2 and S3 were evaluated. These models have 
been presented in sections 3.7.3.1.2 and 3.7.3.1.3 in Chapter 3. The results are presented 
in Tables 23 - 28. The same data used in Set 1 analysis was used in Set 2 analysis. The 
parameter models (P21 to P32) are depicted in Table 23 (page 97). 
The MOF values obtained with the Michaelis-Menten model (S1) were compared with 
those obtained with the parallel Michaelis-Menten and first-order elimination model (S2). 
Given the nonlinear pharmacokinetics of phenytoin, unrealistic phenytoin concentrations, 
such as infinite concentrations, can be predicted. Both models, therefore, used dose as 
the dependent variable. l\llodel S2 (Run 22) fitted the data significantly better, as indicated 
by a decrease in the MOF and a OOBF of 2922.524 (p < 0.0005), compared with model 
S1 (Run 21, Table 24, page 99). The results indicate that linear clearance is important 
in model S2. 
As the same parameter and structural models are used in many of the NONMEM runs 
(e.g. when a run was performed with or without the conditional estimation method), the 
results are often reported by comparing runs and not parameter models as was previously 
the case. l\llodel S3 predicted steady-state serum concentration ( Cpss} and used Cpss as 
the dependent variable. For this reason, the MOF obtained with models S1 and S2 which 
predicted dose could not be compared with that obtained with model S3. The importance 
of Cl in model S3 was evaluated by using a variation of a method described by Sheiner 
et al. (1973). To illustrate the importance of Cl in model S3, the MOF was used to 
construct the 90% confidence interval for the Cl estimate by evaluating the MOF 
associated with a change in the Cl value. This entailed the Cl value being fixed at different 
values ranging from 0.9 to 4.5 I/day, and the resulting MOF generated by each run was 
observed (Table 26, page 103). The value of Cl was fixed at values greater than or less 
than the Cl value of 2.681/h (Run 23, Table 25, page 101) which was derived from model 
P21, and which fitted the data best. Cl values were first fixed to values decreasing from 
2.68 1/h and the MOF of each consecutive run was observed until the OOBF exceeded 
the critical value of 3.8 compared with the MOF obtained in Run 23. Similarly, Cl values 
were fixed at values increasing from 2.68 1/h and the same procedure was followed. A plot 
of the Cl values (x-axis) and the corresponding MOF values (y-axis) is shown in Figure 
2 (page 105). The dashed horizontal line in Figure 2 indicates a OOBF of 3.8 (measured 
from the lowest MOF value on the graph), and where this line intersects the graph the 
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TA81...E 23: DETAILS OF NONMEM PARAMETER MODELS FOR SET 2 ANALYSIS 
RUN MODEL PARAMETER MODEL MOF 
NO. 
21 P19 Vm = (91 * wr + 9-;J RACE * SMK + 111 6720.3 
where RACE = 94 if coloured, otherwise = 1 
SMK = 95 if srroker, otherwise = 1 
Km=&.i+11:z 
22 P21 Vm = (91 * wr + 9-;J RACE * SMK + 111 3797.776 
where RACE = 94 if coloured, otherwise = 1 
SMK = 95 if srroker, otherwise = 1 
Km=&.i+11:z 
Cl=Se+lb 
23 P22 Vm = (91 * Wf + 9-;J RACE * SMK * EXP 111 3798.902 
where RACE = 94 if coloured, otherwise 1 
SMK = 95 if srroker, otherwise = 1 
Km=9..i*EXP11:z 
Cl=9e*EXP1b 
39 P23 Vm = (91 * wr + 9-;J RACE * SMK * ALC * SEX * AGE * EXP 111 3791.125 
where RACE = 94 if coloured, otherwise = 1 
SMK = 95 if srroker, otherwise = 1 
ALC = 9a if drinker, otherwise = 1 
SEX = 9g if male, otherwise = 1 
AGE = 910 if ~ 65 years, otherwise = 1 
Km = 9..i * RACE * AGE * EXP 11:z 
where RACE = 9, if coloured, otherwise = 1 
AGE = 911 if ~ 65 years, otherwise = 1 
Cl=9e*EXP1b 
40 P24 Vm = (91 * wr + 9-;J RACE * SMK * ALC * SEX * AGE * EXP 111 3792.412 
where RACE = 94 if coloured, otherwise = 1 
SMK = 95 if srroker, otherwise = 1 
ALC = 98 if drinker, otherwise = 1 
SEX = 9g if male, otherwise = 1 
AGE = 910 if ~ 65 years, otherwise = 1 
Km=9..i*RACE* EXP11:z 
where RACE = 9, if coloured, otherwise = 1 
Cl = 9s * EXP lb 
41 P25 Vm = (91 * wr + 9-;J RACE * SMK * ALC * SEX * EXP 111 3797.908 
where RACE = 84 if coloured, otherwise = 1 
SMK = 85 if srroker, otherwise = 1 
ALC = 88 if drinker, otherwise = 1 
SEX = 9g if male, otherwise = 1 
Km=9..i*RACE *EXP11:z 
where RACE = 9, if coloured, otherwise = 1 
Cl=9a+lb 
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TAB..E 23: continued 
RUN MODEL PARAMETER MODEL MOF 
NO. 
42 P26 Vm = (81 • wr + 8:i) RACE • SMK • ALC • EXP 111 3798.375 
wiere RACE = 84 if coloured, otherwise = 1 
SMK = 85 if srroker, otherwise = 1 
ALC = Ela if drinker, otherwise = 1 
Km = 8:z * RACE * EXP 112 
wiere RACE = 0, if coloured, otherwise = 1 
0=8a*EXPlb 
43 P27 Vm = (81 * wr + 8:i) RACE * SMK * EXP 111 3798.846 
where RACE = 84 if coloured, otherwise = 1 
SMK = 85 if srroker, otherwise = 1 
Km = 8:z * RACE * EXP lb 
wiere RACE = 0, if coloured, otherwise = 1 
Q = 8a*EXPfb 
44 P28 Vm = (81 * wr + 8:i) RACE * SMK * EXP 111 3798.861 
where RACE = 84 if coloured, otherwise = 1 
SMK = 85 if srroker, otherwise = 1 
Km = 8:z * EXP lb 
0=8a*EXPlb 
45 P29 Vm = (81 * wr + 8:i) RACE * EXP 111 3833.681 
where RACE = 84 if coloured, otherwise = 1 
Km=S:z+lb 
0=85+fb 
46 P30 Vm = (81 * wr + 8:i) * EXP 111 3846.102 
Km = 8:z * EXP lb 
Q = 84 * EXP lb 
47 P31 Vm = (81 * wr + 8:i) RACE * SMK * AGE *EXP 111 3796.889 
where RACE = 84 if coloured, otherwise = 1 
SMK = 85 if srroker, otherwise = 1 
AGE = 0, if :?: 60 years, otherwise = 1 
Km = 8:z * EXP lb 
0=8a*EXPfb 
48 P32 Vm = (81 * wr + 8:i) RACE * SMK * AGE *EXP 111 3793.587 
where RACE = 84 if coloured, otherwise = 1 
SMK = 85 if smoker, otherwise = 1 
AGE = 0, if :?: 65 years, otherwise = 1 
Km = 8:z * EXP lb 
0=8s*EXPtb 
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TAB..E 24: COMPARISON OF MODELS FOR SET 2 ANALYSIS 
RUN PARA- STRUCTURAL MODEL USED DOEF p-VAUJE CONMENT 
METER MODEL FOR 
MODEL COMPARISON 
RUN NO. 
21 P19 S1 - - - Same as Run 19 
* 
22 P21 S2 21 (P19) 2922.524 <0.CXXl5 Linear dearance (Cl) 
inµoved fit of rrodel to 
data. Dose was used as 
dependent variable 
23 P21 S3 - - - Cannot be COl'll)8red 'Nith 
Run 22 as serum steady-
state concentration was 
used as dependent variable 
24 See Tables 25 and 26 
to 
35 
36 P22 S3 23 (P21) 1.126 No significant difference 
between additive and 
proportional error rrodels 
37 P22 S3 - - - Posthoc analysis 
38 P22 S3 36 (P22) 145.22 Conditional estimation 
method 
39 P23 S3 - - - All patient characteristics 
induded in the rrodel 
40 P24 S3 39 (P23) 1.29 0.262 Sinilar to Run 39 except 
that the influence of age in 
Km has been removed 
* 41 P25 S3 40 (P24) 5.496 0.021 Sinilar to Run 40 except 
that the influence of age in 
Vm has been removed 
42 P26 S3 41 (P25) 0.467 0.495 Sinilar to Run 41 except 
that the influence of gender 
in Vm has been removed 
43 P27 S3 42 (P26) 0.471 0.494 Slnilar to Run 42 except 
that the influence of mid to 
rroclerate alcohol 
oonsunµion in Vm has 
been removed 
44 P28 S3 43 (P27) 0.014 0.908 Sinilar to Run 43 except 
that the influence of race in 
Km has been removed 
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T AB..E 24: continued 
RUN PARA- STRUCTURAL MODEL USED D08F p-VAWE CONMENT 
METER MODEL FOR 
MODEL COMPARISON 
RUN NO. . 
45 P29 S3 44 (P28) 34.821 <0.0005 Sinilar to Run 44 except 
that the influence of 
srooking in Vm has been 
rerroved . 
46 P30 S3 45 (P29) 12.421 <0.0005 Sinilar to Run 45 except 
that the influence of race in 
Vm has been removed 
47 P31 S3 36 (P30) 2.013 0.165 Vm is not influenced by a 
discontinuity at 60 years of 
age 
. 
48 P32 S3 36 (P22) 5.315 0.022 Vm is influenced by a 
discontinuity at 65 years of 
age 
49 P32 S3 48 (P32) 140.159 Sinilar to Run 48, 
conditional estimation 
procedure performed 
* indicates statistical significance ( p ::;; 0.05) and irrprovement in fit of the rooclel to the data 
corresponding Cl values were read off. The Cl values of 1.49 and 3.89 I/day represent the 
approximate lower and upper limits of the 90% confidence interval of the Cl estimate, 
respectively. As the lower limit of the confidence interval was observed well before the Cl 
value approached zero, the importance of Cl in the model is confirmed. 
4.9.3.1. ERROR MODEL 
The additive error models for inter-individual variability in Vm, Km and Cl were compared 
with proportional error models. Using structural model S3, model P22 (Run 36, Table 24, 
page 99) was compared with model P21 (Run 23) to assess whether the additive or 
proportional error model resulted in a better data fit. A Lmax ratio of 0.569 indicated that 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TAEl.E 26: SUMMARY OF NONMEM RUNS PERFORMED TO DEMONSTRATE 
THE SIGNIFICANCE OF Cl IN STRUCTURAL MODEL S31 
RUN FIXED VAUJE OF a MOF 
24 0.9 3806.293 
25 1.1 3804.345 
26 1.3 3802.712 
27 1.5 3801.341 
28 1.7 3800.25 
29 2.0 3798.917 
30 2.5 3797.838 
23 2.68 3797.776 
31 2.8 3797.829 
32 3.3 3798.870 
33 3.6 3800.118 
34 4.0 3802.483 
35 4.5 3806.505 
1 parameter rrodel P21 was used throughout this analysis 
4.9.3.2. POSTHOC AND CONDITIONAL ESTIMATION IVETHODS 
The posthoc estimates of the population parameters are presented in Table 25 (Run 37, 
page 102). Often a FOCE method is not needed as this is an optional NONMEM run. The 
goodness-of-fit plots between the conventional and the conditional estimation methods 
were similar, this provided additional assurance that the model could not be substantially 
improved. Little difference was found between the two sets of scatterplots, and further 
analysis using the conditional estimation method was therefore not required. 
The FOCE method was used to obtain improved estimates of the parameters (Run 49, 
Table 25, page 102). A decrease in the MOF of 145.22 (Run 38 compared with Run 36) 
was expected, as this procedure allowed for better fitting of the model to the data (Table 
24, page 99). The standard errors of the estimates were found to be smaller, indicating 
a better fit of the model to the data (Yukawa et al., 1991). 
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4.9.3.3. INFWENCE OF COVARIA1ES ON Vm AND Km VALUES 
All patient variables showing possible evidence of influence on the pharmacokinetic 
parameters were re-evaluated using model S3. The influence of the following patient 
characteristics was re-evaluated: ethnicity, smoking, mild-to-moderate alcohol intake, 
gender, age less than 65 and 65 years or older in Vm; and ethnicity, and age less than 
65 and 65 years or older in Km. This was done by comparing the full model with all the 
patient factors induded (P23) with a regression model from which one of the covariates 
was independently removed stepwise (P24 - P30, Table 23, page 97) (Fattinger et al., 
1991). The OOBF compared the difference in the goodness-of-fit between the reduced 
model (which does not indude the parameter in question) and the full model (Sambol and 
Sheiner, 1991). The same factors shown to influence Vm in Set 1 analysis using 
structural model S1 were found to influence Vm in this set of analysis. Removal of the 
influence of covariates on Km did not significantly influence the fit of the model to the data. 
These results are presented in Table 24 (page 99). In this case, an increase in the MOF 
when comparing two models represented an improvement in the fit of the model to the 
data. 
In Set 1 analysis, age was categorized into 2 groups: less than 60 and 60 years or older. 
Wien this was tested in Vm, no improvement in the fit of the model to the data was 
observed (p = 0.363, Table 21, page 89). In this set of analysis, age was categorized into 
2 groups, less than 65 and 65 years or older. As pharmacokinetic changes are expected 
to occur in patients at about 65 years of age, a cut-off point at 65 years was chosen. 
Wien model P32 was compared with model P22, a OOBF of 5.315 (p = 0.022) was 
obtained (Run 48, Table 24, page 100). This difference was statistically significant at p < 
0.05 but not at p < 0.005. Discontinuity at 65 years, therefore, provided a better fit than 
at 60 years. A comparatively small, yet significant, effect of age on Vm was observed. This 
model implies that Vm remains constant up to 65 years of age and then decreases. Only 
2 black and 15 coloured patients were 65 years of age or over. More patients in this age 
group are required to make a sound statistical condusion regarding the effect of age on 
Vm. 
RACE, SMK, ALC, SEX and AGE were indicator variables which had a value of unity for 
the .fth patient if black, non-smoker, teetotaller, female and less than 65 years of age and 
84, 8s, es, 89 and 810 if coloured, smoker, mild-to-moderate alcohol drinker, male and 65 
years of age or older, respectively. 84, es, es, 89 and 810 represent the fractional increase 
or decrease in Vm with the presence of the corresponding indicator variable. The 
inter-individual differences in serum concentration profile of phenytoin could be described 
by assigning inter-individual variability to Vm and Km. 
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FIGURE 2: CONSTRUCTION OF THE 90% CONFIDENCE INTERVAL FOR THE 
CLEARANCE ESTIMATE OF 2.68 I/day. THE MINIMUM OBJECTIVE 
FUNCTION WAS OBTAINED BY FIXING CLEARANCE AT VARIOUS 
VALUES USING MODEL S3. THE POINTS AT WilCH THE DASHED 
HORIZONTAL LINE INTERSECTS THE TWJ ARMS OF THE CURVE 
DELIMIT THE 90% CONFIDENCE INTERVAL FOR THE CLEARANCE 
ESTIMATE OF 2.68 I/day. 
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4.9.3.4. SCATIERPLOTS OF FINAL MODEL (S3) 
A method of assessing the 'goodness-of-fit' was to examine the scatterplots of weighted 
residuals generated by NONMEM. Besides monitoring changes in the MOF, the 
model-building steps were guided by examination of the scatterplots of weighted residuals 
versus the various fixed effects. Predicted concentration more dosely equalled observed 
concentration as the accuracy improved and weighted residuals approached zero. The 
scatterplots of weighted residuals versus the predicted concentrations for black (Figure 
3, page 107) and coloured (Figure 4, page 108) patients were found to be randomly 
scattered about zero. The scatterplots of the measured serum phenytoin concentration 
versus the predicted serum concentration for black (Figure 5, page 109) and coloured 
(Figure 6, page 110) patients are also presented. The scatterplots seem to indicate a 
proportional model as the residuals' variance increases with the mean. 
4.9.4. FINAL NEAN PARMETER ESTIMATES 
The values of the mean parameter estimates of Vm, Km and Cl and their inter-individual 
and intra-individual variability ( expressed as the percentage coefficient of variation - %CV) 
obtained when using structural models S1, S2 and S3 are given in Table 27 (page 111). 
The standard errors of the estimates are given in parentheses. The 95% Cr for the fixed 
effects are also reported. The Vm estimate of 286.4 mg/day (12.3 mg/kg/day) obtained 
with model S2 was the lowest and appeared to be inconsistent with that obtained with 
models S1 and S3. This indicated that different Vm values should be used with different 
models. Thus, when predicting dose by means of model S2 (which indudes Cl) a lower 
Vm value should be used. Wien using this model, the general concept that dose should 
not exceed Vm, is not applicable. The latter concept applies to the Michaelis-Menten 
model (S1). The% CV in Vm obtained with all 3 models was considered acceptable 
(Table 27, page 111) . The square root of the variance of the additive error terms divided 
by 8 (i.e. fixed effect) multiplied by 100% is a reasonable approximation of the CV of the 
fixed effect. 
For all the structural models used, the Vm obtained for black patients was consistently 
lower than for coloured patients. The estimates of Km obtained with all 3 models differed 
markedly. Km values of 3.45, 1.60 and 6.81 mg/I were obtained with model S1, S2 and 
S3, respectively. The high% CV obtained in Km was expected. Although ethnicity was 
found to influence Km, this factor was not induded in the final model as ethnicity 
accounted more for the variability in Vm. This has been discussed in section 4.9.2.5. The 
% CV in Km obtained with models S2 and S3 compared well, whereas that obtained with 
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FIGURE 4: SCAITERPLOT OF \J\EIGHTED RESIDUALS (UPPER AXIS) VERSUS 
PREDICTED SERUM CONCENTRATION (VERTICAL AXIS) OBTAINED 
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FIGURE 5: SCATTERPLOT OF PREDICTED SERUM PHENYTOIN 
CONCENTRATION (UP?ER AXIS) VERSUS MEASURED SERUM 
CONCENTRATION (VERTICAL AXIS) OBTAINED FOR BLACK PATIENTS 
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FIGURE 6: SCATTERPLOT OF PREDICTED SERUM PHENYTOIN 
CONCENTRATION (UPPER AXIS) VERSUS MEASURED SERUM 
CONCENfRATION (VERTICAL AXIS) OBTAINED FOR COLOURED 
PATIENTS V\IITH THE FINAL MODEL 
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TAEl.E 27: FINAL MEAN ESTIMA.TES OF THE POPULATION PHARMA.COKINETIC 
PARAMETERS OBTAINED FOR EACH MODEL 
PARAMETER NONMEM ESTIMATES (± SE) 
S1 S2 S3 
Vm(ngday) 366.7 (6.6) 286.4 (12.3) 338.3 (38.2) 
* * * 
353.8 - 379.6 262.3 - 310.5 263.4 - 413.2 
Vm (rrg'kg'day) 5.71 (0.10) 4.46 (0.19) 5.27 (0.59) 
* * * 
5.51 - 5.91 4.09-4.84 4.10- 6.44 
Km (rrgl) 3.45 (0.24) 1.60 (0.31) 6.81 (1.30) 
* * * 
2.98- 3.92 0.99- 2.21 4.26-9.36 
a (Vday) - 2.09 (0.28) 2.68 (0.78) 
* * 
1.54- 2.64 1.15-4.21 
% Cl/ (Vm) 13.22 17.14 12.5 
% Cl/ (Km) 49.1 66.4 67.9 
% Cl/ (Cl) - 28.5 46.3 
% Cl/ (E) 5.0 4.87 20.1 
indicates the 95% confidence interval for the fixed effects 
The values in parentheses are the standard errors of the estimates 
model S1 was much lower. The mean Cl estimates of 2.09 and 2.68 I/day obtained with 
structural models S2 and S3 were comparable; a much lower % CV in Cl was, however, 
obtained with model S2. The high variability in Km and Cl was expected as no covariates 
were included in the model for these parameters. 
Structural model S3, which was considered the best model in this study, was applied 
together with the FOCE method. The parameter estimates obtained represent improved 
parameter estimates, because the Bayesian feedback procedure was employed. The 
FOCE method calculated individualized Vm, Km and Cl values with all feedback serum 
phenytoin concentrations for every patient, and the mean Vm, Km and Cl values for the 
population were 370.9 mg/day (5.77 mg/kg/day), 6.48 mg/I and 2.15 I/day, respectively 
(Run 49, Table 25, page 102). The% CV for Vm was reduced from 12.5 (FO method) to 
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9.46 (FOCE method). Similarly, the % CV for Km was reduced from 67.9 (FO method) to 
53.9 (FOCE method). The% CV for Cl, however, increased from 46.3 (FO method) to 
96.3 (FOCE method)(T able 27, page 111 ). 
The final regression model (Run 49, Table 25, page 102) obtained with the FOCE method 
can be represented as follows: 
Vm = (01 *WT+ 03)RACE*SMK*AGE*EXPrJ1 
Km=~* EXPfb 
Cl = 06 * EXPfb 
where RACE= 04 if coloured, otherwise= 1 
SMK = 05 if smoker, otherwise = 1 
AGE = 8, if 2 65 years, otherwise = 1 
81 = 3.55 (0.396; 11.15) 
82 = 6.48 (0.653; 10.08) 
83 = 143.0 (35.5; 24.83) 
04 = 1.06 (0.0301; 2.84) 
85 = 1.12 (0.0329; 2.94) 
06 = 2.15 (0.668; 31.07) 
8, = 0.968 (0.077; 7.95) 
The absolute and relative percentage standard errors of the estimates are given in 
brackets. The inter-individual variability estimated as variances of 11Vm, 11Km and 11° 
(random error terms) were 0.00895 (0.00262) rng/day2, 0.29 (0.0426) mg/12 and 0.927 
(0.299) l/day2. The variance of E was 7.67 (0.89) mg/12• The small standard errors 
indicated a good fit with reliable parameter estimates. Km and Cl parameters showed 
considerable variability which was excessively large for Cl - standard deviation of 44.8% 
of the mean. 
In the final model, given the assumption of zero covariances among the individual 
parameters, seven population parameters are present: Vm, Km, Cl, Ovm, O'i<m, cr0 and crE. 
The random effect parameters, the last 4, are often written as standard deviations ( Ovm, 
O'i<n,, cr0 and q; ) rather than variances. 
Since ethnic:ty, smoking status and age were found to influence Vm, the patient population 
was subdivided into 8 subpopulation groups. Table 28 (page 114) summarizes the 
parameter models and mean Vm estimates for the different subgroups of patients. These 
estimates will be useful when using model S3 to predict a serum phenytoin level for a 
patient representative of a subgroup. In this way, the most appropriate Vm value will be 
used in the calculation. Thee values are given in Table 25 (Run 49, page 102). 
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This study yielded no incidence of pauwise correlations for different parameter 
combinations. Low Km and Vm values also occurred concurrently (Taylor et al., 1983). 
The NONMEM control files for the best models for S1, S2 and S3 are given in Annexures 
9, 10 and 11, respectively. 
It should be noted that the Vm reported by NONMEM is in fad Vm/F. 'P is a bioavailability 
factor and is usually assumed to have a value of one. However, any value of F less than 
one will increase the corresponding value of Vm. 
The values of Vm obtained were normalized to standard body mass. Normalization is 
important for averaging data from individuals of markedly different sizes and for purposes 
of comparison with other data. Vm was expressed in mg/kg/day or mg/day. 
4.9.5. VALIDATION OF THE POPULATION PARAIVETER ESTIMATES AND 
STRUCTURAL IVIODELS 
Predictions of the phenytoin dose or serum concentration were made with the prior 
knowledge of actual dose or measured serum phenytoin concentration and the patient 
variables which were found to influence the pharmacokinetics of phenytoin. The Vm value 
was calculated for each patient based on the individual's ethnic group, mass, smoking 
status and age group. The same Km and Cl estimates were used for all patients. The 
predictions obtained with the mean population estimates derived with FO and FOCE 
methods were compared. These population estimates were then used to predict dose or 
Cpss and compared with the actual dose or the measured concentrations (Fattinger et al., 
1991 ). The pharmacokinetic parameter estimates were obtained using the parameter 
models discussed previously (Tables 20 and 23), with estimates for the fixed effects 
obtained from Table 29 (page 115). 
The influence of experimental error on the prediction performance was unlikely to be 
significant because in all the patients at least two serum phenytoin levels were obtained 
on the same dose, compliance was meticulously assessed, and at least a month elapsed 
before a blood sample for phenytoin concentration was taken to ensure that steady state 
was reached. 
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TA8l..E 28: FINAL MEAN Vm ESTll\t1ATES OBTAINED FOR SUBPOPULATION 
GROUPS USING MODEL S3 AND THE CONDITIONAL ESTll\t1ATION 
METHOD 
(1) Black nonsmoker, < 65 years: 
Model: Vm = e, •wr+~ 
= 378. 7 rrg/day 
= 5. 70 rrg'kg/day 
(2) Black nonsmoker, ;?: 65 years: 
Model: Vm = (O,*Wf+~S, 
= 366.58 rrg/day 
= 5.52 rrg'kg/day 
(3) Black smoker, < 65 years: 
Model: Vm = (O,*Wf+~Os 
= 424.14 rrg/day 
= 6.39 rrg'kg/day 
(4) Black smoker, ;?: 65 years: 
Model: Vm = (01 *Wf+~Os*6r 
= 410.57 rrg/day 
= 6.18 rrg'kg/day 
(5) Coloured nonsmoker, < 65 years: 
Model: Vm = (01 * Wf + ~ 84 
= 384.51 rrg/day 
= 6.21 rrg'kg/day 
(6) Coloured nonsmoker, ;?: 65 years: 
Model: Vm = (01 * wr + ~ 04 * 0, 
= 372.21 rrg/day 
= 6.01 rrg'kg/day 
(7) Coloured smoker, < 65 years: 
Model: Vm = (81 * Wf + ~ 84 * Os 
= 430.65 rrg/day 
= 6.96 rrg'kg/day 
(8) Coloured smoker, ;?: 65 years: 
Model: Vm = (01 * Wf + ~ 04 * Os * 0, 
= 416.87 rrg/day 
= 6. 73 rrg'kg/day 
Average mass d black aoo coloued patiel1s WIS 66.4 aoo 
61.9 kg, respectively. Refer to RLll 49 (Ta~ 25) b' the 
parameter estimates 
TA81.E 29: PARAMETER ESTll\t1ATES OBTAINED FOR SET 3 ANALYSIS (VALIDATION PROCEDURE) 
CTvrr,2 CTm,2 <Jci2 0:2 
. 
RUN MODEL GROUP 81 ~ ~ 84 85 8s Sr CE E 
50 S1 1 2.38 3.74 223 1.03 1.07 0.949 - 1950 3.40 - 257 No 
51 S1 2 2.21 3.39 224 1.08 1.05 0.781 - 2640 2.77 - 228 No 
52 S1 1 2.98 4.97 211 1.03 1.11 0.909 - 1.1x1o-9 0.366 - 388 Yes 
53 S1 2 2.05 4.48 264 1.00 1.07 0.751 - 0.031 0.496 - 335 Yes 
54 S2 1 2.25 2.0 160 1.03 1.10 1.83 0.928 2380 1.15 0.233 233 No 
55 S2 2 2.20 1.5 137 1.12 1.08 2.28 0.700 2410 1.18 0.458 186 No 
56 S2 1 1.55 2.35 233 1.02 1.07 0.89 0.951 2x1o-13 0.53 1.27 250 Yes 
57 S2 2 2.21 1.57 154 1.12 1.04 1.71 0.671 1.8x1o-13 1.03 0.68 194 Yes 
58 S3 1 3.30 7.72 202 1.02 1.11 0.945 0.91 1740 13.1 0.37 8.86 No 
59 S3 2 3.46 4.93 49 1.22 1.20 3.64 0.724 2880 17.3 1.81 8.57 No 
60 S3 1 2.66 8.04 290 1.04 1.00 0.162 0.911 0.011 0.204 6.09 8.18 Yes 
61 S3 2 3.16 6.58 165 1.13 1.12 1.86 0.703 0.014 0.21 0.97 6.98 Yes 





4.9.5.1. PREDICTION PERFORMANCE EVALUATION 
Mer exduding patients producing one steady-state concentration on a single dose of 
phenytoin, the patients were randomly divided into two equally matched groups of 122 
patients each and stratified according to the following: ethnicity, smoking (non-smoker, 
smoking less than 10 cigarettes per day, 10 to 20 cigarettes per day, or more than 20 
cigarettes per day) and age (less than 65 or 65 years or older). Refer to Section 3.7.5. in 
Chapter 3. The predictive performance was assessed using 770 (388 and 382 in Groups 
1 and 2, respectively) paired predicted versus actual dose or measured serum 
concentrations. 
The dose or serum concentration predictions were based on the estimated parameter 
values obtained with each structural model used (Table 29, page 115). 
4.9.5.2. NAIVE FEEDBACK NETHOD USING ESTIMATES OBTAINED 
WITH THE FO AND FOCE NETHODS 
The purpose of this part of the work was to compare the predictive performance of the 3 
structural models using the mean population estimates obtained with the FO and FOCE 
methods. 
Tables 30-32 present the previously described measures of bias (MPE) and precision 
(RMSE) obtained with the population estimates derived with the FO and FOCE methods. 
The separate and combined results are reported for Groups 1 and 2. IVlodels S1 and S2, 
when the FO method was used, underpredicted the phenytoin dose by an average of 5.88 
and 3.95 mg/day, respectively (Table 30, page 117). Model S3 overpredicted phenytoin 
concentration by an average of 2.54 mg/I (Table 31, page 118). The FOCE-derived 
parameter estimates were generally less biased than the FO-derived parameter 
estimates. Wien the FOCE method was used, models S1 and S2 underpredicted the 
phenytoin dose by an average of 1.32 and 3.73 mg/day, respectively (Table 32, page 
118), and model S3 was found to overpredict phenytoin concentration by an average of 
0.91 mg/I (Table 31, page 118). This was remarkable for a pharmacokinetic analysis 
where a number of variables can influence the results. It indicated that the prediction error 
was reduced in all 3 models when the FOCE-derived estimates were used. Reductions 
of 77.6, 5.7 and 64.2% in the MPE with the FOCE-derived estimates were obtained for 
models S1, S2 and S3, respectively. The MPEs of -0.43, -1.20 and 5.67% obtained wth 
models S1, S2 and S3 with the FOCE-derived estimates were all considered acceptable 
(Tables 31 and 32). Wien the results of Groups 1 and 2 were combined, only the FOCE-
derived estimates using model S1 were unbiased, as reflected by the 95% confidence 
interval which induded zero (Toscano and Jameson, 1986)(Table 32, page 118). However, 
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when the groups were analyzed separately, Groups 1 and 2 (FO method - model S2; 
FOCE method - models S1 and S2) were unbiased (Tables 30 and 32). Only Group 1 
predictions obtained with model S3 using the FOCE-derived estimates were unbiased 
(Table 31, page 118). The width of the 95% CI for MPE did not differ much between 
models S1 and S2 for the FO- and FOCE-derived estimates (Table 30). The width of the 
95% CI for MPE was substantially shorter for model S3 when using the FOCE-derived 
estimates. This was expected with model S3 which predicted steady-state serum 
concentration. Wien model S3 was used for the combined data set, the 95% Cis of MPE 
when using the FO- and FOCE-derived estimates did not overlap. The bias had a wider 
range with the FO- (1.9 to 3.18 mg/I) than the FOCE-derived estimates (0.27 to 1.55 
mg/l)(Table 31, page 118). This indicated a significant difference (p < 0.05) between the 
FO- and the FOCE-derived estimates when predicting steady-state serum concentrations 
with model S3. 
TAEl.E 30: PREDICTIVE PERFORMANCE EVALUATION OF MODELS S1 AND S2 
USING THE FD-DERIVED PARAMETER ESTIMATES 
MODELS 
S1 S2 
GROUP 1 GROUP2 COMBINED GROUP1 GROUP2 COMBINED 
MPE {ng'day) -5.80 -5.96 -5.88 -4.13 -3.77 -3.95 
MPE (%) -1.86 -1.92 -1.89 -1.32 -1.21 -1.27 
MSE (ng'day)2 2671.01 2857.43 2764.22 2671.0 2817.21 2744.11 
RMSE (ng'day) 51.68 53.45 52.57 51.68 53.08 52.38 
RMSE (%) 16.56 17.19 16.88 16.56 17.07 16.82 
95°/o CI cl El~ -10.92- -11.29- -9.56- -9.3- -9.15 - -7.69-
(ng'day) -0.68 -0.63 -2.18 1.04 1.61 -0.23 
Does the 95°/o CI cl No No No Yes Yes No 
El~ irdi.m zero? 
95°/o CI cl RMSE 50.64- 52.37 - 51.81 - 50.64- 52.0- 51.62-
52.64 54.46 53.31 52.64 54.1 53.10 
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TAB..E 31: PREDICTIVE PERFORMANCE EVALUATION OF MODEL S3 USING 
THE FO AND THE FOCE-DERIVED PARAMETER ESTIMA.TES 
MODELS 
S3 (FO) S3 (FOCE) 
GROUP1 GROUP2 COMBINED GROUP1 GROUP2 COMBINED 
MPE (ng'I) 2.25 2.83 2.54 0.79 1.03 0.91 
MPE (%) 14.23 17.50 15.87 4.97 6.37 5.67 
MSE (rrg'l)2 95.12 125.92 110.52 93.30 122.2 107.75 
RMSE (ng'I) 9.76 11.22 10.49 9.66 11.05 10.36 
RMSE (%) 61.81 69.43 65.62 61.18 68.38 64.78 
95% CI cl BIAS 1.39- 1.88- 1.90- -0.07 - 0.08- 0.27-
(rrg'day) 3.11 3.78 3.18 1.65 1.98 1.55 
Does the 95% CI cl No No No Yes No No 
BIAS iool.de mro? 
95°/o CI cl RMSE 9.56- 10.99- 10.36- 9.46- 10.83- 10.23-
9.93 11.43 10.66 9.84 11.26 10.52 
TAB..E 32: PREDICTIVE PERFORMANCE EVALUATION OF MODELS S1 AND 
S2 USING THE FOCE-DERIVED PARAMETER ESTIMA.TES 
MODELS 
51 52 
GROUP1 GROUP2 COMBINED GROUP1 GROUP2 COMBINED 
MPE (rrg'clay) -1.59 -1.05 -1.32 -2.64 -4.81 -3.73 
MPE (%) -0.51 -0.34 -0.43 -0.85 -1.54 -1.20 
MSE (rrg'day)2 2962.65 3035.67 2999.16 2639.33 2877.35 2758.34 
RMSE (rrg'day) 54.4 55.1 54.75 51.37 53.64 52.51 
RMSE (%) 17.44 17.72 17.58 16.46 17.25 16.86 
95% CI cl BIAS -7.01 - -6.58- -5.26- -7.72 - -9.93- -7.33-
(rrg'clay) 3.83 4.48 2.6 2.44 0.31 -0.11 
Doesthe95% Yes Yes Yes Yes Yes No 
CI clBIAS 
iool.demro? 
95%Cic1 53.34- 53.98- 53.96- 50.34- 52.55- 51.75 -
RMSE 55.44 56.14 55.52 52.33 54.65 53.25 
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The models S1 and S2 (FO and FOCE methods) tend to be slightly more conservative, 
usually underestimating the dose required (Tables 30 and 32). Given the nonlinear kinetics 
of phenytoin, this may be more clinically appropriate. All predictions lacked precision. The 
poor precision of the prediction obtained with model S3 was expected due to the nonlinear 
pharmacokinetics of phenytoin. The precision of all 3 models did not improve with the 
FOCE-derived estimates 
The mean actual doses and the mean predicted doses were 311.2 and 307.6 and 311.2 
and 307.4 for models S1 and S2, respectively. The mean measured and predicted 
steady-state concentrations were 15.97 and 17.7 mg/I, respectively. The predicted doses 
or steady-state serum concentrations represent a mean value obtained with the FO- or 
FOCE-derived parameter estimates. These results show a good relationship between the 
mean actual and predicted values. 
For the combined data set, a significant difference (p = 0.028) was found between the 
actual and predicted doses for model S1 when using the FO-derived parameter estimates. 
No such difference (p = 0.64) was found when the FOCE-derived parameter estimates 
were used. This confirmed that the FOCE-derived estimates predicted better than the FO-
derived estimates. For model S2, no significant differences were found for the FO (p = 
0.142) and FOCE (p = 0.153) methods. This indicated the importance of Cl in the model. 
For model S3, a significant difference (p = 4.39 x 10"8) was found between the measured 
and predicted steady-state serum concentrations when the FO-derived estimates were 
used; however, no such difference (p = 0.0502) was found when the FOCE-derived 
estimates were used. Wien all the groups were analyzed separately, only the FO-derived 
estimates when used in model S3 showed a statistical difference between measured and 
predicted steady-state serum concentrations in Groups 1 (p = 3.93 x 10-5) and 2 (p = 3.0 
x 1 o-4). The absence of a significant difference between most groups, particularly when the 
FO-derived estimates were used, indicated that the parameter and structural models were 
adequate. These results clearly indicate that model S3 can be used with confidence when 
the FOCE-derived parameter estimates are used. 
Simply ranking the methods on the basis of bias and precision does not always predict 
their ranking in respect of superiority of clinical use (Toscano and Jameson, 1986). For 
this reason, our study also examined the relative frequencies of satisfactory predictions. 
The ability to predict a dose or steady-state serum concentration with precision within 
10% of the actual dose or within 20% of measured serum concentration was tested for the 
various models (Yuen et al., 1983a). These results were tabulated for each method and 
expressed as a percentage of the total predictions for that method (Table 33, page 120). 
Our conclusions are therefore also based on the latter. 
120 
TAEI.E 33: PREDICTIVE PERFORrv1ANCE EVALUATION OF MODELS S1, S2 
AND S3 
MODELS 
51 S2 S3 S1 S2 S3 
FO FO FO FOCE FOCE FOCE 
% % % % % % 
UNDERPREDICTION 55.8 55.3 38.6 51.2 55.6 45.7 
OVERPREDICTION 44.2 44.7 61.4 48.8 44.4 54.3 
PE1 > 10% FOR DOSE 54.9 55.7 - 58.2 54.5 -
PE1 > 20% FOR CJlss - - 76.4 - - 75.3 
1 denotes prediction error 
No significant difference between the frequency of under- and overprediction of dose was 
found when comparing models S1 and S2. There was a trend towards conservative 
predictions, i.e. underpredictions of dose. This is an important attribute for a phenytoin 
dosing method since even a small overdosage may lead to substantial toxicity. Thus, in 
most clinical situations, underdosing is more desirable than overdosing. Model S3 tended 
to overpredict steady-state serum concentration in 61.4% of cases when the FO-derived 
estimates were used. Wth the FOCE-derived estimates, the tendency to overpredict was 
reduced to 54.3% which was considered satisfactory (Table 33). The percentage of 
prediction errors greater than 10% did not differ substantially between models S1 and S2. 
Using the latter models, on average 44.2% of predictions had errors less than 10%. Wth 
model S3, the percentage of prediction errors greater than 20% did not differ substantially 
when the FO- and FOCE-derived estimates were used. On average, only 24.2% of the 
predictions of steady-state serum concentrations had errors less than 20% (Table 33). The 
FOCE-derived estimates also resulted in fewer extreme dosing errors. 
Although model S2 fitted the data better than model S1, the results showed that Cl was 
not clinically important when predicting the dose, as the percentage bias (% MPE) was not 
much lower when Cl was incorporated in the model. The frequency of prediction errors 
also did not differ between models S1 and S2. A definite statement about superiority 
cannot easily be made. 
Because of the poor precision, the 3 models evaluated in this study should be applied with 
caution when predicting dose or serum concentration. As clearly demonstrated in this 
study, FOCE-derived estimates improved the bias to a variable extent but not to the point 
of precision. Given the larger variability in the kinetics of phenytoin, one or more feedback 
concentrations are probably required to improve precision. The more feedback serum 
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concentrations available, the more the precision of the predictions can be expected to 
improve. 
4.9.5.3. PREDICTIONS OF STEADY-STATE SERUM CONCENTRATIONS 
USING THE NICHAEUS-NENTEN MODEL (S4) 
In many cases, predictions could not be made since the maintenance dose administered 
exceeded the predicted Vm value for the individual, resulting in unrealistic steady-state 
serum concentration values. This made accurate assessment of prediction performance 
difficult. In such a case, the equation yielded a negative value for the steady-state 
concentration when conceptually it should have resulted in infinity. This would have 
confounded the analyses of bias and precision (Toscano and Jameson, 1986). For this 
reason, 53 dose-concentration pairs where the latter occurred were removed from the data 
set. Therefore, with the Michaelis-Menten model, dosing rate was used as a basis of 
comparison since it was always possible to calculate an estimated dosing rate required 
to achieve an observed steady-state concentration. Wien the maintenance dose 
administered exceeded the predicted Vm value, steady state would theoretically never 
have been reached (Yuen et al., 1989). 
The estimates of Vm and Km obtained with model S1 were used in this analysis. The 
results obtained when using model S4 are presented in Tables 34 and 35 (page 122). 
Model S4 tended to overpredict grossly the steady-state serum concentration when the 
F~erived estimates were used - a % MPE of 76.2%. Wien linear clearance was taken 
into account (model S3), the% MPE decreased to 15.87% (Table 31, page 118), reflecting 
a 79.2% reduction. The precision of the prediction improved markedly when Cl was 
included from 379.4% (Table 34, page 122) for model S4 to 65.62% (Table 31, page 118) 
for model S3. Using the estimates obtained with the FOCE method, the RMSE was not 
substantially reduced (Table 34). The 95% CI for bias did not include zero when the FO-
and FOCE-derived estimates were used. Wien the FD-derived estimates were used, 
model S3 tended to overpredict the Cp55 (61.4%)(Table 33, page 120) more than model 
S4 (52.4%)(Table 35, page 122). However, the frequency of PEs greater than 20% did not 
differ much (Table 35). Wien interpreting the results, one should take into consideration 
that 53 dose: concentration pairs had to be removed from the data set when model S4 
was used (Table 34). 
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TAEI..E 34: PERFORMANCE EVALUATION OF MICHAELIS-MENTEN MODEL (S4) 
TO PREDICT STEADY-STATE SERUM CONCENTRATION USING THE 
FO-AND THE FOCE-DERIVED PARAMETER ESTIMA.TES OBTAINED 
FOR MODEL S1 
MODELS 
S4 {FO) S4{FOCE) 
GROUP1 GROUP2 COMEINED GROUP 1 GROUP2 COMBINED 
n 357 360 717 374 376 7flJ 
MPE {rrql) 10.17 13.44 11.81 7.37 8.88 8.13 
MPE {%) 67.49 84.9 76.2 48.0 55.81 52.0 
MSE (rrg'day)2 4322.94 2555.77 3439.36 2001.63 2635.0 2798.3 
RMSE {rrql) 65.75 flJ.55 58.15 54.42 51.34 52.9 
RMSE {%) 436.3 319.3 379.4 354.52 322.7 338.5 
95% CI c:i BIAS 3.42- 8.4 - 7.6- 1.9- 3.76- 4.39-
{rrql) 16.92 18.48 16.02 12.84 14.0 11.87 
Does the 95% CI c:I No No No No No No 
BIAS irdooe zero? 
95% CI c:I RMSE 64.32- 49.46- 57.73- 53.29- flJ.27 - 52.14-
67.08 51.57 59.45 55.47 52.32 53.62 
No. c:I p-ecictia,s 31 22 53 14 6 20 
exdooed 
No. c:I ...-realistic 16 32 48 11 14 25 
p-ecictia,s > 75 rrg'I 




n =717 n =7flJ 
% % 
UNDERPREDICTIONS 47.6 flJ.5 
OVERPREDICTIONS 52.4 49.5 
PE> 20% FOR CP!;..c: 80.2 79.7 
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\/\tlen the FCH:terived estimates were used (model S4), 48 of the predictions of Cpss were 
unrealistically greater than 75 mg/I. \/\tlen estimates obtained with the FOCE method were 
used, the number of unrealistic predictions fell to 25. The combined number of patients 
excluded due to the dose being greater than Vm was reduced from 53 for the FCH:terived 
estimates to 20 for the FOCE-derived estimates (Table 34). The standard deviation for the 
bias and predicted concentration was substantially lower for model S3 than for model S4. 
A statistical difference between the measured and predicted concentrations was found with 
model S4 when the FO- (p = 7.56 x 1~) and the FOCE- (p = 3.06 x 10-5) derived 
estimates were used. Wth model S3, a statistical difference was only found when using 
the FCH:terived estimates (p = 4.39 x 1 ~). 
The results clearly indicate that Cl in model S3 was clinically important when predicting 
steady-state serum concentrations, because the % MPE was much lower when clearance 
was incorporated in the model. Model S3 should therefore be used in preference to model 
S4. The estimates obtained with the FOCE method also performed better than those 
obtained with the FO method. 
4.9.5.4. PREDICTIONS OF DOSE AND STEADY-STATE SERUM 
CONCENTRATION USING ESTIMATES OBTAINED FROM 
lHE STUDY OF VOZEH et al. (1981) IN MODELS 51 and 54 
The results obtained when using model S1 are presented in Tables 36 and 38. Only the 
FCH:terived estimates were used in this part of the analysis. \/\tlen using model S1, the 
% MPE of -1.89% obtained with our estimates was much lower than that of 11.4% 
obtained with the estimates of Vozeh et al. (1981). The estimates of Vozeh et al. (1981) 
also tended to overpredict the dose in 69% of cases (Table 38, page 125) and this may 
be problematic with phenytoin considering its nonlinear pharmacokinetics. \/\tlen our 
estimates were used the dose was overpredicted in 44.2% of cases (Table 33, page 120). 
The precision of the prediction was superior with our estimates of Vm and Km. The width 
of the 95% CI for MPE was narrower with our estimates of the pharmacokinetic 
parameters. The frequency of PE greater than 10% for dose was 54.9% for our estimates, 
and 70.1% when the estimates of Vozeh et al. 1981 were used. 
The results obtained with the estimates of Vozeh et al. (1981) in model S4 are presented 
in Tables 37 and 38 (page 123). \/\tlen the estimates from the latter study were used, 
large differences were found in the % MPE and % RMSE between Groups 1 and 2. This 
indicated instability in the model or the estimates. \/\tlen our estimates were used, model 
S4 overpredicted Cpss in 52.4% of cases (Table 35, page 122), in comparison with 30.7% 
(Table 38, page 124) with the estimates of Vozeh et al. (1981). 
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TAEI..E 36: PERFORMANCE EVALUATION OF THE MICHAELIS-MENTEN MODEL 
(S1) TO PREDICT PHENYTOIN DOSE USING THE ESTIMATES OF Vm 
AND Km OBTAINED BY VOZEH et al. (1981) 
51 
GROUP1 GROUP2 COMBNED 
n 388 382 770 
MPE (ng'day) 33.7 36.6 35.15 
MPE (%) 10.9 11.9 11.4 
MSE (ng'day)2 6644 6525 6584.5 
RMSE (ng'day) 81.51 80.78 81.15 
RMSE (%) 26.13 25.97 26.05 
95% CI<IEIAS 26.5- 29.6- 30.33-
40.9 43.6 40.67 
Does the 95% CI a No No No 
EIAS incll.de zaro? 
95%CI<IRMSE 79.88- 79.13- 79.96-
83.03 82.30 82.28 
TAEI..E 37: PERFORMANCE EVALUATION OF THE MICHAELIS-MENTEN MODEL 
(S4) TO PREDICT SERUM PHENYTOIN CONCENTRATION USING THE 
ESTIMATES OF Vm AND Km OBTAINED BY VOZEH et al. (1981) 
54 
GROUP 1 GROUP2 COMBNED 
n 380 373 753 
MPE (ng'I) 0.13 7.42 3.78 
MPE (%) 0.83 46.92 23.88 
MSE (ng'l)2 1104 12345 6724.50 
RMSE (nq'I) 33 111.1 72.05 
RMSE (%) 211.9 703.16 457.53 
95% CI<IEIAS -3.22- -3.85- -2.05-
3.48 18.69 9.61 
Does the 95% CI a Yes Yes Yes 
EIAS incll.de mm? 
95%CI<1RMSE 32.55- 108.79- 80.78-
33.86 113.26 83.17 
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TA81..E 38: PREDICTIVE PERFORrvlANCE EVALUATION OF MODELS S1 AND S4 






UNDERPREDICTIONS 31.0 69.3 
OVERPREDICTIONS 69.0 30.7 
PE > 10% FOR IX>SE 70.1 -
PE > 2()0/o FOR CPs,c; - 85.5 
The frequency of PE greater than 20% did not differ much between the 2 evaluations 
(Tables 35 and 38). This analysis indicated that predictive performance improved when 
population estimates representative of a specific population were used. 
In summary, the study demonstrated that the parallel Michaelis-Menten model with 
first-order elimination (model S3) was superior to the Michaelis-Menten model when 
predicting Cp55• Wien using the Michaelis-Menten model to predict dose, our estimates 
performed better than those of Vozeh et al. (1981). However, when predicting Cp55 , our 
estimates did not perform substantially better than those of Vozeh et al. (1981). 
The bias decreased and the precision increased as the number of individuals in the 
sample increased (Sheiner and Beal, 1983). Wien using the estimates determined in the 
whole population, improved estimates of bias and precision were obtained even though 
patients with one dose-concentration pair were not exduded. These results are not 
reported here. It is therefore emphasized that the estimates obtained in sets 1 and 2 
analysis (i.e. 332 patients) should be used in dinical practice. The parameter estimates 
obtained in set 3 analysis (122 patients in each group) were solely for the purpose of 




As no data are available on the population pharmacokinetics of phenytoin in the \/Vestem 
Cape, this study was undertaken to address this issue. This study was conducted 
prospectively primarily to: (1) investigate the influence of various patient variables on the 
population pharmacokinetic parameters of phenytoin, (2) assess whether the parallel 
Michaelis-Menten and first-order elimination model provides a better fit to the data than 
the Michaelis-Menten model, (3) determine population pharmacokinetic parameter 
estimates of phenytoin representative of the patient population, and (4) validate and 
compare the clinical applicability of the parameter estimates and the models. 
More appropriate initial estimates of population pharmacokinetic parameters may greatly 
improve the performance of the Michaelis-Menten model or other models that use 
phenytoin population pharmacokinetics (Burton et al., 1985) to predict phenytoin dose or 
serum concentration. However, before establishing the best estimates of the population 
pharmacokinetic parameters, it was necessary first to evaluate the influence of selected 
patient factors on these pharmacokinetic parameters. Generally, concomitant factors such 
as age, weight, serum albumin, liver and renal function, and concurrent drug therapy must 
be used to provide appropriate prior information (Ludden et al., 1986). The importance of 
appropriate prior information for Bayesian regression analysis has been reported (Peck 
and Chen, 1985). Although many factors are known to influence the disposition of 
phenytoin, their relative effects on Vm and Km are difficult to quantify (Bryson et al., 1988). 
Application of a model to a diverse patient population will require that the mean values for 
pharmacokinetic variables be defined appropriately for various subpopulations. The 
estimates of the proportionality factors that adjust the mean population parameters for 
inter-individual differences, the magnitudes of the inter-individual and residual variability 
of these parameters in the dose to serum concentration relationship should also be 
quantified. As mentioned before, it is important that the estimates of this variability be 
obtained in a patient population in whom the drug is used clinically (Vozeh et al., 1982). 
The estimates of this variability are helpful in the development of dosage 
recommendations, because they enable calculation of the proportion of patients at risk of 
producing toxic or ineffective concentrations (Fattinger et al., 1991). A recent conference 
report (Peck et al., 1992) has once again emphasized the importance of the appreciation 
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of inter- and intra-patient variability and its causes, so that better individualization of 
treatment can be achieved. 
Interpretation and comparison of practically all earlier studies are difficult because of their 
retrospective nature, small patient populations, multiple drug therapy, questionable 
compliance, different analytical techniques, different methods of data analysis and too 
many uncontrolled factors. The use of multiple regression analysis and the calculation of 
correlation coefficients to determine the effect of patient attributes on the pharmacokinetic 
parameters and predictive performance have been demonstrated by Sheiner and Beal 
(1981) to be an inappropriate method. In many earlier studies, the performance of a 
prediction method was evaluated by computing the correlation coefficient of the actual and 
predicted values. However, as demonstrated by Sheiner and Beal (1981), this statistical 
method provided a poor description of predictive performance. The correlation coefficient 
assesses the degree of association rather than the true closeness of the predicted and 
actual values (Beck et al., 1987). This method was therefore not used in this study. 
It is possible that in many studies the relationship between phenytoin dosage requirements 
and patient attributes was concealed by the presence of other anticonvulsants (Barot, 
1978). How much confidence can be placed in these studies is not known (V\tliting, 1986). 
There has been a need for investigations that include prospective evaluations of predictive 
performance (Pryka et al., 1991). To our knowledge, this is the first prospective 
investigation to study population pharmacokinetics of phenytoin in South African patients. 
There is undoubtedly much to be gained from prospective planning in population 
pharmacokinetic studies (Fattinger et al., 1991). 
None of the predictive dosing methods based solely on population estimates has proven 
satisfactory. Ideally, these methods should apply before phenytoin therapy is initiated; 
alternatively, as soon as possible after therapy is started (Slattery et al., 1980). 
Furthermore, predicting the proper maintenance dose early in therapy may be particularly 
valuable for a drug like phenytoin where the desired effect is delayed, a fact which 
complicates the temporal relationship between dose adjustment and observed clinical 
result. This study therefore concentrated on the naive feedback approach to validate the 
factors influencing the population pharmacokinetic parameters, the different structural 
models and the pharmacokinetic parameter estimates. Previous studies have shown the 
naive feedback method to be inaccurate. There is a need for a simple and general method 
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to predict individual dosage requirements, a method which extracts the maximum 
pharmacokinetic information about a given patient from the minimum of data obtained after 
an initial dose (Godley et al., 1987; Slattery et al., 1980). 
Although nomograms (predictive algorithms) are useful as starting points for drug therapy, 
most are generally based on invalid assumptions of either a constant Vm or Km, and their 
error in achieving target concentration is considerable (Chiba et al., 1980; Richens and 
Dunlop, 1975). Because of the large variability of both Vm and Km in a population, 
nomograms that assume either an average Vm or Km are inherently imprecise (Vozeh et 
al., 1980). This imprecision is exacerbated by the fad that most of the algorithms have 
been developed using small populations of patients. The relationship between phenytoin 
pharmacokinetics and one or more clinical parameters is then applied to larger groups of 
patients. The groups from which the data are originally derived are often relatively 
homogenous, and the data do not necessarily apply to the population as a whole (Burton 
et al., 1985). Since the therapeutic range usually exceeds the Km for phenytoin, the 
effects of this imprecision are magnified when phenytoin concentrations are above the 
lower limit of the therapeutic range. Algorithms are most successful when they are used 
in the same population for which they were developed (Miller et al., 1989). 
5.1. FACTORS INFWENCING THE PHARMACOKINETICS OF 
PHENYTOIN 
It is important to understand why variation in pharmacokinetic parameters occurs so that 
the dose can be tailored to achieve an optimal response in a given patient (Berman, 
1976). Our study demonstrated that estimates of Vm improved when selected 
demographic factors were considered. Mass, ethnicity, smoking and age contributed 
significantly to explaining variability in Vm. Other factors, as yet undetermined, may also 
affect the pharmacokinetics of phenytoin. 
It is clear that when phenytoin dose is individualized as a linear function of weight 60- 70% 
of patients attain steady-state concentrations outside the therapeutic range (Koch-VVeser, 
1975). VVeight alone, therefore, cannot account for the wide variation seen in clinical 
practice (Richens, 1975). Other influential factors should also be taken into account, as 
demonstrated in this study. 
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Other than weight, the most influential factor related to Vm was smoking. To our 
knowledge, there are no studies in the literature that address this. Studies do address the 
effect of smoking on serum phenytoin concentration, but not on Vm. Serum phenytoin 
concentrations have been reported not to be appreciably affected by smoking (Benetello 
et al., 1987; Crowley et al., 1988; De Leacy et al., 1979). Our study has demonstrated that 
smoking increased Vm significantly (p < 0.0007) on average by a factor of 12%. 
Wth increased recognition that genetically determined polymorphism in drug metabolism 
is an important factor affecting drug disposition, interest has developed in the 
individualization of dose to account for racial differences 0,Nood and Zhou, 1991). Failure 
to take into account these differences may result in therapeutic failure and toxicity. Clearly 
discernible differences have been found to exist between South African blacks and 
coloureds in the kinetics of phenytoin. This may arise from the interplay of genetic as well 
as environmental factors, e.g. diet and alcohol intake (Branch et al., 1978; Kalow, 1982). 
Our results are contrary to those of Grasela et al. (1983) in that our study showed that 
ethnicity influenced Vm. On the other hand, our study is in agreement with that of Grasela 
et al. (1983) in that ethnicity was found to influence Km in both studies. Our final model, 
however, did not include the influence of ethnicity in Km for the reasons discussed 
previously. Ethnicity has been reported to influence the effect of a number of drugs, e.g. 
ephedrine (Smith, 1989), beta-blockers (Seedat, 1980; Venter and Joubert, 1984), 
hydrochlorothiazide (Smith, 1989), theophylline (Driscoll et al., 1989), diazepam (Ghoneim 
et al., 1981), isoniazid (Sunahara et al., 1961), procainamide, hydralazine, dapsone (Horai 
and lshizaki, 1988) and mephenytoin (Jurima et al., 1985; Nakamura et al., 1985; V\/edlund 
et al., 1984). 
Our study did not detect a continuous effect of age on Vm. The same effect was reported 
by Grasela et al. (1983). The latter investigators reported that discontinuity at 15 years of 
age provided the best fit of the model to the data, their patient population differing from 
ours in that their study included children. It is for this reason that our study included 
patients over the age of 15. Another reason for this is that the OP~ computer programme 
has not been validated for persons under 15 years of age. Our study showed that 
discontinuity at 65 years of age provided the best fit. The conditional estimation method 
showed that the effect of age on phenytoin metabolism was less compared with that of 
smoking. These results are similar to those of Vestal et al. (1975) who showed that the 
effect of age on antipyrine clearance was insignificant compared with that of smoking. Our 
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results agree with those of Bauer and Blouin (1982) who showed that Vm values for 
geriatric patients are lower than those for younger adults. Our results also agree in that 
age did not influence Km. This study of Bauer and Blouin (1982) is discussed here as it 
is probably one of the few studies, if not the only one, on population pharmacokinetics of 
phenytoin performed prospectively in adult patients. 
Our results also agree with Bauer and Blouin (1982) in that sex difference did not 
influence Vm and Km. Failure to find an effect of gender was also the case with other 
studies (Grasela et al., 1983; Houghton et al., 1975). This does not necessarily mean that 
such interaction may not occur on an individual patient basis. Gender-related differences 
in the disposition of drugs such as paracetamol, chlordiazepoxide, diazepam, oxazepam 
and theophylline have been reported. None of these gender-related differences has so far 
necessitated the modification of the dosage regimen (Driscoll et al., 1989; Wison, 1984). 
A priori methods based on patient characteristics such as age, body mass, renal function, 
smoking status and degree of congestive heart failure have proved useful in predicting 
initial estimates of pharmacokinetic parameters and dose requirements. Greater precision 
has been obtained with predictive methods based on individual characterization of the 
pharmacokinetic parameters (Slattery et al., 1980). 
5.2. POPULATION PHARMACOKINETIC PARMETER ES11MA1ES 
Further details of the studies cited below can be found in Chapter 2, and especially Table 
1 in that chapter. 
The information on the population pharmacokinetic parameter estimates was obtained 
mainly from Caucasian populations and information from other population groups seems 
to be fragmentary and scarce. 
The Vm and Km values obtained in our study were compared with those obtained in other 
studies, especially where NONMEM was used. Wien comparing Vm and Km estimates 
obtained in other studies, it is important to consider the structural models used, the 
methods used to derive the parameter estimates, the number of patients in the study, 
131 
whether other drugs including anticonvulsants that may interfere with phenytoin 
pharmacokinetics were taken, and the compliance checks that were used. 
A Km of 3.66 (inter-individual SD 1.69, CV 49.1 %) obtained in our study for black patients 
compared favourably with that of 3.43 mg/I (inter-individual SD 2.27, CV 73%) obtained 
by Miller et al. (1987) for black patients attending the outpatient clinic at Baragwanath 
Hospital in Johannesburg, South Africa. In our study, a Vm of 5.71 mg/kg/day (inter-
individual SD 0.73; CV 13.22%) was obtained for black patients when no covariates were 
taken in account. This was lower than that of 6.5 mg/kg/day (inter-individual SD 1.3, CV 
20%) obtained by Miller at al. (1987) for black South African patients. The NONMEM 
approach was also used by Miller et al. (1987). In our study, a larger number of black 
patients was recruited (149 compared with 37 in Miller's study) and more serum phenytoin 
concentrations were measured (411 versus 100). Our study also had an advantage in that 
it was performed prospectively, reducing the chances of error. 
The mean Vm value of 5. 71 mg/kg/day obtained in our study with the Michaelis-Menten 
model compared well with that of 5.93 mg/kg/day reported in adult male European patients 
by Grasela et al. (1983). The Km value, on the other hand, differed markedly from that of 
adult European patients. A mean Km value of 3.45 mg/I was obtained in our study 
whereas a mean Km value of 5. 7 mg/I was obtained in adult male European patients using 
the same model and procedure of analysis (i.e. NONMEM). Grasela et al. (1983) reported 
a mean Km value of 3.8 mg/I for Japanese patients over 15 years of age and this 
compared closely with the mean Km value obtained in our study. Grasela et al. (1983) 
reported that even after adjustments for covariates, the apparent Vm and Km varied 
unpredictably among individuals with a CV between 1 O and 20% and approximately 50%, 
respectively. The% CV in our study varied from 12.5 to 17.14 and 49.1 to 67.9 for Vm 
and Km, respectively, depending on the structural model and the method (naive or 
conditional estimation) used. A CV of 13.22 and 49.1 % for Vm and Km, respectively, 
obtained with the Michaelis-Menten model correlated well with that of Grasela et al. 
(1983). The estimate of the residual variability (5%) obtained in our patients was lower 
than that of 8% and 12% obtained in European and Japanese patients, respectively. In the 
same study, some patients in all the groups (German, Japanese and English) received 
other medication in addition to phenytoin. Information on these medications was unknown 
and it was assumed that they had no appreciable effect on the observations. This study 
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also assumed 100% compliance with the prescribed dosage regimen. There were large 
age differences between the groups. 
The Vm value of 8.05 mg/kg/day obtained in Singapore Chinese patients was much higher 
than that obtained in our study. Ethnic differences may account for the greater metabolic 
capacity in the Chinese population. This study used the nonlinear mixed-effects model in 
the MUL Tl(ELS) programme. The possibility that the observed differences in Vm may have 
been due to differences in the bioavailability of phenytoin between different patient groups 
cannot be ruled out (Chan and Lee, 1990). On the other hand, the mean Km value of 3.45 
mg/I obtained in our study was higher than that of 2.31 mg/I obtained in the study of Chan 
and Lee (1990). The latter study, however, included paediatric patients, which makes 
comparison difficult. Chan and Lee (1990) reported an inter-individual variability in Vm and 
Km of 28.5% and 65.7%, respectively, and a residual variability of 21.3%. The latter values 
are much higher than those obtained in our study. 
Vozeh et al. (1981) studied 49 Swiss patients and reported the following parameter 
estimates: mean Vm = 7.22 mg/kg/day (inter-individual SD 1.72; CV 24%) and mean Km 
= 4.44 mg/I (inter-individual SD 2.4; CV 54%). The NONMEM method was used in this 
study. These estimates have been widely used in clinical practice for the calculation of 
phenytoin dose and prediction of steady-state concentration. These estimates were also 
used in the 'orbit plot' and in the OP~ computer programme. Both Vm and Km estimates 
obtained in our study were lower than those reported by Vozeh et al. (1981). 
In a retrospective study of 334 adult and paediatric patients, Yukawa et al. (1990) 
determined the population pharmacokinetics of phenytoin from routine clinical data in 
Japanese patients using the NONMEM approach. Only 101 of these patients were 
receiving phenytoin monotherapy. Duplicate steady-state phenytoin concentrations on the 
same dose were not obtained and therefore compliance was not confirmed. The data 
analysis using the Michaelis-Menten model estimated Vm and Km values of 5.42 
mg/kg/day and 2.41 mg/I, respectively. In this study, the typical magnitude of 
inter-individual variability, as expressed by the coefficient of variation, was 17.2% for Vm 
and 53.3% for Km. The typical magnitude of the intra-individual variability, expressed as 
the coefficient of variation, was 11 %. This study again confirmed that our estimates of 
Vm, Km, the inter-individual and residual variability in these parameters are acceptable. 
This study revealed that the Vm for patients taking phenytoin combined with other 
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anticonvulsants was 80% higher than that of patients taking phenytoin alone. Similarly, the 
Km for patients taking phenytoin combined with other anticonvulsants was 32% higher 
than that of patients taking phenytoin alone. It is, therefore, essential for the patients to 
be on phenytoin monotherapy in studies to assess population pharmacokinetic parameters 
of phenytoin. 
5.3. PARAl.lEL MCHAEUS-IVENTEN AND FIRST-ORDER KINETICS 
Correct interpretation of phenytoin concentrations requires an accurate and precise 
method that takes the nonlinear and linear disposition of phenytoin into account (Bryson 
et al., 1988). 
Ludden et al. (1991) in a simulation based study, reported that the sensitivity of mean 
steady-state phenytoin concentrations to the change in effective dosing rate was 
influenced by a parallel, first-order elimination pathway, the magnitude of which was 
unknown. Our study determined that the magnitude of the mean Cl was 2.68 (0.78) I/day 
with the upper and lower bounds of the 95% confidence interval of 1.49 and 3.89 I/day, 
respectively. The standard error of the estimate is presented in parentheses. 
In previous studies, the contribution of the parallel first-order elimination pathway was 
assumed to be negligible. This study proved that, on the contrary, taking linear clearance 
of phenytoin into account does indeed improve the fit of the model to the data. Such a 
model, especially when predicting serum phenytoin concentrations, provides predictions 
that are less biased. 
5.4. VALIDATION OF POPULATION PARAMElERS AND STRUCTURAL 
MODELS 
In the validation procedure, it was assumed that each patient behaved as the average. If 
a subsequently obtained serum concentration differed from that predicted, the patient 
clearly did not behave as average, and his/her pharmacokinetic parameters should be 
re-estimated to derive future dosing guidelines (Burton et al., 1985). 
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For the validation of the population parameter estimates, only model S1 can be compared 
with other studies as, according to our knowledge, models S2 and S3 have never been 
validated. In our study, with the FO-derived parameter estimates a MPE of 5.88 (SD 
52.31) mg/day were obtained using model S1. This is equivalent to a bias of 1.89%. Miller 
et al. (1989), also using the Michaelis-Menten model, obtained a MPE of 13.1 (SD 16.7) 
mg/day. In our study the MPE was 55% lower than that obtained by Miller et al. (1989). 
The latter study on average overpredicted the dosage rate whereas our study 
underpredicted the dosage rate. A positive bias in phenytoin dosage is a more serious 
error than a negative bias (Toscano and Jameson, 1986). Our results produced a RMSE 
of 52.57 mg/day, which was lower than that of 61.5 mg/day obtained by Miller et al. 
(1989), a 14.5% difference. A smaller prediction error was expected in our study as the 
Vm values were adjusted for ethnicity, weight, age and smoking status. The Vm value in 
the study of Miller et al. (1989) was not adjusted for any patient characteristic except for 
weight. The fact that the study was conducted in black patients only, however, 
automatically took ethnicity into account. The latter study was also not designed to study 
the influence of patient factors on Vm and Km values. 
The predicted doses obtained with model S1 have a mean absolute deviation of 1.89% 
when compared with the actual doses. This was considered acceptable, as the mean error 
was approximately of the same magnitude as the assay error. Despite the relatively 'good' 
predictability of the models examined, it is disconcerting that there was a sizeable number 
of predictions with an error of greater than 10%. Wlile this is trivial for most other drugs, 
such an error can become significant in the case of phenytoin because of the 
Michaelis-Menten characteristics of the drug (Mawer et al., 1974). The majority of the 
predictions of dose were underpredictions, which minimized the risk of potentially toxic 
dosages. 
The data of Flint et al. (1985) clearly demonstrated that two previous dose : serum 
concentration pairs are superior to one in the prediction of subsequent serum 
concentrations. The more information available about the patient, the more accurate the 
predictions. Such a finding is not surprising in view of the considerable variability 
associated with the clearance of phenytoin. However, the accuracy of the predictions 
cannot improve indefinitely because of assay variability and other factors that cannot be 
completely controlled. The constraints imposed by inter- and intra-patient pharmacokinetic 
variability will continue to limit prediction accuracy (Armijo et al., 1989). Misspecification 
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of the pharmacokinetic model could be partly responsible for the difference in prediction 
accuracy (Vozeh et al., 1984). In our study, the naive prediction method was used and 
therefore the worst scenario or highest prediction errors were expected. The forecasting 
of steady-state serum phenytoin concentrations from mean population parameter values 
was remarkably inaccurate (Bryson et al., 1988). The bias and precision of our predictions 
would undoubtedly have improved if one or more feedback serum concentrations had 
been used. 
Knowledge of the estimates of the pharmacokinetic parameters and their influential factors 
allows a prediction only of the mean concentration; concentrations in individual patients 
may differ substantially from this (Burton et al., 1985). Only the additional knowledge of 
the variance components permits one to estimate how large the inter-individual differences 
in the actually achieved concentrations are expected to be, or in other words, how 
confident one can be about the predicted dose or concentration (Maitre et al., 1987). Our 
study provides estimates of the inter- and intra-individual variability for the study 
population. 
Few evaluative studies have been done to compare different models that may be useful 
in predicting dose or steady-state serum phenytoin concentrations. Most studies have used 
the same structural model, the Michaelis-Menten model, with different methods of analysis, 
(e.g. the Bayesian or naive prediction methods) and different estimates of Vm and Km. 
This study, in addition to the Michaelis-Menten model, also evaluated the parallel 
Michaelis-Menten and first-order elimination models. 
5.5. THERAPEUTIC INPUCATIONS 
Wth more knowledge about factors infl·Jencing the pharmacokinetic parameters of 
phenytoin and the attainment of an improved pharmacokinetic model for prediction of 
serum phenytoin concentrations, the potential for further improvement is considerable. 
Using a simple model such as the Michaelis-Menten model has a drawback in that one 
must be satisfied with limited success. 
A fundamental drawback with phenytoin is that it requires an extended period of initial 
evaluation to determine individual kinetics. The relationship between phenytoin dose and 
level is unpredictable if a patient's Vm and Km values are unknown (Dodson, 1982). This 
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study served to improve the understanding of this relationship by determining not only 
mean Vm and Km values but also these parameters in subsets of patients. 
A lower Km value obtained in our patients in comparison with other population groups ( e.g. 
Swiss and European patients) implied that our patients were particularly sensitive to 
changes in dosage when concentrations were in or near the therapeutic range. This also 
implies that toxic serum concentrations would be achieved in our population group at lower 
doses than in Swiss and European populations. It is therefore recommended that smaller 
increments of dose should be used in South African blacks and coloureds. The findings 
in the above studies suggested that the variability in Km was the main factor causing 
inter-individual differences in the dosage and steady-state concentration relationship. The 
magnitude of the inter-individual variability in Km emphasized the need for careful 
therapeutic drug monitoring employing Bayesian feedback. The lower Vm value obtained 
in our population in comparison with that obtained in other population groups (e.g. Swiss 
and Singapore Chinese) implied that lower doses of phenytoin were required for our 
patients to obtain the same serum phenytoin concentration. The implications of the present 
results are that if coloureds are to achieve the same serum level of total phenytoin as 
recommended for blacks, they must receive a higher dosage as their Vm is higher. For 
this reason, the side-effects of phenytoin should theoretically occur less frequently in 
coloured than in black patients receiving the same doses. However, it is important to 
emphasize that this difference alone may not be sufficiently relevant clinically to require 
an altered dosage policy. A combination of all the factors affecting the pharmacokinetics 
of phenytoin together will be clinically relevant. 
The decline in Vm value for patients 65 years of age or older implies a decreased 
phenytoin metabolizing capacity in this age group. This probably reflects age-dependent 
changes in the amount or efficiency of drug-metabolizing enzymes in the liver. Because 
of this, caution should be used when prescribing phenytoin in patients 65 years of age or 
older. 
Although a specific ethnic group (coloured patients) and a positive smoking history 
correlated with an increase in Vm (6% and 12% respectively), none of these correlations 
alone may be clinically significant. Similarly, the relationship of Vm to body weight alone 
indicated that there was a modest influence of weight on Vm. An age of 65 years or more 
was associated with a decrease in Vm of 3.2%. Therefore, in a coloured, non-smoking 
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patient 65 years of age or older, the overall effect on Vm may be minimal as the factors 
increasing or decreasing Vm may counterbalance each other. However, multiple factors, 
each of which is relatively minor, may together produce a significant contribution to the Vm 
value predicted by the parameter model (Mungall et al., 1985). 
It has been shown that systems utilizing Bayesian feedback techniques perform better 
than other methods previously reported (Burton et al., 1985; Vozeh and Steimer, 1985). 
A prerequisite of such methods is good estimates of the population or subpopulation 
parameter distributions (means and variances). The greater the confidence in these (prior) 
distributions, the better will be the performance of the associated Bayesian system. This 
study has provided estimates of Vm, Km and Cl, and their inter- and intra-individual 
variability for use in a pharmacokinetic programme with Bayesian forecasting. Regardless 
of which dosing technique is used, some individuals will receive an inappropriate regimen. 
It is thus always important to monitor serum phenytoin concentrations and dinical status 





The following conclusions were drawn from this investigation with regard to the 
pharmacokinetics of phenytoin: 
(a) Mass, smoking, ethnicity and age (65 years or older) significantly influenced 
Vm of phenytoin in descending order of importance. Although a significant 
difference in Km between black and coloured patients was found, the incor-
poration of ethnicity in Km in the parameter model did not significantly improve 
the description of the data. The scaling factors for smoking, coloured patients 
and age 65 years or older in Vm were 1.12, 1.06 and 0.968, respectively when 
the parallel Michaelis-Menten and first-order elimination model and the FOCE 
method were used. Our study confirmed that different populations have differ-
ences in phenytoin disposition. These can be attributed to genetic differences 
associated with ethnic origin and/or to social and environmental factors. 
(b) For the parallel Michaelis-Menten and first-order elimination model, the mean 
population parameter estimates (standard error in parentheses) for Vm, Km 
and Cl were 5.27 (0.59) mg/kg/day, 6.81 (1.30) mg/I and 2.68 (0.78) I/day, 
respectively. The inter-individual variability for these parameters was 12.5, 67.9 
and 46.3%, respectively and the intra-individual variability was 20.1 %. The 
mean population estimates for Vm and Km obtained with the Michaelis-Menten 
model were 5.71 (0.10) mg/day and 3.45 (0.24) mg/I, respectively. The inter-
individual variability of these parameters was 13.2 and 49.1 %, respectively, and 
the intra-individual variability was 5%. A set of mean Vm estimates for 
subpopulation groups stratified according to ethnicity, smoking status and age 
have been determined. 
( c) The population parameters of Vm and Km obtained in this study were generally 
lower than those reported in the literature for other population groups. 
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( d) A parallel Michaelis-Menten and first-order elimination model provided a better 
fit of the model to the data than one comprising Michaelis-Menten metabolism 
only. 
(e) The parallel Michaelis-Menten and first-order elimination model was not much 
better than the Michaelis-Menten model when predicting dose. However, when 
predicting steady-state serum concentration, the former model was superior to 
the latter. 
(f) Wien representative parameter estimates (taking into account factors shown 
to influence these parameters) for a population were used, predictive perform-
ance improved. As expected, all predictions using the estimates obtained with 
the FO method were biased. Wien the estimates obtained with the FOCE 
method were used, the bias improved without an improvement in the precision 
of the predictions. 
(g) This study has provided a predictive model that is useful for the design and 
adjustment of phenytoin regimens in clinical practice. However, none of the 
predictive methods was precise enough to substitute for confirmatory serum 
phenytoi n concentrations. 
(h) The findings of this study stressed the importance of accurate, 
population-based, pharmacokinetic parameter estimates for specific patient 
populations. 
The following still needs to be accomplished: 
(a) The estimates ofVm, Km and Cl, and their inter- and intra-individual variability, 
will be included in a pharmacokinetic computer programme that will be used 
to optimize phenytoin therapy in patients residing in the \/Vestem Cape. The 
Bayesian method will be incorporated into this programme to improve predic-
tions. 
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(b) A Bayesian graphic method will be designed to assist clinicians who do not 
have immediate access to a computer to predict phenytoin doses or serum 
concentrations. 
( c) An assessment of the factors which influence the Cl of phenytoin will be under-
taken. 
( d) Now that a better understanding of the characteristics of the Michaelis-Menten 
and the parallel Michaelis-Menten and first-order pharmacokinetic behaviour 
for phenytoin exists, non-steady-state serum phenytoin concentrations will be 
utilized as feedback. 
(e) The improvement in the predictive performance using two or more feedback 
serum phenytoin concentrations will be assessed. 
(f) Wlether the difference in kinetics between the coloured and black patients is 
a result of genetic or environmental factors will be assessed. 
(g) Now that more information is available on the pharmacokinetics of phenytoin 
in South African patients, a prospective trial assessing the clinical utility of the 
models with the patients' response as the clinical end-point needs to be 
performed. 
Finally, it is hoped that this study will provide impetus for the establishment of clinical 
pharmacokinetic consulting services and for further research in the field of population phar-
macokinetics. The clinician now has an additional predictive method available, which also 
takes into account Cl of phenytoin to predict steady-state serum concentrations more 
accurately. This study has contributed to an improvement in the population parameter 
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PHARMACOKINETIC GUIDELINES FOR ORAL PHENYTOIN USE 
(1) Therapeutic range for total serum phenytoin concentration: 40-80 µmol/1 
10-20 mg/I 
(2) The therapeutic range should serve as a guideline only. Patients may respond well to 
treatment below and above the therapeutic range. 
(3) To convert from mg/I to µmol/1: x 3.96 
(4) Wien a patient has achieved steady state on an oral dosing regimen, the fluctuation 
in phenytoin concentration is relatively small. It therefore makes little difference when 
a sample is obtained. The most reliable value to be used for phenytoin dosage 
adjustments is the trough concentration obtained at the end of a steady state dosing 
interval. 
(5) A blood sample for phenytoin assay should only be taken when the concentration of 
phenytoin in blood is at steady state. Due to the non-linear pharmacokinetics of 
phenytoin, the time taken to reach steady-state varies with the rate of administration 
and depends on the values of Vm and Km . The time to reach steady state can range 
from 5 days to 6 weeks and could be determined by calculation. Blood sampling 
before steady-state is of little value as phenytoin at this time is still accumulating 
except in cases where toxicity or non-compliance is suspected. 
(6) Following a change in phenytoin dose, the time required to reach a new steady-state 
concentration should be determined. 
(7) Blood sampling for phenytoin assay should be delayed if compliance is suboptimal. 
Do not increase the dose unless you are reasonably sure of the patient's drug 
compliance. If the dose is increased as a result of non-compliance and the patient 
becomes compliant thereafter, this may lead to toxicity especially with phenytoin ( due 
to its non-linear pharmacokinetics). 
(8) Due to the non-linear pharmacokinetics of phenytoin, a small increase in dose may 
lead to a disproportionately large increase in serum phenytoin levels. Similarly, a small 
decrease in dose may lead to a large decrease in serum phenytoin levels. It is 
therefore difficult to adjust empirically the dose based on serum phenytoin 
concentrations. 
(9) The daily dose of phenytoin should not exceed an individual's Vm (maximum 
metabolic rate) value. If this occurs, then the patient will rapidly experience toxicity. 
(10) It may be advisable to initially target serum phenytoin levels at the lower end of the 
therapeutic range, i.e. 48 µmol/1 (12 mg/I) as there may initially be a tendency to 
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overshoot the target concentration. 
(11) If a patient shO\NS evidence of seizures at a time corresponding to the trough serum 
concentration, seizure frequency may be decreased by shortening the dosage interval 
without necessarily changing the daily dose. Transient symptoms of toxicity associated 
with excessively high peak concentrations may also be avoided by decreasing the 
dose and shortening the dosing interval, without necessarily having to alter the daily 
dose. 
(12) The total phenytoin concentration (which assumes normal protein binding) may be 
misleading in patients with altered protein binding. Total phenytoin concentrations 
should be carefully interpreted in the presence of the following conditions in which 
plasma protein binding of phenytoin is decreased: bums, hepatic cirrhosis, nephrotic 
syndrome, pregnancy, cystic fibrosis, renal failure, severe jaundice and uraemia. 
In severe hepatic failure, total phenytoin concentration that is apparently therapeutic 
or subtherapeutic may actually be associated with phenytoin toxicity. Total phenytoin 
concentrations in the elderly should also be interpreted with caution. 
The therapeutic range is decreased in uraemia or low blood protein to a level of 1640 
µmol/1 (4-10 mg/I). No change in the daily dose of phenytoin may be required in 
uraemic patients de :;pite observations of lower total phenytoin concentrations. 
(13) Increased clearance of phenytoin may occur in pregnancy, head trauma and cerebral 
infection. Because children have higher phenytoin clearances, the daily phenytoin 
dose may have to be divided into two or three doses. 
(14) Sudden withdrawal of phenytoin from epileptics may lead to status epilepticus. 
Phenytoin should be withdrawn over a few weeks. 
(15) Regular monitoring of phenytoin levels is advisable, especially during the first two 
months after initiation of therapy so that the patient can be optimized on phenytoin as 
soon as possible. An upward adjustment of phenytoin dose may be required after 5 
to 12 months as a result of phenytoin auterinduction. 
( 16) Different brands of phenytoin are not interchangeable. Because the formulation is such 
an important determinant of phenytoin bioavailability, patients who are stabilized on 
one brand of phenytoin should not be switched to another unless necessary. If a 
change is necessary, phenytoin concentrations should be monitored when a new 
steady-state is achieved. 
(17) Since phenytoin sodium tablets (manufactured by Lennons Pty Ltd) on hospital code 
are available only in 50 and 100 mg strengths, it may be necessary to prescribe two 
different forms of phenytoin if small increments in dose is required. Phenytoin acid 
(Epanutin lnfatabsR and suspension) may be prescribed with phenytoin sodium 
provided that the difference in the salt form factor is taken into account. 
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( 18) It is preferable not to add a second anticonvulsant unless attempts to optimize the 
patient on phenytoin have failed. 
(19) Common drugs interactions: 
( a) Drugs wich may elevate phenytcin levels: 
ethosuximide, clonazepam, chloramphenicol, sulphonamides, isoniazid, 
disulfiram, chlordiazepoxide, nitrazepam, thioridazine, chlorpromazine, 
prochlorperazine, lithium, methylphenidate, propoxyphene, cimetidine, 
ranitidine, omeprazole, chlorpheniramine, tolbutamide, oestrogens, acute 
alcohol intake, warfarin, amiodarone and allopurinol. 
(b) Drugs wich may deaease phenytcin levels: 
carbamazepine, reserpine, antacids, sucralfate, chronic alcohol abuse, 
nitrofurantoin, rifampicin, theophylline, dexamethasone, folic acid and 
pyridoxine. 
( c) Drugs wich may either increase er deaease phenytcin levels: 
diazepam, phenobarbitone and valproate. 
( d) Phenytcin may deaease 1he efficacy d the follOMng drugs: 
carbamazepine, clonazepam, primidone, valproic acid, 
tetracyclines, levodopa, mianserin, oxazepam, paracetamol, pethidine, 
methadone, oral contraceptives, glucocorticosteroids, quinidine, dysopyramide, 
verapamil, mexilitine, coumarin anticoagulants, furosemide, theophylline, 
thyroxine, folic acid, pyridoxine and vitamin D. 
(e) Other interactions: tricyclic antidepressants. 
PRANEET VALODIA M.Pharm. 
ANNEXURE 2 
DEPARTMENT OF PHARMACOLOGY 
MEDICAL SCHOOL 
UNIVERSITY OF CAPE TO'M'J 
DATA COl.1.ECTlON FORM 
PATIENTS SURNAME: ........................................................ INITIALS: ......... . 
FIRST NAME(S): .................................................................... HOSPITAL: ............ . 
ADDRESS:.............................................................................. OCCUPATION: ............. . 
POSTAL ADDRESS: ............................................................. . 
FOLDER NUMBER: ............................................................... TEL NO: (H) ................ . 
HOME LANGUAGE: .................. . 0/'I) ............... .. 
DATE OF FIRST CONSULTATION: ......................... . 
ENTRY CRITERIA 
( 1) AGE 15 years and older: YES o NO o 
(2) DISEASE: HEPATIC o RENAL o 
(3) EVIDENCE OF ABUSE: ALCOHOL o DRUG o 
(4) MAJOR DEPRESSIVE OR PSYCHIATRIC DISEASE: YES o NO o 
(5) INTAKE OF INTERFERING DRUGS: YES o NO o 
(6) TAKING PHENYTOIN AS THE ONLY ANTICONVULSANT: YES o NO o 
(7) PREGNANCY: YES o NO o NIA o 
(8) BREASTFEEDING: YES o NO o NIA o 
(9) ABLE TO UNDERSTAND INSTRUCTIONS: YES o NO o 
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AGE: ......... . 
DATE OF BIRTH: ................... . 
SEX: ....... . 
RACE: ........... . 
l'v1ASS (kg): ......... FRAME SIZE: ......... . 
HEIGHT: ............ cm SOCIAL CLASS: ................. . 
CONCURRENT MEDICATION, DURATION OF THERAPY AND DOSAGES: 
(1) ............................................................................................................................................. . 
(2) ............................................................................................................................................. . 
(3) .............................................................................................................................................. . 
SMOKING STATUS: YES o NO o If yes, how many cigarettes per day .................. . 
ALCOHOL INTAKE: YES o NO o If yes, give details : ................................................. . 
DATE OF ENTRY INTO STUDY: ............................ .. 
SEIZURE TYPE (If information available) ............................................................................... . 
CAUSEOFSEIZURES: ............................................................................................................... . 
PREVIOUS HISTORY OF OTHER DISEASES: 
HISTORY OF SEIZURES AND FREQUENCY: 
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NUMBER OF SEIZURES IN PREVIOUS \/\£EK: 
NUMBER OF SEIZURES IN PREVIOUS MONTH: 
NUMBER OF SEIZURES IN PREVIOUS 3 MONTHS: 
NUMBER OF SEIZURES IN PREVIOUS YEAR: 
DESCRIPTION OF SEIZURES PRIOR TO ENTERING STUDY: 
PRESENT CLINICAL STATUS: 
PREVIOUS ADMISSIONS TO HOSPITAL: 




ANNEXURE 2: continued 
TABLET COUNTS: 
Date dispensed Quantity Date checked Quantity Result 
(1 ) ............................................................................................................................................. . 
(2) ............................................................................................................................................. . 
(3) ................................................................................................................................................. . 
EVALUATION OF PATIENTS DIARY: 
Date Accuracy 
Good Average Poor 
(1) ............................................................................................................................................. . 
(2) .............................................................................................................................................. . 
(3) ............................................................................................................................................... . 
SERUM PHENYTOIN LEVELS: 
Date Accuracy of prediction 
Good Average Poor 
(1 ) ............................................................................................................................................. . 
(2) ............................................................................................................................................. . 
(3) .............................................................................................................................................. . 

















TIME OF LAST DOSE 
BEFORE SAMPLING 
(1) ................................................................................................................................................. . 
(2) ................................................................................................................................................. . 
(3) ................................................................................................................................................... . 
DATE DOSE PRESCRIBED 
BY DOCTOR 
MEASURED RECOMMENDED PREDICTED 
Cpss DOSE Cpss 
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ADVERSE EFFECTS: Type Mild Moderate Severe 
Date Dose 
.............................. (1) .................................................................................................................. . 
.............................. (2) .................................................................................................................. . 
.............................. (3) .................................................................................................................. . 
LABORATORY INVESTIGATION: NORMAL o ABNORMAL D 
If abnormal, give details: 
REASON FOR REFERRAL FROM DOCTOR: 
o Routine to establish optimal dose 
o Insufficient control 
o Toxicity 
o Compliance in question 
o Other ( specify) 
NAME OF REFERRING DOCTOR: ........................................................... . 
ADDITIONAL INFORrv1ATION: 
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For ttis rnecicine to VI.Ork viell, it rrust be taken exactly as instructed. Take the 
rnecicine at m:>re or less the same time every day and for as long as prescribed by 
you' doctor. 
Do not stop taking this medicine without first checking with your doctor, nurse or 
pharmacist at the hospital. 
Before you begin taking any medicine that could be bought over the counter from a 
pharmacy, please first check with the investigator. 
If you become sick or pregnant whilst you are taking phenytoin, please tell the 
doctor, nurse or investigator. 
If you go to a doctor not working in this part of the hospital, please tell him'her that 
you are taking part in this study and that he/she should check with the investigator 
before giving you any other medicines. 
Many liquid medicines contain alcohol. Don't take such medicines during this study. 
If you have any questions, write them down and bring these questions with you when 
you visit the hospital again. 
HOW TO USE 1H1S MEDICINE 
If you n'issed taking phenytoin and you are taking your medicine as follows: 
Once a day - Take the missed tablets as soon as you remember and as long as it is at least 
12 hours before the next dose. If you remember the missed tablets within 12 hours before the 
next dose, then skip the dose. Do not use double your tablets. 
More than once a day- Take the tablets you forgot to take as soon as you remember. If you 
remember when you have to take your tablets again, the tablets you had missed could be 
taken at that time. If you missed taking your tablets for 2 or more days in a row, do not stop 
taking your tablets, but contact the investigator. 
For patients taking the tablets or capsues: 
SwallO\N the tablet or capsule whole. 
For patients taking the chewable tablets: 
Chew or crush the tablet before swallowing. 
For patients taking the liqlid: 
Shake the bottle well before using. 
Use a medicine measuring spoon or plastic syringe to measure the medicine accurately. Do 
not use an ordinary teaspoon. 
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HOW TO STORE THE MEDICINE 
Keep your medicine in a cool, dry place. Do not store the medicine in the bathroom, near the 
kitchen sink or in other damp places. Heat or moisture may cause the medicine to break down 
and reduce its effect. 
Do not keep the liquid form of this medicine in the fridge. 
Keep all medicines away from children. 
WHAT TO EE CAREFUL OF WHEN USING THIS MEDICINE 
Your doctor should check your treatment regularly, especially during the first few months. 
During this time the amount of phenytoin that you need may have to be changed. 
Do not start or stop taking any new medicines without checking with your doctor or pharmacist 
first. Other medicines may affect the way phenytoin works. 
Phenytoin may worsen the drowsiness caused by alcohol and medicines normally used for 
colds, hayfever, allergies, pain, muscle cramps and sleeping. Check with the investigator 
before taking any other medicine while you are taking phenytoin. 
Do not take phenytoin within 2 to 3 hours after taking antacids such as Eno or other 
medicines used for heartburn or upset stomach. The same applies for medicines used for 
running stomach. 
Do not change the amount of phenytoin you are taking without first checking with your doctor 
or the investigator. Also do not change to a tablet made by another company, although the 
amount you are taking is the same. The effect of tablets made by different companies may 
be different, although the dose is the same. W'len you obtain a repeat prescription and the 
tablets do not look the same, check with the pharmacist. 
Never stop taking this medicine suddenly. If necessary, your doctor will probably want you to 
reduce your dose gradually before stopping completely. 
SIDE EFFECTS OF THIS MEDICINE 
Occasionally phenytoin may cause some people to become dizzy, drowsy, light-headed and 
less alert than normal. After you have taken phenytoin for a while, this effect may not be 
troublesome any more. Make sure that you know how phenytoin will affect you before you 
drive a motor car, use machines, climb heights or buildings, or do other jobs that could be 
dangerous if you feel drowsy or dizzy. 
Check with your doctor or investigator if any of the following side effects occur: 
Behavioural changes; bleeding, tender or enlarged gums; clumsiness or unsteadiness; 
confusion; uncontrolled back-and-forth and/or rolling eye movements; enlarged glands in the 
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neck or armpits; fever; increase in fits; mood or mental changes; muscle weakness; skin rash; 
slurring of speech; trembling of hands; unusual excitement; nervousness or irritability. 
The folloMng will happen if you take too rruch phenytcin: 
Blurred or double vision; clumsiness or unsteadiness; confusion; severe dizziness or 
drowsiness; nausea; slurred speech; staggering walk and uncontrolled eye movements. 
Other side effeds ITBY oca.r that are usually harmess. These side effeds ITBY go away 
cuing treatment as your body aqusts 1o the mecicine. 
NAME OF INVESTIG!\TOR: PRANEET VALODIA 
ADDRESS: DEPARTMENT OF PHARMACOLOGY 
MEDICAL SCHOOL 
UNIVERSITY OF CAPE TOW'-J 
TELEPHONE: 4046036 ( Office ) 
6385932 (Home) 
ANNEXURE 5 
DEPARTMENT OF PHARMACOLOGY 
MEDICAL SCHOOL 
UNIVERSITY OF CAPE TOV\N 
INFORMED CONSENT 
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Tl1LE OF PROTOCOL: THE DETERMINATION AND VALIDATION OF POPULATION 
PHARMA.COKINETIC PARAMETERS OF PHENYTOIN IN ADULT EPILEPTIC PATIENTS 
IN THE \A.ESTERN CAPE USING NONLINEAR MIXED-EFFECTS MODELLING 
SURNAME OF PATIENT: ..................................................... . INITIALS: ............. . 
FIRST NAME(S): .................................................................... . 
FOLDER NUMBER: .......................... . 
DATE OF BIRTH: ................................ AGE: ................. SEX: ................ . 
ADDRESS: .......................................................................................................................... . 
TELEPHONE NO: ............................... . 
(1) PURPOSE OF THIS STIJDY 
Phenytoin is a medicine used for many years to treat fits. Best results are obtained when 
it is prescribed to meet the needs of each patient. Regular monitoring of blood levels of 
phenytoin is necessary to ensure that it is effective and to lessen the chance of taking too 
much or too little phenytoin. 
Although two people may take the same amount of phenytoin, the amount of phenytoin 
in their bloodstream may not be the same. This difference is due to a number of factors, 
for example, age, amount of phenytoin absorbed, weight, genetics, or patients not taking 
the medicine as prescribed. The reason for this study is to determine the effect of factors, 
such as age, sex and race, on the parameters that are used to work out the amount of 
phenytoin needed. 
(2) WHAT IS GOING TO BE DONE 
In this study you will be asked to take your medicine regularly and not to miss a dose, if 
possible. PJ. least two blood samples will be taken at specific times during this study. You 
will be taking part in this study for at least two months provided you follow all the in-
structions. 
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(3) RISKS 
Your medicine should be safe if used properly. It is, however, not entirely without 
side-effects as described in the information brochure. Your taking part in this study will not 
cause you to have any added risks that would not have happened if you were not part 
of this study. The medicine being given to you is the best available for the treatment of 
your illness. If problems develop at larger amounts of phenytoin that may be required to 
control your fits, then the amount of phenytoin will be reduced or another way to control 
your fits will be looked at. 
(4) EENEFITS 
This study will make sure that you will receive the greatest benefit from your medicine. 
Your taking part will improve the treatment and quality of life for all patients taking 
phenytoin. 
(5) IF PROB.EMS OCCUR 
If any serious problems occur, which is very unlikely, you will receive quick and proper 
medical treatment. Money will not be given for medical treatment elsewhere, loss of work 
or other expenses. 
(6) BASIS OF YOU TAKING PART 
You are free to stop taking part in this study at any time. If you do stop participating in this 
study, this will in no way affect the way you are being treated for your illness. This study 
has been approved by the Ethics Committee, Medical School, University of cape Town. 
I agree to take part in this study. I have been given a copy of this consent form. 
Signature _________ _ Date ------
PATIENT 
I, the undersigned, have fully explained the relevant details of this study to the patient 
named above. 
Signature _________ _ Date ------INVESTIGA.TOR 
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DEPARTMENT OF PHARf.J1ACOLOGY 
MEDICAL SCHOOL 
UNIVERSITY OF CAPE TOV\N 
PROCEDURE FOR NURSES 
CLINICAL PHARfv1ACOKINETICS PROJECT 
REQUEST FOR TAKING OF BLOOD SAMPLE 
DATE: ............................... . 
PATIENT'S NAME: ........................................................................................................... . 
ADDRESS: ......................................................................................................................... . 
HOSPITAL: ............................................................ . 
FOLDER NUMBER ............................................ .. 
PRANEET VALODIA 
PROCEDURE: 
( 1) Collect blood for the following tests as indicated below: 
o serum phenytoin concentration. 3 ml clotted blood (red-top tube) 
o SMAC. 5 ml clotted blood. (tiger-top tube) 
o full blood count. 3ml blood with anticoagulant (purple-top tube) 
(2) DOSE: .................. . 
(3) TIME BLOOD SAMPLE TAKEN: ................................. (use a 24-hr clock time e.g. 
16h10) 
(4) TIME OF LAST DOSE: ............................................ DATE: ................................ . 
(5) Ensure that the patient's initials and surname, as well as the hospital's name or 
number are on the label of the collection tube. 
(6) Store the samples in a cool place. 
(7) The blood samples for the SMAC and the full blood count should be processed 
as usual. Please hand the phenytoin blood sample and this form to the investiga-
tor at the end of this clinical session. 
(Please print) 
NAME OF NURSE 
ANNEXURE 7 
DEPARTMENT OF PHARMACOLOGY 
MEDICAL SCHOOL 
UNIVERSllY OF CAPE TO\/\,tJ 




DATE DOSE CONCENTRATION 
(µmol/1) 
(1 ) ........................................................................................................................................ . 
(2) ........................................................................................................................................ . 
(3) ........................................................................................................................................ . 
Therapeutic range 10-20 mg/I ( 40-80 µmol/1) 
COMMENTS AND RECOMMENDATIONS OF INVESTIGATOR 
PRANEET VALODIA DATE 
TO BE COMPLETED BY THE DOCTOR (Please tick) 
(1) RECOMMENDATIONS ACCEPTED: o 
(2) RECOMMENDATIONS NOT ACCEPTED: o 
If recommendations are not accepted, please indicate what you have decided: 
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ID l>GE SEX RACE WT HT BSA SMK /tJ..J:; EVID rN CP TIME 
1 16 1 0 62.5 168.5 1.71 0 0 1 200 9.3 15.0 
1 16 1 0 62.5 168.5 1.71 0 0 4 250 21.2 15.0 
2 22 1 0 69.2 170.5 1.80 0 0 1 400 16.4 15.8 
2 22 1 0 69.2 170.5 1.80 0 0 4 400 16.7 13.5 
2 22 1 0 69.2 170.5 1.80 0 0 4 427 18.9 14.0 
2 22 1 0 69.2 170.5 1.80 0 0 4 427 16.7 14.0 
3 52 0 0 78.2 158.0 1.80 0 0 1 300 39.1 14.3 
3 52 0 0 78.2 158.0 1.80 0 0 4 250 29.8 13.5 
4 40 1 0 58.0 172.0 1.68 0 0 1 300 41.4 14.0 
4 40 1 0 58.0 172.0 1.68 0 0 4 300 41.4 15.5 
4 40 1 0 58.0 172.0 1.68 0 0 4 250 29.0 14.8 
5 32 1 0 58.6 160.0 1.61 0 1 1 350 21.0 17.3 
6 38 0 0 50.5 156.5 1.48 0 0 1 300 8.6 15.0 
6 38 0 0 50.5 156.5 1.48 0 0 4 300 11.9 12.5 
7 44 0 0 93.5 166.0 2.01 0 1 1 300 22.0 14.0 
7 44 0 0 93.5 166.0 2.01 0 1 4 250 13.1 13.5 
7 44 0 0 93.5 166.0 2.01 0 1 4 250 10.6 14.8 
7 44 0 0 93.5 166.0 2.01 0 1 4 277 18.2 15.5 
8 33 0 0 69.1 153.0 1.67 0 0 1 300 9.6 13.3 
8 33 0 0 69.1 153.0 1.67 0 0 4 350 14.9 12.8 
8 33 0 0 69.1 153.0 1.67 0 0 4 350 17.2 16.3 
9 33 1 0 71.4 168.0 1.81 2 0 1 200 7.1 14.3 
9 33 1 0 71.4 168.0 1.81 2 0 4 200 7.8 13.5 
10 53 1 0 98.5 184.0 2.22 0 0 1 300 16.2 12.5 
10 53 1 0 98.5 184.0 2.22 0 0 4 300 14.1 12.5 
11 34 1 0 85.8 180.0 2.00 2 1 1 300 9.1 14.8 
11 34 1 0 85.8 180.0 2.00 2 1 4 300 9.3 14.3 
12 17 0 0 54.8 161.0 1.57 0 0 1 300 32.8 13.8 
12 17 0 0 54.8 161.0 1.57 0 0 4 300 41.4 13.0 
13 54 1 0 94.0 161.0 1.97 0 0 1 300 4.6 15.0 
13 54 1 0 94.0 161.0 1.97 0 0 4 300 5.3 16.0 
14 41 1 0 66.0 171.0 1.77 2 0 1 300 7.1 16.8 
14 41 1 0 66.0 171.0 1.77 2 0 4 300 6.3 16.0 
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14 41 1 0 66.0 171.0 1.77 2 0 4 350 21.2 15.5 
14 41 1 0 66.0 171.0 1.77 2 0 4 350 22.7 2.5 
14 41 1 0 66.0 171.0 1.77 2 0 4 350 21.7 15.0 
15 34 0 0 88.2 162.0 1.93 0 0 1 300 18.4 13.3 
16 47 1 0 66.7 179.0 1.84 1 1 1 300 12.1 17.3 
16 47 1 0 66.7 179.0 1.84 1 1 4 300 10.5 13.5 
17 29 1 0 99.5 183.0 2.22 2 0 1 300 7.8 15.0 
17 29 1 0 99.5 183.0 2.22 2 0 4 300 8.6 13.8 
18 17 1 0 51.0 161.0 1.52 0 0 1 300 29.3 3.5 
18 17 1 0 51.0 161.0 1.52 0 0 4 200 6.8 15.0 
18 17 1 0 51.0 161.0 1.52 0 0 4 200 7.8 15.0 
19 21 1 0 51.0 153.0 1.47 0 0 1 300 26.8 15.3 
19 21 1 0 51.0 153.0 1.47 0 0 4 300 23.5 14.3 
20 49 1 0 85.6 174.0 2.00 2 1 1 450 20.2 13.5 
20 49 1 0 85.6 174.0 2.00 2 1 4 450 26.0 14.0 
20 49 1 0 85.6 174.0 2.00 2 1 4 450 28.8 13.3 
21 19 1 0 63.5 178.0 1.80 0 0 1 300 30.6 15.5 
21 19 1 0 63.5 178.0 1.80 0 0 4 277 26.5 14.5 
22 29 1 0 58.4 178.0 1.73 1 1 1 300 17.2 17.3 
22 29 1 0 58.4 178.0 1.73 1 1 4 300 14.1 15.0 
23 32 0 0 57.3 159.5 1.59 0 0 1 200 27.3 16.0 
24 40 1 0 63.2 168.0 1.72 0 0 1 300 17.4 17.3 
25 18 0 0 53.4 161.0 1.55 0 0 1 300 9.9 16.0 
25 18 0 0 53.4 161.0 1.55 0 0 4 300 8.1 16.8 
25 18 0 0 53.4 161.0 1.55 0 0 4 300 6.1 15.3 
26 36 0 0 67.0 156.0 1.67 0 0 1 300 12.4 14.8 
26 36 0 0 67.0 156.0 1.67 0 0 4 300 10.1 17.8 
27 25 0 0 94.0 166.0 2.02 0 0 1 300 10.4 13.5 
27 25 0 0 94.0 166.0 2.02 0 0 4 300 12.6 16.5 
28 24 0 0 66.5 163.0 1.72 0 0 1 300 15.7 15.3 
29 25 0 0 58.6 160.0 1.61 0 0 1 300 18.9 15.5 
29 25 0 0 58.6 160.0 1.61 0 0 4 300 21.2 14.5 
29 25 0 0 58.6 160.0 1.61 0 0 4 300 15.4 15.8 
30 25 1 0 62.0 166.0 1.69 1 0 1 400 7.6 14.0 
30 25 1 0 62.0 166.0 1.69 1 0 4 400 5.3 14.5 
30 25 1 0 62.0 166.0 1.69 1 0 4 450 19.7 13.8 
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30 25 1 0 62.0 166.0 1.69 1 0 4 450 21.7 14.0 
31 37 1 0 77.6 171.0 1.00 0 0 1 300 7.6 14.0 
31 37 1 0 77.6 171.0 1.00 0 0 4 300 8.8 13.0 
31 37 1 0 77.6 171.0 1.00 0 0 4 350 12.6 14.8 
31 37 1 0 77.6 171.0 1.00 0 0 4 350 13.9 15.0 
32 25 1 0 44.0 166.0 1.46 0 0 1 300 27.3 16.0 
32 25 1 0 44.0 166.0 1.46 0 0 4 250 20.5 15.0 
32 25 1 0 44.0 166.0 1.46 0 0 4 250 23.5 15.5 
33 20 1 0 77.1 182.0 1.98 0 0 1 300 9.1 14.3 
33 20 1 0 77.1 182.0 1.98 0 0 4 350 12.1 13.5 
33 20 1 0 77.1 182.0 1.98 0 0 4 350 14.7 14.0 
33 20 1 0 77.1 182.0 1.98 0 0 4 400 24.2 15.5 
33 20 1 0 77.1 182.0 1.98 0 0 4 400 25.5 14.8 
33 20 1 0 77.1 182.0 1.98 0 0 4 414 46.5 15.8 
33 20 1 0 77.1 182.0 1.98 0 0 4 414 45.7 13.0 
34 31 1 0 89.0 182.0 2.11 2 0 1 300 21.0 16.8 
34 31 1 0 89.0 182.0 2.11 2 0 4 300 19.2 14.0 
35 22 1 0 60.0 178.0 1.75 1 1 1 300 25.3 14.0 
35 22 1 0 60.0 178.0 1.75 1 1 4 300 28.8 16.0 
35 22 1 0 60.0 178.0 1.75 1 1 4 277 23.2 15.3 
35 22 1 0 60.0 178.0 1.75 1 1 4 250 16.2 16.0 
35 22 1 0 60.0 178.0 1.75 1 1 4 250 17.9 14.8 
36 31 1 0 57.4 164.0 1.62 2 1 1 300 10.9 12.5 
37 43 1 0 69.6 167.0 1.78 2 0 1 300 4.0 13.0 
37 43 1 0 69.6 167.0 1.78 2 0 4 300 7.3 14.0 
38 31 0 0 64.4 162.5 1.69 0 0 1 300 13.1 14.0 
38 31 0 0 64.4 162.5 1.69 0 0 4 300 11.9 17.8 
38 31 0 0 64.4 162.5 1.69 0 0 4 327 14.7 12.8 
38 31 0 0 64.4 162.5 1.69 0 0 4 350 21.8 15.0 
38 31 0 0 64.4 162.5 1.69 0 0 4 350 14.1 15.5 
38 31 0 0 64.4 162.5 1.69 0 0 4 377 27.8 17.3 
39 25 0 0 73.8 167.0 1.83 0 0 1 300 15.7 14.0 
39 25 0 0 73.8 167.0 1.83 0 0 4 300 14.1 15.8 
39 25 0 0 73.8 167.0 1.83 0 0 4 327 19.2 14.3 
39 25 0 0 73.8 167.0 1.83 0 0 4 327 19.2 15.5 
39 25 0 0 73.8 167.0 1.83 0 0 4 350 20.5 14.5 
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40 48 1 0 66.5 171.5 1.78 0 1 1 3CX) 17.7 13.0 
41 40 1 0 52.0 162.0 1.54 1 1 1 3CX) 8.8 17.3 
41 40 1 0 52.0 162.0 1.54 1 1 4 3CX) 6.3 14.8 
41 40 1 0 52.0 162.0 1.54 1 1 4 350 16.2 13.5 
41 40 1 0 52.0 162.0 1.54 1 1 4 350 13.9 13.3 
41 40 1 0 52.0 162.0 1.54 1 1 4 350 16.7 13.8 
42 82 1 0 59.0 162.0 1.63 1 0 1 200 18.7 15.5 
42 82 1 0 59.0 162.0 1.63 1 0 4 200 19.7 15.0 
42 82 1 0 59.0 162.0 1.63 1 0 4 200 26.3 18.8 
43 40 1 0 57.3 162.0 1.61 1 1 1 3CX) 10.1 18.0 
43 40 1 0 57.3 162.0 1.61 1 1 4 3CX) 9.1 14.3 
43 40 1 0 57.3 162.0 1.61 1 1 4 350 15.9 13.5 
43 40 1 0 57.3 162.0 1.61 1 1 4 350 15.9 15.0 
44 23 1 0 64.5 155.0 1.63 1 1 1 200 7.8 17.5 
45 22 0 0 44.7 147.0 1.35 0 0 1 200 7.3 12.5 
45 22 0 0 44.7 147.0 1.35 0 0 4 200 7.3 13.3 
45 22 0 0 44.7 147.0 1.35 0 0 4 3CX) 30.1 18.8 
45 22 0 0 44.7 147.0 1.35 0 0 4 250 13.9 16.5 
46 31 1 0 52.0 167.5 1.58 1 1 1 3CX) 10.6 15.8 
46 31 1 0 52.0 167.5 1.58 1 1 4 3CX) 15.4 15.0 
47 51 0 0 81.1 153.0 1.78 0 0 1 350 15.9 13.8 
47 51 0 0 81.1 153.0 1.78 0 0 4 350 17.2 15.0 
47 51 0 0 81.1 153.0 1.78 0 0 4 377 15.9 14.0 
47 51 0 0 81.1 153.0 1.78 0 0 4 377 20.0 13.0 
48 36 1 0 51.3 164.5 1.55 0 0 1 3CX) 12.1 15.5 
48 36 1 0 51.3 164.5 1.55 0 0 4 3CX) 13.9 15.5 
48 36 1 0 51.3 164.5 1.55 0 0 4 327 13.1 15.3 
48 36 1 0 51.3 164.5 1.55 0 0 4 350 13.9 15.5 
48 36 1 0 51.3 164.5 1.55 0 0 4 400 17.2 16.3 
49 17 1 0 50.3 150.0 1.44 0 0 1 3CX) 22.7 15.0 
50 27 0 0 89.0 161.0 1.93 1 0 1 327 4.2 14.0 
50 27 0 0 89.0 161.0 1.93 1 0 4 350 7.6 14.5 
50 27 0 0 89.0 161.0 1.93 1 0 4 350 6.6 15.0 
51 17 1 0 56.3 168.5 1.64 0 0 1 200 34.9 14.3 
51 17 1 0 56.3 168.5 1.64 0 0 4 200 45.5 14.3 
51 17 1 0 56.3 168.5 1.64 0 0 4 100 4.3 14.5 
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51 17 1 0 56.3 168.5 1.64 0 0 4 150 21.5 13.5 
51 17 1 0 56.3 168.5 1.64 0 0 4 150 22.5 12.8 
52 40 1 0 00.7 168.5 1.69 2 1 1 300 6.8 16.5 
52 40 1 0 00.7 168.5 1.69 2 1 4 300 4.3 16.0 
52 40 1 0 00.7 168.5 1.69 2 1 4 400 14.4 15.5 
52 40 1 0 00.7 168.5 1.69 2 1 4 400 10.9 16.8 
52 40 1 0 00.7 168.5 1.69 2 1 4 450 16.2 13.5 
52 40 1 0 00.7 168.5 1.69 2 1 4 450 16.7 14.0 
53 30 0 0 48.0 100.0 1.48 0 0 4 300 37.1 14.5 
53 30 0 0 48.0 100.0 1.48 0 0 4 200 14.1 15.0 
53 30 0 0 48.0 100.0 1.48 0 0 4 227 14.7 14.0 
53 30 0 0 48.0 100.0 1.48 0 0 4 227 9.1 14.5 
54 44 1 0 54.5 158.0 1.54 0 0 1 300 13.6 14.5 
54 44 1 0 54.5 158.0 1.54 0 0 4 300 20.5 14.5 
54 44 1 0 54.5 158.0 1.54 0 0 4 300 17.4 15.0 
55 43 0 0 80.4 100.0 1.84 0 0 1 300 9.3 16.0 
55 43 0 0 80.4 160.0 1.84 0 0 4 400 14.7 15.5 
55 43 0 0 80.4 160.0 1.84 0 0 4 400 18.2 15.3 
56 41 1 0 55.6 173.0 1.66 2 1 1 300 5.6 17.0 
56 41 1 0 55.6 173.0 1.66 2 1 4 300 5.6 14.5 
56 41 1 0 55.6 173.0 1.66 2 1 4 400 15.7 15.8 
56 41 1 0 55.6 173.0 1.66 2 1 4 400 10.6 17.0 
56 41 1 0 55.6 173.0 1.66 2 1 4 400 13.6 14.5 
57 31 1 0 53.0 168.5 1.60 1 1 1 300 14.7 17.8 
57 31 1 0 53.0 168.5 1.00 1 1 4 300 16.4 16.8 
58 16 1 0 60.0 183.0 1.79 0 0 1 200 3.5 14.5 
58 16 1 0 00.0 183.0 1.79 0 0 4 300 14.7 16.5 
58 16 1 0 00.0 183.0 1.79 0 0 4 300 15.2 18.0 
59 55 1 0 74.9 169.0 1.85 1 0 1 300 5.1 14.0 
59 55 1 0 74.9 169.0 1.85 1 0 4 300 6.1 14.0 
59 55 1 0 74.9 169.0 1.85 1 0 4 400 16.2 14.3 
59 55 1 0 74.9 169.0 1.85 1 0 4 400 .21.5 14.0 
59 55 1 0 74.9 169.0 1.85 1 0 4 400 11.6 13.8 
60 47 1 0 55.3 166.5 1.61 1 0 1 300 7.3 15.5 
61 27 1 0 73.6 178.0 1.91 0 0 1 300 7.1 14.0 
61 27 1 0 73.6 178.0 1.91 0 0 4 300 9.1 16.3 
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62 29 0 0 68.8 158.0 1.70 0 0 1 250 11.9 13.5 
62 29 0 0 68.8 158.0 1.70 0 0 4 250 11.1 13.5 
62 29 0 0 68.8 158.0 1.70 0 0 4 277 13.4 14.5 
63 23 0 0 86.0 159.0 1.88 0 0 1 300 8.3 13.0 
63 23 0 0 86.0 159.0 1.88 0 0 4 300 7.6 14.5 
64 36 1 0 69.0 164.5 1.76 1 0 1 300 10.6 19.5 
65 32 1 0 63.3 164.5 1.69 0 0 1 300 14.4 15.5 
65 32 1 0 63.3 164.5 1.69 0 0 4 350 27.0 12.3 
65 32 1 0 63.3 164.5 1.69 0 0 4 350 26.0 14.0 
65 32 1 0 63.3 164.5 1.69 0 0 4 364 31.6 12.8 
65 32 1 0 63.3 164.5 1.69 0 0 4 364 35.6 16.5 
66 20 0 0 77.3 178.0 1.95 0 0 1 200 6.3 14.8 
66 20 0 0 77.3 178.0 1.95 0 0 4 200 6.1 15.5 
66 20 0 0 77.3 178.0 1.95 0 0 4 300 21.7 14.8 
66 20 0 0 77.3 178.0 1.95 0 0 4 300 19.2 13.5 
67 38 0 0 67.9 152.0 1.65 0 0 1 300 12.4 14.3 
67 38 0 0 67.9 152.0 1.65 0 0 4 300 12.9 14.8 
67 38 0 0 67.9 152.0 1.65 0 0 4 327 19.7 15.0 
67 38 0 0 67.9 152.0 1.65 0 0 4 327 17.2 15.0 
68 34 1 0 57.6 166.5 1.64 0 0 1 300 21.2 14.5 
69 40 1 0 135 190.0 2.59 0 0 1 400 8.8 14.3 
69 40 1 0 135 190.0 2.59 0 0 1 400 8.6 15.0 
69 40 1 0 135 190.0 2.59 0 0 4 500 17.4 13.3 
69 40 1 0 135 190.0 2.59 0 0 4 500 17.7 14.0 
70 24 1 0 67.5 173.0 1.80 0 0 1 200 6.6 16.8 
71 20 1 0 56.5 172.0 1.67 0 0 1 300 10.4 16.0 
71 20 1 0 56.5 172.0 1.67 0 0 4 300 12.6 16.8 
71 20 1 0 56.5 172.0 1.67 0 0 4 300 12.6 17.0 
71 20 1 0 56.5 172.0 1.67 0 0 4 250 6.1 12.8 
71 20 1 0 56.5 172.0 1.67 0 0 4 250 7.1 16.5 
72 24 1 0 63.1 166.5 1.71 0 1 1 300 13.4 13.8 
73 43 1 0 60.8 165.0 1.67 2 0 1 300 13.4 13.8 
73 43 1 0 60.8 165.0 1.67 2 0 4 300 13.6 15.0 
74 40 1 0 58.5 172.0 1.69 2 1 1 300 8.6 14.0 
75 30 1 0 54.3 184.0 1.72 1 0 1 300 20.7 14.5 
76 53 1 0 58.7 166.0 1.65 0 0 1 300 6.3 14.0 
186 
ID AGE SEX RACE wr HT BSA SM< I.J.f; EVID DV CP TIME 
76 53 1 0 58.7 166.0 1.65 0 0 4 300 8.1 15.0 
77 22 0 0 66.7 153.0 1.64 0 0 1 300 6.1 13.0 
77 22 0 0 66.7 153.0 1.64 0 0 4 350 10.4 15.5 
77 22 0 0 66.7 153.0 1.64 0 0 4 350 12.1 15.5 
78 41 0 0 47.0 161.5 1.47 1 0 1 200 4.8 17.5 
78 41 0 0 47.0 161.5 1.47 1 0 4 300 13.1 17.0 
78 41 0 0 47.0 161.5 1.47 1 0 4 300 12.1 17.0 
79 41 1 0 55.2 168.0 1.62 2 1 1 300 18.4 18.8 
80 20 0 0 72.0 150.0 1.67 0 0 1 300 9.1 12.5 
80 20 0 0 72.0 150.0 1.67 0 0 4 350 16.7 13.5 
80 20 0 0 72.0 150.0 1.67 0 0 4 350 21.7 13.5 
81 40 1 0 88.0 186.0 2.13 3 0 1 300 6.6 13.3 
81 40 1 0 88.0 186.0 2.13 3 0 4 300 6.1 14.0 
82 22 0 0 58.0 162.0 1.61 0 0 1 300 17.7 14.3 
82 22 0 0 58.0 162.0 1.61 0 0 4 300 28.8 16.5 
82 22 0 0 58.0 162.0 1.61 0 0 4 300 23.7 16.5 
82 22 0 0 58.0 162.0 1.61 0 0 4 314 25.0 15.0 
82 22 0 0 58.0 162.0 1.61 0 0 4 327 25.3 17.5 
82 22 0 0 58.0 162.0 1.61 0 0 4 327 34.3 15.0 
83 70 1 0 55.9 167.0 1.62 1 0 1 300 6.6 19.0 
84 26 1 0 64.5 188.0 1.88 2 0 1 300 18.9 16.5 
84 26 1 0 64.5 188.0 1.88 2 0 4 300 24.2 17.8 
85 26 1 0 61.9 162.5 1.66 2 1 1 300 14.9 15.0 
85 26 1 0 61.9 162.5 1.66 2 1 4 300 13.4 15.3 
85 26 1 0 61.9 162.5 1.66 2 1 4 327 16.4 14.5 
86 19 1 0 66.6 171.0 1.78 0 0 1 300 14.4 14.5 
86 19 1 0 66.6 171.0 1.78 0 0 4 300 15.9 13.8 
86 19 1 0 66.6 171.0 1.78 0 0 4 327 23.0 15.3 
86 19 1 0 66.6 171.0 1.78 0 0 4 327 23.7 15.3 
87 20 1 0 62.0 172.5 1.74 1 0 1 200 8.8 12.5 
87 20 1 0 62.0 172.5 1.74 1 0 4 200 10.9 14.3 
88 29 1 0 62.0 172.5 1.74 0 0 1 300 24.5 17.0 
89 45 1 0 72.9 165.5 1.81 1 1 1 300 19.2 13.0 
89 45 1 0 72.9 165.5 1.81 1 1 4 300 13.6 14.3 
90 45 1 0 62.7 178.5 1.79 1 1 1 300 20.5 15.5 
90 45 1 0 62.7 178.5 1.79 1 1 4 300 24.5 15.3 
187 
ID N3E SEX RACE WT HT BSA SMK J,J.J:; EVID DV CP TIME 
91 34 1 0 78.9 178.0 1.97 1 1 1 300 19.2 13.5 
91 34 1 0 78.9 178.0 1.97 1 1 4 300 17.9 16.5 
91 34 1 0 78.9 178.0 1.97 1 1 4 '327 10.9 16.3 
91 34 1 0 78.9 178.0 1.97 1 1 4 '327 16.4 12.3 
92 54 0 0 48.2 157.0 1.46 0 0 1 300 29.0 16.5 
93 28 1 0 83.9 177.0 2.01 0 0 4 350 27.5 14.3 
93 28 1 0 83.9 177.0 2.01 0 0 4 350 24.0 14.5 
93 28 1 0 83.9 177.0 2.01 0 0 4 350 23.5 17.5 
93 28 1 0 83.9 177.0 2.01 0 0 4 '327 20.7 16.5 
93 28 1 0 83.9 177.0 2.01 0 0 4 '327 12.6 14.8 
94 28 1 0 66.3 180.0 1.84 2 1 1 300 10.4 15.0 
94 28 1 0 66.3 180.0 1.84 2 1 4 300 8.6 16.3 
94 28 1 0 66.3 180.0 1.84 2 1 4 '327 26.5 13.5 
94 28 1 0 66.3 180.0 1.84 2 1 4 '327 8.6 15.3 
95 58 1 0 76.4 188.0 2.02 0 0 1 300 9.1 16.5 
95 58 1 0 76.4 188.0 2.02 0 0 4 300 11.4 14.8 
95 58 1 0 76.4 188.0 2.02 0 0 4 '327 10.1 15.0 
95 58 1 0 76.4 188.0 2.02 0 0 4 '327 10.4 14.8 
95 58 1 0 76.4 188.0 2.02 0 0 4 350 14.4 15.5 
96 56 1 0 58.1 172.5 1.69 2 1 1 300 13.4 17.0 
96 56 1 0 58.1 172.5 1.69 2 1 4 300 13.6 16.8 
97 40 0 0 51.0 150.0 1.44 0 0 1 200 6.3 14.0 
97 40 0 0 51.0 150.0 1.44 0 0 4 250 11.9 14.5 
97 40 0 0 51.0 150.0 1.44 0 0 4 250 13.1 14.3 
98 31 1 0 65.3 170.0 1.76 1 1 1 300 15.4 13.8 
98 31 1 0 65.3 170.0 1.76 1 1 4 300 17.9 13.0 
99 43 1 0 76.8 178.0 1.95 2 1 1 300 11.4 14.0 
99 43 1 0 76.8 178.0 1.95 2 1 4 300 14.1 14.5 
100 31 1 0 66.6 180.0 1.85 0 0 1 300 20.0 15.0 
100 31 1 0 66.6 180.0 1.85 0 0 4 300 18.4 15.5 
101 37 1 0 58.7 185.0 1.79 1 1 1 300 3.7 26.0 
101 37 1 0 58.7 185.0 1.79 1 1 4 300 3.3 15.0 
102 21 0 0 59.0 165.0 1.65 0 0 1 350 36.4 19.0 
102 21 0 0 59.0 165.0 1.65 0 0 4 350 36.9 15.0 
102 21 0 0 59.0 165.0 1.65 0 0 4 '327 25.0 15.8 
102 21 0 0 59.0 165.0 1.65 0 0 4 277 21.7 15.3 
188 
ID AGE SEX RACE WT HT BSA SMK /,,J..C EVID DV CP TIME 
103 33 1 0 81.6 177.0 1.99 2 1 1 300 16.2 14.8 
104 21 1 0 56.0 160.0 1.58 1 1 1 300 7.1 14.5 
104 21 1 0 56.0 160.0 1.58 1 1 4 300 3.8 14.5 
104 21 1 0 56.0 160.0 1.58 1 1 4 350 6.6 14.8 
104 21 1 0 56.0 160.0 1.58 1 1 4 350 9.9 13.5 
105 59 1 0 72.8 168.0 1.82 0 0 1 300 6.8 16.0 
106 40 1 0 72.0 176.0 1.88 2 0 1 300 12.6 16.0 
106 40 1 0 72.0 176.0 1.88 2 0 4 300 15.7 16.5 
106 40 1 0 72.0 176.0 1.88 2 0 0 327 21.7 15.0 
106 40 1 0 72.0 176.0 1.88 2 0 4 327 20.5 14.0 
106 40 1 0 72.0 176.0 1.88 2 0 4 341 25.5 14.5 
107 26 1 0 63.1 163.0 1.68 0 0 1 300 8.3 17.0 
107 26 1 0 63.1 163.0 1.68 0 0 4 400 44.4 15.0 
107 26 1 0 63.1 163.0 1.68 0 0 4 400 36.1 15.8 
108 56 0 0 63.5 168.0 1.72 0 1 1 300 3.5 14.0 
108 56 0 0 63.5 168.0 1.72 0 1 4 300 5.8 14.5 
109 23 0 0 66.5 171.0 1.78 0 0 1 300 9.6 14.5 
109 23 0 0 66.5 171.0 1.78 0 0 4 300 11.4 10.5 
109 23 0 0 66.5 171.0 1.78 0 0 4 300 11.1 14.0 
109 23 0 0 66.5 171.0 1.78 0 0 4 327 10.9 10.8 
109 23 0 0 66.5 171.0 1.78 0 0 4 327 10.4 14.5 
109 23 0 0 66.5 171.0 1.78 0 0 4 350 12.9 11.5 
110 26 0 0 89.3 162.0 1.94 0 0 1 300 21.2 14.5 
110 26 0 0 89.3 162.0 1.94 0 0 4 300 22.0 16.3 
111 21 0 0 88.3 158.0 1.89 0 0 1 300 17.2 15.8 
111 21 0 0 88.3 158.0 1.89 0 0 4 300 13.9 16.5 
112 42 0 0 64.5 158.5 1.66 0 1 1 300 7.8 5.0 
113 23 0 0 67.0 162.0 1.72 0 0 1 300 9.6 12.5 
114 27 0 0 60.3 150.0 1.55 0 0 1 300 10.4 16.0 
115 40 1 0 64.0 176.0 1.79 1 0 1 300 10.6 14.0 
115 40 1 0 64.0 176.0 1.79 1 0 4 300 11.6 14.0 
116 59 1 0 65.5 169.0 1.75 0 0 1 300 27.8 14.8 
116 59 1 0 65.5 169.0 1.75 0 0 4 300 26.3 13.0 
116 59 1 0 65.5 169.0 1.75 0 0 4 250 15.4 13.5 
116 59 1 0 65.5 169.0 1.75 0 0 4 250 18.2 14.5 
117 68 1 0 83.7 168.5 1.94 0 0 1 300 7.8 15.0 
189 
ID AGE SEX RACE WT HT BSA SMK ~ EVID DV CP TIME 
118 49 1 0 72.9 174.0 1.87 2 0 1 300 4.0 16.5 
119 38 0 0 56.0 161.5 1.59 0 0 1 300 12.4 15.0 
119 38 0 0 56.0 161.5 1.59 0 0 4 300 13.6 15.0 
120 35 1 0 60.8 182.5 1.79 2 1 1 300 13.6 14.8 
120 35 1 0 60.8 182.5 1.79 2 1 4 300 15.9 13.0 
120 35 1 0 60.8 182.5 1.79 2 1 4 327 11.9 13.3 
120 35 1 0 60.8 182.5 1.79 2 1 4 327 11.6 13.0 
120 35 1 0 60.8 182.5 1.79 2 1 4 377 31.8 13.3 
121 35 0 0 75.1 161.0 1.79 0 0 1 300 5.8 16.3 
121 35 0 0 75.1 161.0 1.79 0 0 4 300 6.1 14.0 
121 35 0 0 75.1 161.0 1.79 0 0 4 350 13.4 14.0 
122 29 1 0 71.0 171.0 1.83 0 0 1 300 7.6 15.0 
122 29 1 0 71.0 171.0 1.83 0 0 4 300 10.1 16.0 
122 29 1 0 71.0 171.0 1.83 0 0 4 300 8.1 14.8 
123 23 1 0 57.8 186.0 1.78 1 0 1 350 10.9 13.5 
123 23 1 0 57.8 186.0 1.78 1 0 4 350 11.6 14.3 
123 23 1 0 57.8 186.0 1.78 1 0 4 400 14.1 13.5 
123 23 1 0 57.8 186.0 1.78 1 0 4 400 15.9 16.3 
123 23 1 0 57.8 186.0 1.78 1 0 4 427 19.2 14.5 
124 17 1 0 54.2 176.0 1.66 1 0 1 300 21.5 16.8 
125 32 1 0 65.0 163.0 1.70 1 1 1 300 12.9 14.8 
125 32 1 0 65.0 163.0 1.70 1 1 4 300 12.6 15.3 
126 15 0 0 51.5 156.0 1.49 0 0 1 300 25.5 15.0 
126 15 0 0 51.5 156.0 1.49 0 0 4 277 33.8 15.5 
127 19 1 0 58.9 164.5 1.64 0 0 1 300 35.6 16.8 
127 19 1 0 58.9 164.5 1.64 0 0 4 300 37.1 11.8 
127 19 1 0 58.9 164.5 1.64 0 0 4 200 14.7 16.5 
127 19 1 0 58.9 164.5 1.64 0 0 4 200 15.9 15.8 
128 28 0 0 76.4 159.0 1.79 0 0 1 300 11.9 16.3 
128 28 0 0 76.4 159.0 1.79 0 0 4 300 13.6 15.3 
129 22 0 0 56.5 160.5 1.58 0 0 1 200 3.0 15.8 
129 22 0 0 56.5 160.5 1.58 0 0 4 200 4.3 14.0 
130 16 1 0 61.7 160.0 1.64 0 0 1 300 20.2 13.5 
130 16 1 0 61.7 160.0 1.64 0 0 4 300 19.4 16.8 
131 21 1 0 62.7 167.0 1.70 0 0 1 300 8.8 15.3 
132 27 0 0 80.2 164.0 1.87 0 0 1 300 18.7 18.8 
190 
ID AGE SEX RACE wr HT BSA SMK /,U; EVID DV CP TIME 
132 27 0 0 80.2 164.0 1.87 0 0 4 300 14.4 15.5 
133 39 1 0 54.0 166.0 1.59 1 1 1 250 33.6 14.0 
133 39 1 0 54.0 166.0 1.59 1 1 4 200 16.7 14.0 
133 39 1 0 54.0 166.0 1.59 1 1 4 200 14.1 14.0 
134 25 0 0 64.5 162.5 1.69 0 0 1 300 25.3 15.5 
134 25 0 0 64.5 162.5 1.69 0 0 4 250 12.9 12.8 
135 28 1 0 52.4 169.5 1.60 0 0 1 300 26.5 14.0 
135 28 1 0 52.4 169.5 1.60 0 0 4 300 25.0 14.0 
136 25 1 0 54.0 166.0 1.59 0 0 1 400 45.5 15.0 
136 25 1 0 54.0 166.0 1.59 0 0 4 400 51.8 14.5 
136 25 1 0 54.0 166.0 1.59 0 0 4 300 13.9 14.8 
136 25 1 0 54.0 166.0 1.59 0 0 4 300 24.8 14.0 
136 25 1 0 54.0 166.0 1.59 0 0 4 300 18.7 16.5 
136 25 1 0 54.0 166.0 1.59 0 0 4 200 6.3 14.8 
137 30 1 0 58.2 168.0 1.66 0 0 1 300 19.4 4.5 
137 30 1 0 58.2 168.0 1.66 0 0 4 300 16.4 14.0 
138 38 0 0 64.7 164.0 1.71 0 0 1 300 31.6 16.0 
138 38 0 0 64.7 164.0 1.71 0 0 4 250 24.0 16.0 
138 38 0 0 64.7 164.0 1.71 0 0 4 250 18.9 16.8 
139 25 0 0 73.2 159.5 1.76 0 0 1 300 30.1 17.8 
139 25 0 0 73.2 159.5 1.76 0 0 4 200 9.1 16.0 
139 25 0 0 73.2 159.5 1.76 0 0 4 200 5.1 16.5 
139 25 0 0 73.2 159.5 1.76 0 0 4 200 6.6 13.5 
139 25 0 0 73.2 159.5 1.76 0 0 4 250 15.7 17.5 
140 31 1 0 86.0 172.0 1.99 1 1 1 300 11.4 13.4 
141 45 1 0 65.5 170.0 1.76 1 0 1 300 21.2 16.0 
141 45 1 0 65.5 170.0 1.76 1 0 4 300 27.0 15.5 
142 31 1 0 57.4 151.0 1.53 1 1 1 300 6.8 14.3 
142 31 1 0 57.4 151.0 1.53 1 1 4 300 5.3 15.0 
142 31 1 0 57.4 151.0 1.53 1 1 4 350 24.0 15.0 
143 34 0 0 84.0 150.0 1.79 0 0 1 300 13.4 16.8 
143 34 0 0 84.0 150.0 1.79 0 0 4 300 10.9 15.8 
143 34 0 0 84.0 150.0 1.79 0 0 4 350 18.9 16.8 
143 34 0 0 84.0 150.0 1.79 0 0 4 350 18.2 13.5 
143 34 0 0 84.0 150.0 1.79 0 0 4 350 16.2 14.0 
143 34 0 0 84.0 150.0 1.79 0 0 4 327 13.2 14.5 
191 
ID AGE SEX RACE WT HT BSA SM< liJ.[; EVID DV CP TIME 
144 25 1 0 54.9 166.0 1.60 0 0 1 300 19.7 14.8 
144 25 1 0 54.9 166.0 1.60 0 0 4 300 16.7 15.5 
145 57 0 0 74.0 158.5 1.76 0 0 1 300 11.1 12.8 
145 57 0 0 74.0 158.5 1.76 0 0 4 300 13.1 12.0 
146 26 1 0 53.4 178.5 1.67 1 1 1 300 38.6 15.5 
147 42 1 0 61.0 165.5 1.67 1 0 1 300 10.4 13.5 
147 42 1 0 61.0 165.5 1.67 1 0 4 300 8.3 12.0 
147 42 1 0 61.0 165.5 1.67 1 0 4 250 7.6 11.8 
147 42 1 0 61.0 165.5 1.67 1 0 4 250 6.8 13.5 
148 35 1 0 70.4 169.0 1.81 2 0 1 300 20.0 14.3 
148 35 1 0 70.4 169.0 1.81 2 0 4 300 17.4 13.0 
149 23 1 0 60.0 166.5 1.67 0 0 1 300 35.4 15.8 
149 23 1 0 60.0 166.5 1.67 0 0 4 300 35.6 20.8 
149 23 1 0 60.0 166.5 1.67 0 0 4 250 11.4 16.8 
149 23 1 0 60.0 166.5 1.67 0 0 4 250 9.3 17.8 
150 41 1 2 66.0 183.0 1.86 2 0 1 400 14.1 3.3 
150 41 1 2 66.0 183.0 1.86 2 0 4 400 22.2 3.5 
151 28 1 2 51.0 171.0 1.59 2 0 1 100 2.3 17.0 
151 28 1 2 51.0 171.0 1.59 2 0 4 200 7.8 16.3 
151 28 1 2 51.0 171.0 1.59 2 0 4 250 9.1 14.0 
151 28 1 2 51.0 171.0 1.59 2 0 4 250 11.4 13.0 
152 32 1 2 84.6 173.0 1.99 0 0 1 400 12.1 12.0 
153 42 1 1 71.6 165.0 1.79 0 0 1 400 11.4 17.5 
153 42 1 1 71.6 165.0 1.79 0 0 4 400 8.1 15.0 
154 49 1 2 68.5 166.0 1.76 0 0 1 300 10.1 17.5 
154 49 1 2 68.5 166.0 1.76 0 0 4 300 12.9 18.3 
155 38 0 1 49.4 151.0 1.43 0 0 1 200 9.1 14.5 
155 38 0 1 49.4 151.0 1.43 0 0 4 200 5.3 15.0 
155 38 0 1 49.4 151.0 1.43 0 0 4 250 22.7 15.0 
155 38 0 1 49.4 151.0 1.43 0 0 4 250 19.4 13.8 
156 25 0 1 49.7 144.0 1.39 1 0 1 300 21.0 5.0 
156 25 0 1 49.7 144.0 1.39 1 0 4 300 18.7 3.4 
157 22 1 1 64.3 174.0 1.78 1 1 1 400 22.7 15.5 
157 22 1 1 64.3 174.0 1.78 1 1 4 400 27.3 16.8 
158 30 1 1 80.0 170.0 1.92 0 0 1 300 11.4 12.8 
159 30 0 1 53.2 154.5 1.50 0 0 1 400 35.6 3.3 
192 
ID AGE SEX RACE wr HT BSA SMK /IJ.J:, EVID DV CP TIME 
159 30 0 1 53.2 154.5 1.50 0 0 4 350 28.0 4.5 
159 30 0 1 53.2 154.5 1.50 0 0 4 350 28.3 4.5 
159 30 0 1 53.2 154.5 1.50 0 0 4 327 17.7 4.0 
160 76 1 1 58.7 158.5 1.60 1 0 1 300 8.1 16.0 
161 34 1 1 54.5 173.5 1.65 2 1 1 300 27.5 15.0 
161 34 1 1 54.5 173.5 1.65 2 1 4 307 29.8 15.0 
161 34 1 1 54.5 173.5 1.65 2 1 4 314 25.8 15.0 
162 28 1 1 68.5 159.0 1.71 0 0 1 300 11.4 15.0 
163 35 1 1 65.4 1n.5 1.78 2 0 1 300 7.1 14.0 
163 35 1 1 65.4 1n.5 1.78 2 0 4 300 8.8 16.0 
163 35 1 1 65.4 1n.5 1.78 2 0 4 350 14.4 15.3 
163 35 1 1 65.4 1n.5 1.78 2 0 4 350 12.6 15.5 
164 52 1 1 62.0 165.0 1.68 2 0 1 300 17.2 11.5 
165 33 0 2 66.0 170.5 1.77 2 0 1 400 6.8 17.8 
165 33 0 2 66.0 170.5 1.77 2 0 4 400 5.1 16.8 
165 33 0 2 66.0 170.5 1.77 2 0 4 400 6.6 13.5 
166 52 1 1 62.0 165.0 1.68 1 0 1 400 6.8 3.0 
167 34 1 2 60.1 161.0 1.63 2 0 1 400 29.3 2.3 
168 32 1 2 61.5 169.0 1.71 1 0 1 300 23.2 14.8 
169 54 1 2 79.5 162.5 1.85 0 0 1 300 25.0 14.0 
169 54 1 2 79.5 162.5 1.85 0 0 4 200 7.1 13.0 
170 42 1 1 65.9 179.0 1.83 0 0 1 400 30.3 13.5 
170 42 1 1 65.9 179.0 1.83 0 0 4 350 13.1 1.8 
170 42 1 1 65.9 179.0 1.83 0 0 4 350 16.7 13.5 
170 42 1 1 65.9 179.0 1.83 0 0 4 350 15.4 5.0 
171 26 1 1 52.1 165.5 1.57 1 0 1 300 18.9 16.5 
1n 30 0 2 48.0 150.0 1.41 2 0 1 400 23.2 12.8 
1n 30 0 2 48.0 150.0 1.41 2 0 4 400 20.0 14.0 
1n 30 0 2 48.0 150.0 1.41 2 0 4 425 28.3 14.0 
173 56 1 1 61.5 162.5 1.66 1 0 1 300 20.0 14.0 
173 56 1 1 61.5 162.5 1.66 1 0 4 300 17.4 13.5 
173 56 1 1 61.5 162.5 1.66 1 0 4 300 18.4 14.0 
174 21 0 1 57.2 168.0 1.65 1 0 1 300 31.1 15.8 
174 21 0 1 57.2 168.0 1.65 1 0 4 250 17.7 16.5 
175 23 1 1 73.5 185.0 1.96 2 1 1 300 5.8 12.0 
175 23 1 1 73.5 185.0 1.96 2 1 4 300 4.8 12.5 
193 
ID AGE SEX RACE wr HT BSA SM< /J,J.C EVID DV CP TIME 
175 23 1 1 73.5 185.0 1.96 2 1 4 350 10.1 12.8 
175 23 1 1 73.5 185.0 1.96 2 1 4 350 11.6 13.8 
176 29 0 1 59.0 160.0 1.61 3 0 1 350 13.1 15.8 
176 29 0 1 59.0 160.0 1.61 3 0 4 350 14.4 14.0 
176 29 0 1 59.0 160.0 1.61 3 0 4 377 13.6 13.8 
176 29 0 1 59.0 160.0 1.61 3 0 4 377 13.1 13.5 
176 29 0 1 59.0 160.0 1.61 3 0 4 400 17.7 2.5 
177 18 1 2 113 197.0 2.47 0 0 1 500 12.4 11.5 
177 18 1 2 113 197.0 2.47 0 0 4 500 14.1 12.3 
177 18 1 2 113 197.0 2.47 0 0 4 500 11.9 13.5 
178 33 1 1 64.0 167.0 1.72 1 1 1 300 15.2 3.5 
178 33 1 1 64.0 167.0 1.72 1 1 4 300 14.9 1.8 
178 33 1 1 64.0 167.0 1.72 1 1 4 '327 36.9 4.5 
178 33 1 1 64.0 167.0 1.72 1 1 4 '327 34.9 3.5 
178 33 1 1 64.0 167.0 1.72 1 1 4 314 30.1 4.5 
178 33 1 1 64.0 167.0 1.72 1 1 4 314 27.8 3.0 
179 37 0 2 62.0 165.0 1.68 1 0 1 300 11.4 16.5 
180 71 0 1 49.5 147.0 1.41 0 0 1 300 44.2 16.8 
180 71 0 1 49.5 147.0 1.41 0 0 4 300 52.0 16.0 
180 71 0 1 49.5 147.0 1.41 0 0 4 200 9.3 17.5 
181 22 1 2 60.0 167.0 1.67 1 1 1 300 8.1 11.8 
182 37 0 1 62.0 165.0 1.68 0 0 1 '327 40.9 14.0 
182 37 0 1 62.0 165.0 1.68 0 0 4 300 25.3 2.0 
183 70 0 1 49.5 149.0 1.42 0 0 1 350 10.9 17.0 
184 50 1 1 56.0 174.5 1.68 2 1 1 300 5.3 14.5 
184 50 1 1 56.0 174.5 1.68 2 1 4 300 5.3 10.0 
184 50 1 1 56.0 174.5 1.68 2 1 4 400 10.9 4.0 
184 50 1 1 56.0 174.5 1.68 2 1 4 400 10.6 4.0 
184 50 1 1 56.0 174.5 1.68 2 1 4 427 13.4 3.5 
184 50 1 1 56.0 174.5 1.68 2 1 4 427 15.2 4.3 
184 50 1 1 56.0 174.5 1.68 2 1 4 450 28.5 4.0 
185 41 1 1 46.4 173.0 1.54 1 1 1 300 19.4 15.5 
185 41 1 1 46.4 173.0 1.54 1 1 4 300 22.7 15.5 
186 39 0 1 58.0 158.0 1.58 2 0 1 300 10.9 4.5 
186 39 0 1 58.0 158.0 1.58 2 0 4 300 8.8 2.5 
187 41 1 1 65.0 173.0 1.78 0 0 1 300 21.0 12.5 
194 
ID AGE SEX RACE WT HT E5A SNI< AJJ; EVID rN CP TIME 
187 41 1 1 65.0 173.0 1.78 0 0 4 300 16.4 13.8 
188 43 1 1 62.0 173.0 1.74 1 0 1 300 14.9 17.0 
188 43 1 1 62.0 173.0 1.74 1 0 4 300 14.7 19.8 
189 26 0 2 88.8 167.5 1.98 0 0 1 450 23.7 15.0 
100 49 1 2 62.0 165.0 1.68 2 0 1 300 13.4 14.8 
191 42 0 1 76.0 158.0 1.78 0 0 1 300 14.7 11.5 
191 42 0 1 76.0 158.0 1.78 0 0 4 300 13.1 15.0 
191 42 0 1 76.0 158.0 1.78 0 0 4 300 12.9 13.8 
191 42 0 1 76.0 158.0 1.78 0 0 4 300 13.8 13.1 
192 78 1 1 f:13.7 166.5 1.63 0 1 1 300 9.6 14.0 
193 38 1 1 61.5 177.0 1.76 0 1 1 400 13.1 4.5 
193 38 1 1 61.5 177.0 1.76 0 1 4 400 18.4 3.0 
194 60 0 1 59.3 146.5 1.51 1 0 1 300 15.9 14.0 
195 24 1 2 55.0 172.5 1.65 0 0 1 300 7.8 16.3 
195 24 1 2 55.0 172.5 1.65 0 0 4 300 7.6 12.0 
195 24 1 2 55.0 172.5 1.65 0 0 4 32.7 10.4 11.3 
195 24 1 2 55.0 172.5 1.65 0 0 4 32.7 8.1 14.3 
195 24 1 2 55.0 172.5 1.65 0 0 4 350 11.9 12.5 
195 24 1 2 55.0 172.5 1.65 0 0 4 350 11.6 13.5 
196 29 0 1 54.5 159.0 1.55 0 0 1 200 24.2 4.5 
196 29 0 1 54.5 159.0 1.55 0 0 4 200 17.2 3.8 
196 29 0 1 54.5 159.0 1.55 0 0 4 150 14.1 3.5 
196 29 0 1 54.5 159.0 1.55 0 0 4 150 9.9 4.5 
197 39 1 1 f:13.0 169.0 1.64 1 0 1 100 2.3 4.3 
198 20 1 1 59.6 169.5 1.69 2 0 1 300 17.7 16.0 
198 20 1 1 59.6 169.5 1.69 2 0 4 300 15.7 16.0 
198 20 1 1 59.6 169.5 1.69 2 0 4 32.7 21.0 13.5 
198 20 1 1 59.6 169.5 1.69 2 0 4 32.7 27.0 15.3 
199 27 0 2 54.7 161.5 1.57 0 0 1 350 21.0 5.0 
199 27 0 2 54.7 161.5 1.57 0 0 4 32.7 15.2 6.0 
200 17 1 1 85.0 173.0 1.99 0 0 1 300 14.9 15.5 
200 17 1 1 85.0 173.0 1.99 0 0 4 300 13.6 14.0 
201 39 1 1 50.0 164.5 1.53 1 1 1 300 12.6 15.3 
201 39 1 1 50.0 164.5 1.53 1 1 4 300 13.1 15.3 
201 39 1 1 50.0 164.5 1.53 1 1 4 327 9.6 15.0 
201 39 1 1 50.0 164.5 1.53 1 1 4 32.7 12.4 3.0 
195 
ID AGE SEX RACE WT HT BSA SM< ~ EVID DV CP TIME 
201 39 1 1 5().0 164.5 1.53 1 1 4 32.7 10.1 4.0 
202 32. 1 1 71.8 172.0 1.84 1 1 1 300 8.1 13.5 
203 25 1 1 64.5 174.5 1.78 0 0 1 300 10.1 13.0 
203 25 1 1 64.5 174.5 1.78 0 0 4 300 11.4 14.5 
203 25 1 1 64.5 174.5 1.78 0 0 4 32.7 12.1 11.5 
203 25 1 1 64.5 174.5 1.78 0 0 4 32.7 11.6 13.0 
204 25 1 1 62.0 165.0 1.68 2 1 1 300 9.9 3.0 
205 25 0 1 78.3 161.0 1.82 2 0 1 300 6.3 14.75 
205 25 0 1 78.3 161.0 1.82 2 0 4 300 6.6 17.5 
205 25 0 1 78.3 161.0 1.82 2 0 4 350 12.4 14.3 
205 25 0 1 78.3 161.0 1.82 2 0 4 400 19.4 15.0 
206 29 0 1 58.0 144.0 1.48 0 0 1 200 5.6 19.0 
206 29 0 1 58.0 144.0 1.48 0 0 4 200 5.6 16.0 
207 45 1 1 49.8 166.0 1.54 2 0 1 300 21.0 13.3 
207 45 1 1 49.8 166.0 1.54 2 0 4 300 23.2 15.5 
208 35 0 1 71.0 160.0 1.74 1 0 1 300 12.9 13.0 
208 35 0 1 71.0 160.0 1.74 1 0 4 300 10.6 12.3 
208 35 0 1 71.0 160.0 1.74 1 0 4 300 13.9 13.0 
208 35 0 1 71.0 160.0 1.74 1 0 4 350 24.0 13.0 
208 35 0 1 71.0 160.0 1.74 1 0 4 350 25.3 16.5 
209 46 1 1 59.6 173.0 1.71 2 0 1 300 9.3 16.5 
210 65 1 1 55.0 167.0 1.61 1 0 1 300 8.3 11.3 
210 65 1 1 55.0 167.0 1.61 1 0 4 300 7.8 12.8 
211 30 1 1 95.0 182.5 2.17 0 0 1 400 21.5 19.8 
211 30 1 1 95.0 182.5 2.17 0 0 4 400 23.7 17.8 
212 36 1 1 62.6 177.0 1.78 2 1 1 300 11.9 17.3 
212 36 1 1 62.6 177.0 1.78 2 1 4 300 9.1 14.0 
213 28 1 2 67.5 172.5 1.80 1 0 1 300 10.1 14.8 
214 38 0 1 65.0 152.5 1.62 0 0 1 300 7.8 17.5 
214 38 0 1 65.0 152.5 1.62 0 0 4 300 7.6 16.0 
215 20 1 2 82.1 171.5 1.95 0 0 1 400 19.2 4.5 
215 20 1 2 82.1 171.5 1.95 0 0 4 400 22.0 4.8 
215 20 1 2 82.1 171.5 1.95 0 0 4 427 27.3 6.3 
216 25 1 1 53.5 174.0 1.64 0 0 1 300 13.1 15.0 
216 25 1 1 53.5 174.0 1.64 0 0 4 32.7 20.5 13.8 
216 25 1 1 53.5 174.0 1.64 0 0 4 32.7 19.2 12.3 
196 
ID AGE SEX RACE WT HT BSA SM< ,v:; EVID DV CP TIME 
217 35 1 1 69.6 176.0 1.85 1 0 1 300 5.1 13.8 
217 35 1 1 69.6 176.0 1.85 1 0 4 300 7.8 14.5 
218 57 1 1 61.9 169.0 1.71 2 1 1 300 25.5 13.0 
218 57 1 1 61.9 169.0 1.71 2 1 4 300 34.9 3.8 
219 25 1 1 56.0 170.5 1.65 0 0 1 300 13.1 15.3 
219 25 1 1 56.0 170.5 1.65 0 0 4 300 12.9 15.5 
219 25 1 1 56.0 170.5 1.65 0 0 4 350 26.0 16.8 
219 25 1 1 56.0 170.5 1.65 0 0 4 350 23.7 14.5 
219 25 1 1 56.0 170.5 1.65 0 0 4 327 14.7 4.0 
219 25 1 1 56.0 170.5 1.65 0 0 4 327 9.3 2.8 
219 25 1 1 56.0 170.5 1.65 0 0 4 327 10.6 3.8 
220 42 0 1 75.0 154.0 1.73 1 0 1 300 11.4 14.5 
220 42 0 1 75.0 154.0 1.73 1 0 4 350 11.1 13.5 
221 72 1 1 60.0 165.5 1.66 0 0 1 300 37.6 17.8 
221 72 1 1 60.0 165.5 1.66 0 0 4 300 29.3 15.0 
221 72 1 1 60.0 165.5 1.66 0 0 4 250 15.4 15.0 
222 30 0 1 54.0 156.5 1.53 0 0 1 250 12.9 15.0 
222 30 0 1 54.0 156.5 1.53 0 0 4 277 26.3 16.5 
223 31 1 1 96.0 169.0 2.00 2 1 1 400 9.6 1.8 
223 31 1 1 96.0 169.0 2.00 2 1 4 400 12.4 5.0 
224 47 0 1 56.5 153.5 1.53 0 0 1 300 22.0 13.5 
224 47 0 1 56.5 153.5 1.53 0 0 4 300 16.9 15.3 
225 29 0 2 45.0 148.5 1.36 1 0 1 300 20.0 2.8 
226 48 0 1 65.6 156.5 1.66 1 0 1 400 11.1 14.5 
226 48 0 1 65.6 156.5 1.66 1 0 4 400 10.9 13.8 
227 55 1 1 60.0 173.0 1.72 2 1 1 100 3.3 14.0 
228 51 1 2 68.6 174.5 1.83 0 0 1 300 8.3 15.0 
228 51 1 2 68.6 174.5 1.83 0 0 4 300 6.8 15.0 
229 47 1 1 54.2 170.0 1.62 1 0 1 300 7.1 14.0 
229 47 1 1 54.2 170.0 1.62 1 0 4 300 6.8 13.8 
229 47 1 1 54.2 170.0 1.62 1 0 4 350 16.4 15.0 
230 64 0 1 62.0 146.0 1.54 0 0 1 400 21.0 2.5 
230 64 0 1 62.0 146.0 1.54 0 0 4 400 31.8 2.5 
231 67 0 1 62.0 165.0 1.68 0 0 1 200 5.8 16.0 
231 67 0 1 62.0 165.0 1.68 0 0 4 200 3.8 15.5 
232 50 1 1 53.3 165.5 1.58 1 0 1 300 13.6 2.5 
197 
ID AGE SEX RACE wr HT BSA SMK ~ EVID DV CP TIME 
233 41 0 1 n.5 166.0 1.81 0 0 1 300 15.4 15.0 
233 41 0 1 72.5 166.0 1.81 0 0 4 350 13.4 14.8 
233 41 0 1 72.5 166.0 1.81 0 0 4 350 14.4 14.5 
234 30 1 1 67.0 175.5 1.82 1 0 1 300 10.9 14.0 
234 30 1 1 67.0 175.5 1.82 1 0 4 350 17.9 12.5 
234 30 1 1 67.0 175.5 1.82 1 0 4 350 14.1 14.3 
234 30 1 1 67.0 175.5 1.82 1 0 4 377 25.8 14.5 
235 32 1 1 51.2 173.5 1.61 0 0 1 300 12.1 17.8 
236 40 1 1 80.9 179.0 2.00 2 1 1 450 36.6 5.0 
236 40 1 1 80.9 179.0 2.00 2 1 4 450 40.4 5.3 
236 40 1 1 80.9 179.0 2.00 2 1 4 427 35.1 4.8 
236 40 1 1 80.9 179.0 2.00 2 1 4 427 26.3 3.3 
237 19 1 2 55.9 173.0 1.67 0 0 1 300 31.6 5.0 
237 19 1 2 55.9 173.0 1.67 0 0 4 300 24.0 4.0 
237 19 1 2 55.9 173.0 1.67 0 0 4 250 23.7 3.5 
238 45 0 1 60.2 159.5 1.62 0 0 1 300 12.9 14.3 
238 45 0 1 60.2 159.5 1.62 0 0 4 300 13.6 14.0 
239 29 0 1 64.2 157.0 1.65 1 0 1 300 15.7 15.0 
240 19 0 1 44.1 153.5 1.38 0 0 1 300 12.4 17.0 
241 57 1 1 51.0 158.0 1.50 2 1 1 300 17.4 12.5 
242 61 1 1 51.4 161.0 1.53 0 0 1 300 22.2 2.5 
242 61 1 1 51.4 161.0 1.53 0 0 4 250 11.9 17.8 
243 20 1 1 62.0 167.5 1.70 0 0 1 300 15.7 10.0 
243 20 1 1 62.0 167.5 1.70 0 0 4 300 14.7 10.0 
244 31 0 1 64.7 158.0 1.66 2 0 1 377 48.0 19.3 
245 33 1 1 77.0 169.0 1.88 0 0 1 400 14.1 18.5 
245 33 1 1 77.0 169.0 1.88 0 0 4 400 9.3 16.5 
245 33 1 1 77.0 169.0 1.88 0 0 4 400 11.1 17.8 
245 33 1 1 77.0 169.0 1.88 0 0 4 450 14.4 17.0 
246 55 0 1 42.5 150.5 1.34 0 0 1 300 40.9 6.8 
246 55 0 1 42.5 150.5 1.34 0 0 4 200 16.4 5.8 
247 19 0 1 55.0 154.0 1.52 2 1 1 300 10.1 14.8 
247 19 0 1 55.0 154.0 1.52 2 1 4 300 8.8 16.3 
248 33 0 1 79.9 167.5 1.89 0 0 1 300 13.4 15.0 
248 33 0 1 79.9 167.5 1.89 0 0 4 300 9.3 13.8 
249 38 0 1 61.2 158.0 1.62 2 0 1 400 35.6 17.0 
198 
ID AGE SEX RACE WT HT BSA SMK PJ...C EVID DV CP TIME 
249 38 0 1 61.2 158.0 1.62 2 0 4 300 11.4 16.8 
249 38 0 1 61.2 158.0 1.62 2 0 4 300 17.2 15.3 
250 28 1 1 78.6 184.5 2.02 2 1 1 300 12.1 16.5 
250 28 1 1 78.6 184.5 2.02 2 1 4 300 13.6 14.0 
251 66 0 1 62.0 165.0 1.68 0 0 1 300 5.6 21.8 
252 49 0 1 45.8 152.0 1.39 0 0 1 100 4.0 14.0 
252 49 0 1 45.8 152.0 1.39 0 0 4 100 3.8 16.5 
253 44 1 1 49.7 163.5 1.52 1 0 1 300 3.4 14.5 
253 44 1 1 49.7 163.5 1.52 1 0 4 327 6.6 14.5 
253 44 1 1 49.7 163.5 1.52 1 0 4 327 8.6 14.5 
253 44 1 1 49.7 163.5 1.52 1 0 4 327 8.6 14.0 
254 37 1 1 82.0 170.0 1.94 0 0 1 300 5.8 12.5 
254 37 1 1 82.0 170.0 1.94 0 0 4 300 7.1 4.8 
254 37 1 1 82.0 170.0 1.94 0 0 4 350 9.1 5.8 
254 37 1 1 82.0 170.0 1.94 0 0 4 350 10.1 13.0 
255 66 1 1 62.0 165.0 1.68 0 0 1 200 2.8 19.5 
256 69 1 1 60.4 168.5 1.69 1 0 1 300 10.6 13.0 
257 21 1 1 54.8 170.0 1.63 0 0 1 300 13.4 6.5 
257 21 1 1 54.8 170.0 1.63 0 0 4 300 21.0 4.3 
257 21 1 1 54.8 170.0 1.63 0 0 4 200 7.1 4.8 
257 21 1 1 54.8 170.0 1.63 0 0 4 200 6.6 12.8 
257 21 1 1 54.8 170.0 1.63 0 0 4 250 10.9 10.0 
259 39 1 1 61.2 177.5 1.76 0 0 1 300 24.0 22.0 
260 20 0 1 76.5 157.5 1.78 1 1 1 400 9.1 5.0 
260 20 0 1 76.5 157.5 1.78 1 1 4 400 10.4 5.8 
260 20 0 1 76.5 157.5 1.78 1 1 4 400 11.6 2.5 
261 56 1 1 58.5 153.0 1.55 0 0 1 300 5.1 13.3 
261 56 1 1 58.5 153.0 1.55 0 0 4 300 6.1 14.0 
262 20 1 1 64.5 180.5 1.83 2 1 1 300 10.1 13.0 
263 37 0 1 47.2 154.0 1.42 1 0 1 300 9.9 16.0 
264 19 1 1 72.7 178.5 1.91 0 0 1 200 16.2 16.5 
265 71 0 1 45.4 150.5 1.38 0 0 1 300 27.3 16.0 
265 71 0 1 45.4 150.5 1.38 0 0 4 200 11.4 16.3 
266 34 0 1 46.7 148.0 1.38 1 1 1 200 11.6 18.0 
267 43 0 2 49.0 153.0 1.44 1 0 1 300 15.9 20.0 
267 43 0 2 49.0 153.0 1.44 1 0 4 327 18.9 18.8 
199 
ID AGE SEX RACE wr HT BSA SMK ~ EVID DV CP TIME 
2.67 43 0 2 49.0 153.0 1.44 1 0 4 '32.7 20.2 19.3 
2.67 43 0 2 49.0 153.0 1.44 1 0 4 334 16.4 18.5 
268 '32. 0 2 81.6 153.5 1.79 0 0 1 400 14.9 4.0 
268 '32. 0 2 81.6 153.5 1.79 0 0 4 400 14.4 3.5 
268 '32. 0 2 81.6 153.5 1.79 0 0 4 400 15.2 4.0 
2.69 31 1 1 64.9 179.5 1.82 2 1 1 300 3.8 15.8 
270 2.6 1 1 80.4 169.0 1.91 0 0 1 400 44.4 16.3 
270 2.6 1 1 80.4 169.0 1.91 0 0 4 350 29.6 15.0 
270 2.6 1 1 80.4 169.0 1.91 0 0 4 '32.7 19.7 14.5 
270 2.6 1 1 80.4 169.0 1.91 0 0 4 '32.7 17.9 14.5 
271 31 1 1 60.0 168.0 1.68 1 0 1 200 10.1 14.5 
271 31 1 1 60.0 168.0 1.68 1 0 4 200 8.8 15.5 
271 31 1 1 60.0 168.0 1.68 1 0 4 250 12.6 14.3 
271 31 1 1 60.0 168.0 1.68 1 0 4 250 9.1 14.8 
272 45 1 1 57.0 174.5 1.69 2 0 1 300 7.3 16.0 
273 72 0 1 56.0 142.5 1.45 0 0 1 200 13.1 14.5 
274 29 1 1 49.5 159.5 1.49 2 1 1 300 21.0 15.8 
274 29 1 1 49.5 159.5 1.49 2 1 4 300 16.2 16.5 
275 50 1 1 62.0 168.0 1.70 3 1 1 300 15.4 3.8 
275 50 1 1 62.0 168.0 1.70 3 1 4 300 12.1 3.0 
276 25 1 1 80.3 174.0 1.95 0 1 1 300 5.3 14.0 
276 25 1 1 80.3 174.0 1.95 0 1 4 300 7.3 14.5 
276 25 1 1 80.3 174.0 1.95 0 1 4 300 4.8 14.3 
276 25 1 1 80.3 174.0 1.95 0 1 4 400 15.2 15.3 
276 25 1 1 80.3 174.0 1.95 0 1 4 400 12.1 13.8 
276 25 1 1 80.3 174.0 1.95 0 1 4 427 14.4 13.5 
277 30 1 2 60.6 171.0 1.71 2 0 1 300 12.6 5.3 
277 30 1 2 60.6 171.0 1.71 2 0 4 300 11.9 7.5 
277 30 1 2 60.6 171.0 1.71 2 0 4 '32.7 8.1 9.3 
278 48 1 1 59.3 166.5 1.66 1 1 1 300 13.6 13.5 
279 20 1 1 60.0 174.5 1.73 2 0 1 300 14.9 4.0 
279 20 1 1 60.0 174.5 1.73 2 0 4 300 14.9 3.3 
280 45 1 1 69.5 172.5 1.82 0 0 1 300 24.2 14.3 
280 45 1 1 69.5 172.5 1.82 0 0 4 300 '32..6 15.0 
280 45 1 1 69.5 172.5 1.82 0 0 4 300 27.3 14.0 
281 20 1 1 44.6 152.0 1.38 0 0 1 200 9.1 13.0 
200 
ID AGE SEX RACE wr HT BSA SMK AU:, EVID DV CP TIME 
281 20 1 1 44.6 152.0 1.38 0 0 4 200 12.1 14.0 
281 20 1 1 44.6 152.0 1.38 0 0 4 200 11.4 13.0 
281 20 1 1 44.6 152.0 1.38 0 0 4 200 10.4 14.0 
281 20 1 1 44.6 152.0 1.38 0 0 4 250 23.5 12.0 
281 20 1 1 44.6 152.0 1.38 0 0 4 250 21.2 12.0 
281 20 1 1 44.6 152.0 1.38 0 0 4 227 13.9 13.0 
281 20 1 1 44.6 152.0 1.38 0 0 4 227 16.7 14.0 
282 23 1 1 60.2 181.0 1.78 0 0 1 300 21.2 13.5 
282 23 1 1 60.2 181.0 1.78 0 0 4 300 20.2 13.8 
283 44 1 1 50.5 165.0 1.54 1 1 1 200 12.6 13.3 
283 44 1 1 50.5 165.0 1.54 1 1 4 200 14.1 13.5 
284 55 1 1 64.2 171.0 1.75 0 0 1 300 17.9 16.0 
285 38 1 1 62.4 167.5 1.71 1 0 1 300 21.0 9.0 
286 66 1 1 68.4 166.5 1.77 0 0 1 300 13.1 17.0 
286 66 1 1 68.4 166.5 1.77 0 0 4 300 14.1 15.5 
287 24 1 1 74.1 171.5 1.87 2 1 1 350 7.6 12.0 
287 24 1 1 74.1 171.5 1.87 2 1 4 350 7.1 12.5 
287 24 1 1 74.1 171.5 1.87 2 1 4 400 8.8 12.0 
288 32 1 1 58.0 167.5 1.65 0 0 1 400 28.5 13.0 
289 45 1 1 62.0 165.0 1.68 0 1 1 300 40.2 16.3 
289 45 1 1 62.0 165.0 1.68 0 1 4 200 14.9 15.3 
290 25 0 2 44.0 149.5 1.35 1 0 1 200 12.9 17.5 
290 25 0 2 44.0 149.5 1.35 1 0 4 200 9.9 14.5 
290 25 0 2 44.0 149.5 1.35 1 0 4 227 14.9 14.0 
290 25 0 2 44.0 149.5 1.35 1 0 4 227 14.4 10.0 
291 20 0 2 97.2 167.5 2.06 0 0 1 100 0.8 13.0 
291 20 0 2 97.2 167.5 2.06 0 0 4 200 3.5 12.0 
291 20 0 2 97.2 167.5 2.06 0 0 4 200 2.3 12.8 
292 32 1 1 62.6 167.0 1.70 0 0 1 300 13.1 15.0 
292 32 1 1 62.6 167.0 1.70 0 0 4 300 10.1 16.0 
293 17 1 1 53.0 159.0 1.53 0 0 1 250 4.6 14.0 
293 17 1 1 53.0 159.0 1.53 0 0 4 300 12.9 16.5 
293 17 1 1 53.0 159.0 1.53 0 0 4 300 10.6 14.0 
294 19 1 2 63.0 182.5 1.82 1 0 1 300 10.4 14.0 
294 19 1 2 63.0 182.5 1.82 1 0 4 300 8.8 13.0 
295 58 1 1 55.0 173.5 1.66 1 1 1 300 7.8 16.0 
201 
ID AGE SEX RACE wr HT BSA SIW( /,U; EVID DV CP TIME 
200 46 1 1 54.6 156.0 1.53 0 1 1 300 11.4 12.3 
200 46 1 1 54.6 156.0 1.53 0 1 4 300 7.6 13.0 
297 44 1 1 57.0 169.0 1.65 1 0 1 300 9.3 13.0 
297 44 1 1 57.0 169.0 1.65 1 0 4 300 13.9 15.5 
297 44 1 1 57.0 169.0 1.65 1 0 4 327 11.4 16.0 
297 44 1 1 57.0 169.0 1.65 1 0 4 350 10.1 15.3 
298 68 0 1 40.8 154.0 1.34 1 0 1 200 15.4 3.5 
298 68 0 1 40.8 154.0 1.34 1 0 4 171 8.8 3.5 
299 21 0 1 36.9 143.5 1.22 0 0 1 200 15.2 15.5 
300 59 1 1 55.6 162.5 1.59 1 0 1 300 22.7 3.5 
300 59 1 1 55.6 162.5 1.59 1 0 4 300 23.7 3.5 
301 27 0 1 54.0 160.0 1.55 2 0 1 350 9.9 18.0 
302 17 1 1 51.9 157.5 1.51 0 0 1 300 9.3 15.0 
302 17 1 1 51.9 157.5 1.51 0 0 4 300 12.4 15.0 
302 17 1 1 51.9 157.5 1.51 0 0 4 300 9.1 16.5 
302 17 1 1 51.9 157.5 1.51 0 0 4 350 13.1 15.3 
302 17 1 1 51.9 157.5 1.51 0 0 4 350 15.7 13.5 
303 55 0 1 74.0 154.0 1.72 1 0 1 300 11.4 15.0 
303 55 0 1 74.0 154.0 1.72 1 0 4 300 14.1 15.0 
304 44 1 1 51.2 164.5 1.55 1 1 1 327 12.4 15.5 
304 44 1 1 51.2 164.5 1.55 1 1 4 327 10.4 14.8 
304 44 1 1 51.2 164.5 1.55 1 1 4 350 12.6 15.8 
304 44 1 1 51.2 164.5 1.55 1 1 4 350 11.4 14.5 
304 44 1 1 51.2 164.5 1.55 1 1 4 400 15.4 5.5 
304 44 1 1 51.2 164.5 1.55 1 1 4 427 25.0 2.3 
305 49 1 1 71.0 168.0 1.81 0 0 1 300 8.6 5.0 
305 49 1 1 71.0 168.0 1.81 0 0 4 300 5.8 5.0 
305 49 1 1 71.0 168.0 1.81 0 0 4 350 9.3 5.0 
305 49 1 1 71.0 168.0 1.81 0 0 4 350 11.1 5.5 
300 47 1 1 74.9 169.0 1.85 0 1 1 300 15.9 13.0 
307 32 1 1 51.6 162.0 1.54 2 0 1 300 12.9 15.8 
307 32 1 1 51.6 162.0 1.54 2 0 4 300 10.4 16.8 
307 32 1 1 51.6 162.0 1.54 2 0 4 350 18.7 5.5 
307 32 1 1 51.6 162.0 1.54 2 0 4 350 22.2 4.0 
308 37 1 1 61.0 166.0 1.68 1 0 1 300 9.1 11.5 
308 37 1 1 61.0 166.0 1.68 1 0 4 300 11.1 11.8 
202 
ID AGE SEX RACE wr HT BSA SMK N.J:, EVID DV CP TIME 
308 37 1 1 61.0 166.0 1.68 1 0 4 350 14.4 13.0 
309 48 0 1 85.3 161.0 1.89 2 0 1 300 4.3 14.8 
309 48 0 1 85.3 161.0 1.89 2 0 4 300 2.8 13.5 
309 48 0 1 85.3 161.0 1.89 2 0 4 400 7.3 14.0 
309 48 0 1 85.3 161.0 1.89 2 0 4 500 13.9 15.3 
309 48 0 1 85.3 161.0 1.89 2 0 4 500 18.4 13.8 
310 36 1 1 52.1 169.5 1.59 0 0 1 200 19.7 11.5 
311 20 1 1 65.2 170.5 1.76 1 0 1 350 9.6 16.0 
311 20 1 1 65.2 170.5 1.76 1 0 4 350 9.3 16.0 
311 20 1 1 65.2 170.5 1.76 1 0 4 350 9.3 16.8 
311 20 1 1 65.2 170.5 1.76 1 0 4 350 10.4 16.0 
311 20 1 1 65.2 170.5 1.76 1 0 4 400 11.6 16.0 
312 50 1 1 52.0 168.0 1.58 2 1 1 300 16.9 19.3 
312 50 1 1 52.0 168.0 1.58 2 1 4 327 12.9 19.3 
312 50 1 1 52.0 168.0 1.58 2 1 4 327 14.7 15.0 
312 50 1 1 52.0 168.0 1.58 2 1 4 327 13.6 15.0 
312 50 1 1 52.0 168.0 1.58 2 1 4 350 37.6 15.0 
312 50 1 1 52.0 168.0 1.58 2 1 4 341 17.4 15.0 
313 21 1 2 59.0 173.5 1.71 2 1 1 300 18.7 10.0 
313 21 1 2 59.0 173.5 1.71 2 1 4 300 21.0 12.3 
313 21 1 2 59.0 173.5 1.71 2 1 4 300 18.4 12.3 
313 21 1 2 59.0 173.5 1.71 2 1 4 300 18.4 12.3 
314 15 1 1 71.0 177.0 1.87 0 0 1 300 6.8 19.0 
314 15 1 1 71.0 177.0 1.87 0 0 4 350 13.9 4.0 
314 15 1 1 71.0 177.0 1.87 0 0 4 350 15.2 3.0 
314 15 1 1 71.0 177.0 1.87 0 0 4 400 22.0 2.8 
314 15 1 1 71.0 177.0 1.87 0 0 4 400 23.0 3.3 
315 55 1 1 56.5 169.0 1.65 2 0 1 300 6.3 16.5 
315 55 1 1 56.5 169.0 1.65 2 0 4 300 8.3 15.0 
316 22 1 1 59.8 164.0 1.65 0 0 1 200 28.0 14.0 
316 22 1 1 59.8 164.0 1.65 0 0 4 150 18.7 14.0 
317 42 1 1 64.6 167.5 1.73 2 1 1 300 10.9 15.0 
318 38 1 1 57.6 171.5 1.68 2 1 1 400 33.6 15.5 
318 38 1 1 57.6 171.5 1.68 2 1 4 400 33.6 15.5 
318 38 1 1 57.6 171.5 1.68 2 1 4 350 22.7 15.8 
319 40 0 1 76.0 155.5 1.76 0 0 1 300 10.9 12.5 
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ID AGE SEX RACE WT HT BSA SNI< /,JJ; EVID DV CP TIME 
319 40 0 1 76.0 155.5 1.76 0 0 4 300 8.3 15.0 
320 64 1 1 64.2 157.2 1.65 0 1 1 300 12.1 6.3 
321 16 1 1 54.4 168.5 1.62 0 0 1 350 21.2 3.8 
321 16 1 1 54.4 168.5 1.62 0 0 4 350 16.2 14.0 
321 16 1 1 54.4 168.5 1.62 0 0 4 350 16.4 14.0 
322 71 1 1 53.6 154.5 1.51 0 0 1 200 19.2 15.3 
323 40 1 1 51.7 166.0 1.56 2 1 1 300 11.4 17.3 
324 28 0 C 47.8 149.5 1.40 2 0 4 300 44.4 15.0 
324 28 0 1 47.8 149.5 1.40 2 0 4 250 29.8 4.5 
324 28 0 1 47.8 149.5 1.40 2 0 4 200 22.0 13.5 
324 28 0 1 47.8 149.5 1.40 2 0 4 200 16.4 13.5 
325 60 0 1 59.0 157.5 1.59 0 0 1 300 14.9 15.0 
325 60 0 1 59.0 157.5 1.59 0 0 4 300 13.9 15.0 
326 60 1 1 61.0 161.5 1.64 0 0 1 300 17.9 15.0 
326 60 1 1 61.0 161.5 1.64 0 0 4 300 18.9 18.8 
326 60 1 1 61.0 161.5 1.64 0 0 4 300 20.0 13.8 
326 60 1 1 61.0 161.5 1.64 0 0 4 327 22.2 14.0 
326 60 1 1 61.0 161.5 1.64 0 0 4 327 30.6 18.8 
326 60 1 1 61.0 161.5 1.64 0 0 4 327 26.8 17.3 
327 63 1 1 49.7 166.5 1.54 0 0 1 200 8.1 15.0 
327 63 1 1 49.7 166.5 1.54 0 0 4 250 11.1 15.3 
328 20 1 1 88.0 172.0 2.01 0 0 1 300 12.1 17.0 
328 20 1 1 88.0 172.0 2.01 0 0 4 300 10.6 21.3 
328 20 1 1 88.0 172.0 2.01 0 0 4 350 21.0 17.5 
328 20 1 1 88.0 172.0 2.01 0 0 4 350 18.4 19.5 
329 34 1 1 63.0 171.0 1.74 2 1 1 300 8.8 15.8 
329 34 1 1 63.0 171.0 1.74 2 1 4 300 11.9 16.5 
330 44 1 1 64.0 171.5 1.75 2 1 1 300 22.5 17.5 
331 37 1 1 68.0 175.0 1.83 1 1 1 300 7.3 16.5 
332 39 1 1 56.0 169.0 1.64 1 0 1 300 15.7 16.0 
ANNEXURE9 
NONMEM CONTROL FILE - MODEL S1 
$PROB PHENYTOIN STEADY-STATE MODEL 








MV1 =THETA( 1 )*Wf + THET A(3) 
l\t1\/2=MV1*FLG1+MV1*THETA(4)*(1-FLG1) 
VM=l\t1\/2*FLG2+1\t1\/2*THETA(5)*(1-FLG2)+ETA(1) 






$THETA (0.1, 1.0,20.0) 
$THETA (0.1,1.0,10.0) 




$EST MAXEVAL=4000 MSFO=INTER.OUT 
$SCAT PRED VS DV UNIT BY RACE 
$SCAT V\RES VS PRED BY RACE 
$SCAT V\RES VS Wf 
$SCAT V\RES VS AGE 
$SCAT V\RES VS SEX 
$SCAT V\RES VS BSA 
$SCAT V\RES VS SMK 
$SCAT V\RES VS ID 
;$TABLE ID Wf 
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ANNEXURE 10 
NONMEM CONTROL FILE - MODEL S2 
$PROB PHENYTOIN STEADY-STATE MODEL 







MV1 =THET A(1 )*Wf + THETA(3) 
MV2=MV1 *FLG1 +MV1 *THETA( 4)*( 1-FLG1) 
VM=MV2*FLG2+MV2*THET A(5)*( 1-FLG2)+ET A( 1) 







$THETA (0.1, 1.0,20.0) 
$THETA (0.1, 1.0, 10.0) 
$THETA (0,1.5,5.0) 




$EST MAXEVAL=4000 MSFO=INTEROUT 
$SCAT PRED VS DV UNIT BY RACE 
$SCAT \/\RES VS PRED BY RACE 
$SCAT \/\RES VS wr 
$SCAT \/\RES VS AGE 
$SCAT \/\RES VS SEX 
$SCAT \/\RES VS BSA 
$SCAT \/\RES VS SMK 
$SCAT \/\RES VS ID 
;$TABLE ID wr 
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ANNEXURE 11 
NONMEM CONTROL FILE - MODEL S3 
$PROB PHENYTOIN STE.ADY-STA TE MODEL 







l\t1V1 =THET A(1 )*Wf + THET A(3) 
MV2=1\t1V1*FLG1+1\t1V1*THETA(4)*(1-FLG1) 
VM=MV2*FLG2+MV2*THET A(5)*(1-FLG2)+ET A(1) 










$THETA (0.1, 1.0,20.0) 
$THETA (0.1,1.0,10.0) 
$THETA (0, 1.5,5.0) 




$EST MAXEVAL=4000 MSFO=INTEROUT 
$SCAT PRED VS DV UNIT BY RACE 
$SCAT \/\RES VS PRED BY RACE 
$SCAT \/\RES VS Wf 
$SCAT \/\RES VS AGE 
$SCAT \\RES VS SEX 
$SCAT \/\RES VS BSA 
$SCAT \/\RES VS SMK 
$SCAT \/\RES VS ID 
$SCAT RES VS PRED BY RACE 
$SCAT RES VS wr 
$SCAT RES VS AGE 
$SCAT RES VS SEX 
$SCAT RES VS BSA 
$SCAT RES VS SMK 
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$SCAT RES VS ID 
$TABLE ID VM KM CL 
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